Molecular characterisation of Anopheles gambiae haem oxygenase by Spencer, CS
  
i 
 
Molecular characterisation of 
Anopheles gambiae haem oxygenase 
 
Thesis submitted in accordance with the requirements of the University of Liverpool for the 
degree of Doctor in Philosophy 
 
 
By 
Christopher Stephen Spencer 
March 2016 
 
 
 
Supervisors 
Dr Mark Paine 
Dr Gareth Lycett 
Dr Lu-Yun Lian  
  
ii 
 
Declaration 
 
This work has not previously been accepted in substance for any degree and is not being 
currently submitted in candidature for any degree. 
Signed ………………………………………………………(Candidate) 
Date ……………………………………………………… 
 
 
Statement 1 
This thesis is the result of my own investigation, except where otherwise stated. Other sources 
are acknowledged and bibliography appended. 
Signed ………………………………………………………(Candidate) 
Date ……………………………………………………… 
 
 
Statement 2 
I hereby give my consent for this thesis, if accepted, to be available for photocopying and for 
inter-library loan, and for the title and summary to be made available to outside organisations. 
Signed ………………………………………………………(Candidate) 
Date ………………………………………………………  
  
iii 
 
 
 
 
 
 
 
 
 
“Everybody knows I’m known for dropping science” 
Adam “Ad-Rock” Horovitz 
Root Down 
1995 
  
  
iv 
 
Acknowledgements 
This work would not have been possible without the guidance and support of my primary 
supervisor, Dr. Mark Paine. Mark’s patience and knowledge of the scientific process has been 
invaluable in getting me across the finish line. I am similarly indebted to my secondary 
supervisors, Dr. Gareth Lycett and Prof. Lu-Yun Lian, who were happy to provide advice and 
technical expertise when required. 
I would like to thank the plethora of people around LSTM and the University of 
Liverpool who helped me in one way or another, including (in no particular order) Rodolphe 
Poupardin, Alvaro Acosta Serrano, Kay Hemmings, Hanafy Ismail, Alister Craig, Ashley 
Warman, Shona Moore, Lee Haines, Sravan Pandalaneni, Pryank Patel, Evangelia Morou, 
Jonathan Thornton, John Morgan, Jo Solino, Olga Mayans and Dave Weetman. I am grateful 
to Graham Moores, Tadge Szestak, Walter Fabricio Silva Martins and Jacob Riveron Miranda 
for their kind gifts of cDNA. Thanks to staff at OPPF for their technical assistance. 
Cristina Yunta Yanes, Jacob Riveron Miranda, Amy Lynd, Pat Pignatelli, Adriana 
Adolfi, Chris Williams and Kayla Barnes are people without whom Liverpool would have been 
an extremely drab affair, and I thank you all for making it a fun ride. Glauber Pacelli Gomes 
de Lima and Angela Hughes deserve extra credit for ensuring my chin is kept up. Eilidh 
Carrington deserves so many thanks for being such an incredible flatmate and friend. 
This PhD would have been infinitely tougher without help from friends and family back 
home. Thanks to Nicola Spencer and Carl McLaren for their support. The CC also deserve my 
unreserved gratitude, particularly my friends Joe Windell (“it’s taking you how long?”), Dave 
Livesey, who has cast an enthusiastic eye over some of the tastier sections, and particularly 
Saskia Whelan, who has always been invaluable for proof-reading, venting and always being 
there.  
  
v 
 
Abstract 
Malaria control is heavily reliant on the use of insecticides for interventions such as Indoor 
Residual Spraying (IRS) and Long Lasting Insecticide Nets (LLINs). Widespread resistance to 
insecticides in the malaria vector Anopheles gambiae threatens these interventions. To ensure 
the continued effectiveness of malaria control strategies, novel insecticides and insecticide 
synergists must be formulated, and in order to do so, new insecticide targets must be 
investigated. 
 Digestion of huge volumes of vertebrate blood in the midgut of An. gambiae 
mosquitoes results in the production of large concentrations of free haem: a potentially 
cytotoxic molecule. Amongst the adaptations haematophagous arthropods have for limiting 
haem mediated toxicity is haem degradation by the haem oxygenase system. Haem oxygenase, 
with its obligate redox partner, cytochrome P450 reductase, catalyses the hydrolysis of haem 
into biliverdin, producing carbon monoxide and ferrous iron. 
 To investigate the biochemical properties of An. gambiae haem oxygenase (AgHO), the 
enzyme was cloned and expressed in E. coli. The purified AgHO was observed to catalyse the 
degradation of haem to biliverdin, releasing CO and Fe2+, in the presence of insect and human 
CPR reducing systems. AgHO bound haem stoichiometrically, with a KD closer to that of H. 
sapiens and C. diphtheriae than that of D. melanogaster. 
 Application of the HO inhibitors Sn-protoporphyrin and Zn-protoporphyin to 
mosquitoes as a bloodmeal supplement revealed a dose-dependent reduction in egg laying 
capability of An. gambiae. It is unclear whether this is due to a detrimental effect on mosquito 
health because of haem mediated cytotoxicity, or if this reduction in reproductive fitness is due 
to a key role for AgHO in the reproductive system. 
  A range of truncated CPRs from insects (An. gambiae, A.mellifera, C. 
quinquefasciatus, D. melanogaster, R. prolixus) and H. sapiens were also cloned and 
expressed. The six enzymes were biochemically characterised side-by-side using cytochrome 
c reduction assays in order to determine whether there are any differences in activity between 
those CPRs in blood-sucking insects and others. There were no clear trends in terms of enzyme 
kinetics which associated with a phenotype of haematophagy. The insect enzymes studied had 
higher Vmax values than H. sapiens with respect to both NADPH (1.6-7.8 fold higher) and 
cytochrome c (1.5-5.8 fold higher). Also compared were the enzymes’ sensitivity to nucleotide 
analogue inhibitors and DPIC. HsCPR more sensitive to the nucleotide analogues than insect 
CPRs (by 2-30 fold). DPIC however was more inhibitory to insect CPRs by up to 20 times, 
giving it potential as an insecticide synergist. Again, there were no clear trends aligning 
inhibition profiles with a blood-feeding habit. 
 In conclusion, AgHO has been found to be a true haem oxygenase, with biochemical 
characteristics in keeping with well characterised HOs such as H. sapiens HO-1 and C. 
diptheriae HmuO. AgHO inhibition appears to play a key role in oviposition and mosquito 
fecundity, and therefore may be a potential target for insecticides and insecticide synergists. 
Taken together, these results suggest that knowledge of these enzyme targets may aid the future 
development of novel insecticides. 
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Chapter 1 - Introduction 
1.1 Background 
Vector-borne disease accounts for over 17% of infectious disease, with a mortality of more 
than 1 million deaths per year [1]. Among the arthropod vectors, mosquitoes are responsible 
for most human death. Of the mosquito-borne diseases, malaria is considered to be the most 
important. Malaria is most common in tropical and subtropical regions, and has become 
established in some temperate climates too (See Figure 1.1, [2]). 
Figure 1.1. Global incidence of malaria in 2 -10 year olds [2]. This map reflects the 
tropical and sub-tropical regions where malaria is endemic 
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The estimated global incidence of malaria is huge; 2015 had an estimated 215 million 
cases, with 438,000 deaths [3]. Mortality is not the only problem with malaria infection – most 
of those infected each year are children, and those surviving the disease are prone to learning 
difficulties and brain damage. Infection of pregnant women is a major cause of maternal 
anaemia, low birth weights and infant death [4]. 
Malaria is caused by a protozoan parasites of the genus Plasmodium, which are 
transmitted by female Anopheles mosquitoes [3]. The major anopheline species in sub-Saharan 
Africa are An. gambiae, An. arabiensis and An. funestus [5]. Malaria remains one of the most 
important diseases in the world because of the numerous barriers to its control and eradication. 
There is currently no vaccine [6], Plasmodium parasites have developed resistance to numerous 
anti-malarial drugs [7, 8], and mosquito resistance to insecticide is a growing problem [9].  
Malaria epidemiology is vitally dependent upon mosquito populations and their 
dynamics. The original Ross-MacDonald equation, the mathematical model which describes 
malaria epidemiology, relates to the mosquito in all of its transmission parameters, as do 
numerous of its successor models [10, 11]. It is clear that vector control is of paramount 
importance to breaking the malaria cycle, and that overcoming the hurdle of insecticide 
resistance in vector species is a key aspect. The first step towards the development of a novel 
insecticide is the identification of a new target.  
 
1.2 Vector control methods 
Given the establishment of resistance to Plasmodium species to anti-malarials and the 
importance of the vector life cycle to parasite transmission, vector control strategies continue 
to be a major preventative tool for the control of malaria and other vector borne diseases. There 
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is no single panacea for vector control in malaria, and accordingly, vector control in malaria 
endemic areas should involve numerous parallel efforts to minimise disease incidence. 
 1.2.1 Physical means of vector control 
Non-chemical approaches to vector control are varied, and include strategies to both minimise 
mosquito populations, and to separate adult vectors from humans. Larval source management 
[12] is an approach which involves physical (elimination of breeding and hatching sites, such 
as stagnant water) and chemical means (larvicides such as pyriproxyfen) [13, 14] to reduce the 
populations of mosquito larvae, and therefore adult mosquito population. LSM is not always 
appropriate, particularly where mosquito breeding sites are either vast or ephemeral. It has been 
part of reductions in disease incidence, and it is argued [12] that it has great potential as part of 
an integrated vector control strategy. 
 Other physical means of transmission reduction include the employment of window 
screens [15] and untreated bednets [16] to separate human biting victims from mosquitoes. 
These methods have the potential to be effective due to the nocturnal and endophagic nature of 
Anopheles vector species – houses are the most common places for contact between night biting 
mosquitoes and humans [17]. Untreated bednets are not near as effective as those treated with 
insecticides however. 
 
1.2.2 Insecticides 
Long-lasting impregnated nets (LLINs) and indoor residual spraying (IRS) are the two front 
line means of targeting adult malaria mosquitoes indoors. Table 1.1 shows WHO approved 
insecticides for adult malaria mosquito control. These insecticides each fall into one of four 
categories dependent on their chemical structure; organochlorines, organophosphates, 
carbamates and pyrethroids. 
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Table 1.1. WHO approved insecticides for control of adult malaria mosquitoes [18] 
Dates 
approved 
Insecticide Class Application P450 
resistance IRS ITN 
1940 – 1945 DDT OC X  r 
1940 – 1950 Lindane OC    
1951 - 1955 Malathion OP X  r 
1961 – 1965 Fenitrothion OP X  r 
Propoxur Ca X  r 
1966 – 1970 Chlorpiriphos-methyl OP X  r 
1971 – 1975 Pirimiphos-methyl OP X  r 
Bendiocarb Ca X  r 
Permethrin Pyr X X R 
1976 – 1980 Cypermethrin Pyr X X R 
1981 – 1985 Alpha-cypermethrin Pyr X X R 
Cyfluthrin Pyr X X R 
Lambda-cyhalothrin Pyr X X R 
Deltamethrin Pyr X X R 
Bifenthrin Pyr X X R 
1986 – 1990 Etofenprox Pyr X X R 
OC, organochlorine;  OP, organophosphate;  Ca, carbamate;  Pyr, pyrethroid;  r, weak contribution to resistance;  
R, strong contribution to resistance. 
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1.2.2.1 Organochlorines 
Organochlorine insecticides are chlorinated hydrocarbons which are divided into two 
categories: DDT-type compounds (DDT) and chlorinated alicyclics (lindane). Organochlorines 
have been banned for agricultural use since the 1970s due to their environmental persistence 
and long-term bioaccumulation in non-target organisms at all trophic levels. DDT was 
reapproved for use in IRS programs in limited quantities in 2006 [19]. The DDT mode of action 
is at the voltage-gated sodium channels (VGSC) in the nerve axon [20]. Here, the 
organochlorine molecule binds and prevents deactivation of the sodium gate. The axon 
membrane is prevented from depolarising, and Na+ ions leak through the membrane. The 
affected nerve becomes hyperexcitable, resulting in spontaneous discharge. Chlorinated 
alicyclic insecticides also have the effect of nervous hyperexcitation, but via binding at the 
GABAA site on the GABA chloride ionophore complex, inhibiting Cl
- transport into nerves 
[20]. 
 
1.2.2.2 Organophosphates and carbamates 
Phosphoric acid esters, termed organophosphates, have a toxic effect in animals by binding 
acetylcholinesterase (AChE). AChE is a class of enzymes which catalyses the hydrolysis of 
acetylcholine (ACh) – a neurotransmitter [21]. By binding to AChE, organophosphates inhibit 
the breakdown of ACh, allowing it to build up at nerve synapses leading to improper 
termination of nerve impulses. 
 Carbamates are esters derived from carbamic acid, and directly inhibit AChE, as 
organophosphates do [21]. 
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1.2.2.3 Pyrethroids 
Organic compounds similar to those pyrethrins naturally produced by certain Chrysanthemum 
species are called pyrethroids, and are among the most commonly used insecticides. They are 
significantly advantageous over other classes of insecticides in that they are generally harmless 
to humans and are not environmentally persistent. Pyrethroids work by binding to VGSCs 
whilst they are in an open conformations, resulting in a prolonged influx of Na+ ions, similar 
to DDT-like organochlorines. This results hyperexcitiation of the nerves, and spontaneous 
nerve firing [20]. [22] 
 
1.2.3.4 Pyriproxyfen and fecundity blocking insecticides 
Pyriproxyfen does not belong to one of the four major classes of insecticides already discussed, 
rather it is a pyridine-based pesticide which acts as a juvenile hormone analogue [23]. It is 
 
Figure 1.2. Modes of action of WHO approved insecticides (adapted from [22]) 
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traditionally a larvicide, inhibiting the emergence of adult mosquitoes by targeting insect 
growth regulation. It also has great utility in IRS and LLINs, where it has multiple effects. 
Firstly, mosquitoes can perform autodissemination [24]. Upon resting in a treated area, 
mosquitoes are exposed to pyriproxyfen, which they then take back to breeding sites. These 
breeding sites are then contaminated with pyriproxyfen, having a larvicidal effect.  
Aside from its larvicidal effect, pyriproxyfen directly mediates mortality in adult 
mosquitoes, and decreases fecundity [25]. Juvenile hormone regulates insect ovarian 
development [26], and exposure to pyriproxyfen leads to abnormal hormonal regulation in 
ovarian development, improperly developed ovarian follicles, and sterility. 
 
1.2.3 Insecticide resistance 
The application of synthetic insecticides approved for public health use by WHO has 
dramatically reduced the risk of contracting arthropod-borne diseases. In fact, the 80% 
reduction in malaria incidence this century has come about as a direct result of the application 
of insecticides [27]. However, the widespread application of these insecticides has placed huge 
selection pressure on insect populations to develop adaptations to withstand these insecticides 
[28]. There has been resistance to each of the four major insecticide classes observed in many 
vector species. 
Despite the fact that there are numerous WHO approved insecticides (Table 1.1), they 
only have two modes of action, as illustrated by Figure 1.2 [22]. This means that when 
resistance to one insecticide develops in an insect population, that adaptation can often confer 
resistance to other insecticides of the same class (crossresistance) or of a different class acting 
on the same target (multiresistance). Resistance in mosquitoes can be mediated by one of two 
mechanisms: metabolic resistance (degradation of the insecticide) or target-site resistance 
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(mutation of the target protein) [29]. Metabolic resistance involves detoxification enzymes 
such as esterases, cytochromes P450 and glutathione S-transferases chemically catabolising the 
insecticide molecules. The three known target-site resistance mutations are kdr (knockdown 
resistance – a mutation in the VGSC conferring DDT and pyrethroid resistance), rdl (resistance 
to dieldrin – allowing for resistance to chlorinated alicyclics) and MACE (modified 
acetylcholine esterase – conferring carbamate and organophosphate resistance) [18]. 
The spread of insecticide resistance, and the limited range of insecticide targets led to 
the establishment of the Innovative Vector Control Consortium (IVCC) [30]. The goals of the 
IVCC are to develop novel insecticides with novel modes of action, and to improve vector 
control delivery. Their target is to deliver three new insecticides by 2020, and they are on track 
to meet this target, however it is unlikely that these new insecticides will have reached the 
market by that time [31]. 
The threat posed by insecticide resistance is that it will undo the gains made in 
combatting malaria. It is of vital importance that future vector control strategies are not reliant 
upon insecticides with a single target, as has been the case for decades with pyrethroids. The 
insect bloodmeal has the potential to be an effective insecticide target. 
 
1.3 Relevance of the bloodmeal to arthropod vectors 
Haematophagy as a life strategy has arisen independently numerous times amongst arthropods 
[32], and accordingly, disease vectors are from a diverse range of arthropods, including 
arachnids (ticks), bugs (the kissing bug – Rhodnius prolixus) and true flies (mosquitoes, 
sandflies and tsetse flies). Haematophagy in these arthropods can be divided into obligate and 
optional, but only from the point of view of the individual insect, not from the point of view of 
the species. Obligate haematophages such as the kissing bug must feed on blood simply to 
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survive, however optional haematophages, like mosquitoes, can survive by feeding on nectar 
and fruit juices (indeed, male mosquitoes do not bloodfeed at all, and only feed on sugar 
sources). Optional haematophages do however need to feed on blood in order to develop eggs 
and form progeny. The bloodmeal is an essential aspect of the life cycle of all vector species, 
and is therefore an attractive target for novel insecticides. 
The most obvious adaptations for a blood feeding habit are piercing or cutting 
mouthparts for mechanical disruption of vertebrate skin [33]. Other adaptations of blood-
sucking insects include physiological adaptations which counter the responses of the vertebrate 
host. These include apyrase, which ameliorates a pain response [34]; peroxidase, which 
destroys vasoconstrictors [35] and hamadarin, an anti-factor XII [36]. Behavioural changes 
which aid in host location have also evolved. Some of the most important adaptations unique 
to blood-feeding insects are those which deal with the physiological impact of a huge influx of 
the pro-oxidant molecule, haem. 
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1.4 Haem and haem toxicity 
Haem consists of an iron ion in the centre of a porphyrin ring (Figure 1.2). It is most commonly 
encountered as a prosthetic group in metalloproteins such as haemoglobin and myoglobin 
(where it functions in oxygen transportation and storage), and enzymes such as the 
cytochromes [37], certain peroxidases [38] and nitric oxide synthases [39] (where the function 
is electron transfer). Upon degradation of metalloproteins, the haem moiety is released. Free 
haem is toxic by way of two main mechanisms: prooxidant activity (the acceleration of free 
radical formation) and the physical disturbance of phospholipid bilayers [40]. 
 
Figure 1.2 – Haem b 
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 The haem mediated proliferation of free radicals in biological systems causes 
cytopathology through oxidation of lipids [41], degradation of proteins [42] and DNA strand 
scission [43]. The generation of these radicals is summarised in Figure 1.3 [44]. Free haem is 
particularly toxic due to the fact that it is a general peroxidative catalyst – with several routes 
towards the generation of radicals. Though free haem has been shown to promote the 
production of hydroxyl radicals in vitro, evidence suggests that haem mediated oxidative stress 
comes by way of the decomposition of organic hydroperoxides, rather than the generation of 
molecular hydrogen peroxide [45].  
 
Figure 1.3. Overview of the radical reactions of the haem compounds haematin and 
ferrohaem. O2.
-, superoxide anion radical; ROOH, organic hydroperoxide; ROO., lipid 
hydroperoxyl radical; -R.,alkyl radical; RO., alkoxyl radical; RH, non-protein thiol (reduced 
glutathione, β-mercaptoethanol in 1 and unsaturated fatty acids in 2) Adapted from [45] 
  
12 
 
 The disturbance of phospholipid bilayers 
is brought about by haem’s amphiphilic 
properties, as shown in Figure 1.4 [46]. Up to 
97% of cellular haem can be membrane bound, 
conversely only up to 47% of cellular bilirubin 
(the product of mammalian haem degradation) 
will be membrane bound, emphasising the 
difference in solubility in the two molecules 
[47].  
 Female mosquitoes consume up to two 
times their own body weight in a bloodmeal 
[48-50]), producing haem at a concentration of 
circa 10mM [51]. Oxidative damage to 
membranes occurs maximally at 50-100μM, 
with effects on membrane permeability 
occurring about 100μM [40]. Mechanisms that 
have evolved to mitigate haem toxicity are vital for survival. These include aggregation of 
haem, use of anti-oxidants, haem binding proteins and the degradation of haem by haem 
oxygenases. 
 
1.5 Mechanisms of haem detoxification 
1.5.1 Haem aggregation 
Once haemoglobin has undergone proteolysis and haem has been liberated, it becomes more 
insoluble. This can either result in membrane disturbance which is potentially harmful, or 
 
Figure 1.5. Possible orientation of haem 
in a phospholipid bilayer - At membrane 
level (A) and molecular level (B) [46]. 
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aggregate formation, which reduces haem mediated toxicity by preventing membrane 
disturbance and minimising free radical formation via steric hindrance. Haem aggregates are 
an ordered complex first characterised in Plasmodium falciparum [52]. Plasmodium species 
form an aggregate called haemozoin, and that consists of dimeric haem units constructed with 
iron carboxylate bonds, which mass together through hydrogen bonds between propionate side 
chains on the haem porphyrin ring [53]. Similar haem aggregates occur in the mosquitoes Aedes 
aegypti [54] and An. darlingi [55], and the triatomine insect R. prolixus [56]. The mechanism 
of haem aggregation is best characterised in R. prolixus. Triatomines have perimicrovillar 
intestinal membranes (PMV); extracellular phospholipid membranes situated between the 
midgut epithelium and lumen that form a hydrophobic environment in which haem 
polymerises. [57]. There is debate as to whether the process of polymerising haem is protein 
mediated [58], membrane mediated [59] or is an autocatalytic process [60]. Two lines of 
evidence suggest that protein mediation may play a key role in aggregation. Firstly, 
Plasmodium histidine rich proteins (HRPs) mediate polymerisation activity in vitro [58], 
secondly, heating the triatomine PMV prevents polymerisation [56]. However, a likely scenario 
is that all three mechanisms are in play at the same time – for instance, a haemozoin ‘primer’ 
could be created by a haem-binding protein, and elongate itself through autocatalysis the rate 
of  which could increase in a hydrophobic environment [51]. 
 
1.5.2 Haem binding proteins 
Haem-binding proteins (HBPs) with an antioxidant role have been identified in the haemocoels 
of R. prolixus (Rhodnius haem-binding protein - RHBP) [61, 62] and the cattle tick 
Rhipicephalus microplus (haem lipoprotein - HeLp) [63, 64]. Whilst sharing a similar function, 
these two binding proteins have differences. The antioxidant mechanism for both is unclear; 
there are numerous examples of proteins which bind haem and augment the ability of haem to 
  
14 
 
mediate lipid peroxidation [65], therefore the ability to simply bind haem does not necessarily 
lead to detoxification. R. microplus HeLp has an important role in haem salvage and release, 
and hence maintenance of physiological haem levels, important, as R. microplus lacks a haem 
biosynthesis pathway. Conversely RHBP primarily acts as an antioxidant, but acts as a haem 
source only for embryonic development, as R. prolixus can synthesize its own haem. 
Structurally, the proteins are completely different. HeLp itself is a haemoprotein, possessing 
two haem moieties, and can bind a further six haem molecules. RHBP binds a single haem unit, 
suggesting a completely different evolutionary history. This is unlike haem oxygenases, which 
appear to be orthologous in different species (Chapter 3).  
 In mosquitoes, the haem binding protein AeIMUCI has been identified in the 
peritrophic matrix of Ae. aegypti. AeIMUCI has numerous analogues across the Insecta taxon, 
including in An. gambiae. Whether or not this An. gambiae analogue is a key aspect of gut 
detoxification is a matter of speculation. It may act as HeLp does, salvaging and releasing haem 
in a nutritional role, although as An. gambiae has a biosynthetic haem pathway, this may not 
be as crucial. This uncertainty illustrates a key point; that inhibition of the haem oxygenase 
enzyme as part of a control strategy may have different effects on different arthropod vectors, 
depending on the specific auxiliary strategies employed by each species. 
  
1.5.3 Free radical attenuation 
Rather than targeting haem itself, mechanisms may focus on the detoxification of generated 
free-radicals. Comparison of ESTs in An. gambiae [66-69] has shown increased expression of 
numerous genes coding for detoxification and haem metabolising enzymes 24 hours post blood 
feed. Prevalent amongst the stress proteins upregulated were those related to the thioredoxin 
reductase cascade. AgHO was notably absent from this list, indicating that it is not up- or down-
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regulated by blood feeding, or that it was not identified. Stress response proteins such as Heat 
shock 70 and GRP94 are induced in Ae. aegypti [70], along with hexokinase, a glycolytic 
enzyme has been shown to act as an antioxidant in rats; preventing oxidative damage from free 
radicals generated by the mitochondria [71]. Superoxide dismutase and catalase, well known 
detoxificant enzymes, have been shown to be upregulated post-bloodmeal in R. prolixus [72] 
and An. gambiae [73]. 
Other sources of free-radical detoxification include smaller antioxidant molecules, most 
commonly uric acid. R. prolixus has displayed haem induced uric acid synthesis in the 
haemolymph [74], while xanthurenic acid has been identified as a detoxificant in Ae. aegypti 
[75]. 
 
1.6 The haem oxygenase reaction pathway 
Haem oxygenase (EC 1.14.99.3), is diversely expressed by bacteria, plants and animals. 
While mammalian HOs have been extensively studied, the only insect haem oxygenases to 
have been cloned and characterised is Drosophila melanogaster haem oxygenase (DmHO) 
[76]. Haem oxygenation products have been identified in R. prolixus [77] and Ae. aegypti [78], 
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although RpHO and AaHO have yet to be individually expressed and functionally 
characterised.  
Humans have three haem oxygenases; HO-1 is the best characterised haem oxygenase 
and is inducible in response to oxidative stress. HO-2 and HO-3 are less well studied. HO-2 is 
a constitutively expressed isoform involved with haem homeostasis, whilst HO-3 is not 
catalytically active, but could be involved in oxygen sensing [79]. 
Haem degradation by HO-1 occurs via a well-studied multistep mechanism [80]. The 
reaction requires electrons from NADPH [81, 82], and this transfer being mediated by 
 
Figure 1.6. Schematic for HO-mediated haem degradation into BV IXα 
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cytochrome P450 reductase [83]. The pathway begins with hydroxylation at one of the meso-
carbons on the haem’s porphyrin ring. Next is the oxygen-dependent removal of the 
hydroxylated meso-carbon as carbon monoxide-producing verdohaem, occurring alongside the 
reduction of the ferric complex to the ferrous state before complete elimination of the iron 
(Figure 1.5). 
Figure 1.5 shows the hydroxylation and removal of the α-meso-carbon. Though this is 
the exclusive reaction pathway for HO-1; haem can be similarly oxidised in an enzyme-free, 
aerobic environment with ascorbate as a reducing agent [84]. In the enzyme-free reaction, all 
four meso-carbons are cleaved in equal proportion. Similarly, insect HOs can hydroxylate 
different meso-carbons. It has been established that some insects can hydroxylate and remove 
the γ-meso-carbon [85]; recombinant DmHO has been observed to hydroxylate α-, β- and δ-
meso-carbons simultaneously in vitro [76]. Which carbon is hydroxylated i.e. the 
regiospecificity of the reaction, may be determined by structural motifs in the HO molecule. 
1.6.1 Cytochrome P450 reductase 
NADPH cytochrome P450 reductase (CPR, EC 1.6.2.4) is an integral membrane protein, and 
one of the few eukaryotic enzymes known to contain both FAD and FMN flavin cofactors [86]. 
CPR’s physiological electron acceptors, are chiefly the cytochromes P450 [87]. As has been 
stated above, CPR is the also the obligate electron donor for haem oxygenase mediated haem 
degradation [83]. In this reaction system, electrons originate from NADPH. The NADPH 
cofactor binds in a pocket on CPR, which induces a conformational change in the enzyme, 
moving NADPH adjacent to FAD. Electrons are then passed from NADPH to FAD, then to 
FMN. The FMN cofactor is near to the edge of the enzyme, and close to the redox partner 
binding site. Here, FMN passes electrons to haemoproteins such as haem oxygenase [88] or 
cytochromes P450 [87]. In P450s, electrons drive the monooxygenation of drugs and 
xenobiotics [89], but in haem oxygenase these electrons are used to hydroxylate haem [80]. 
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 Study of An. gambiae cytochrome P450 reductase (AgCPR) is important, because it 
presents another potential target for novel insecticides and insecticide synergists [90, 91]. The 
fact that it is the obligate redox partner of two separate metabolic pathways (haem degradation 
and metabolic insecticide resistance) indicates that this enzyme holds great promise as an 
insecticide target. It has been shown that inhibition of CPR shuts down endoplasmic 
cytochrome P450 activity, which has a direct effect on the ability of an organism to metabolise 
and detoxify xenobiotics. In mice hepatic CPR knockout has been shown to impact drug 
metabolism [92]. Knockdown of CPR has been shown to increase the susceptibility of 
insecticide-resistant mosquitoes to permethrin [91] and similar effects have been observed in 
other insects, such as Cimex lectularius [93]. Whilst previous insect studies have focussed on 
the insecticide resistance phenotype, it is possible that CPR knockdown may be having other 
effects given its role in the haem degradation pathway. The CPR- phenotype is non-lethal in 
mosquitoes and C. lectularius, but there may be more subtle phenotypes, such as diminished 
oviposition and increased oxidative stress. 
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1.6.2 Haematophage biliverdins and regiospecificity 
R. prolixus and Ae. aegypti have been observed to produce modified biliverdins as a result of 
haem degradation (Figure 1.6 [77, 78]). R. prolixus has been shown to hydroxylate haem that 
has been modified to include two cysteinylglycine residues, at the γ-meso-carbon, yielding a 
BV IXγ. This activity is assumed to be through RpHO [77]. Similarly, haem degradation in the 
Ae. aegypti midgut yields a BV IXα modified downstream to include two glutamine residues 
[78]. The enhanced solubility of these molecules facilitate excretion, mirroring the mammalian 
strategy of converting biliverdin into more soluble bilirubin and then glucuronic acid. It can be 
             
Figure 1.7. Haematophage biliverdins. A, R. prolixus biliverdin (RpBV). The porphyrin 
ring is oxidatively cleaved at the γ-meso-carbon after being chemically modified to 
include two cysteinylglycine residues [77]. B, Ae. aegypti biliverdin (AaBV). Here the 
porphyrin ring is cleaved at the α-meso-carbon, and then two glutamine residues are added 
sequentially post-cleavage [78]. 
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expected that other haematophagous arthropods will modify biliverdin in similar ways, in order 
to solubilise the molecule. 
1.7 Haem oxygenase in Anopheles gambiae 
HOs are conserved across microbial and non-haematohphagous organisms, so while it is likely 
that An. gambiae haem oxygenase (AgHO) is a dietary detoxificant of blood, it may play other 
physiological roles in the blood feeding mosquito. 
HO-1 and the other mammalian HOs primarily function in a homeostatic capacity to 
avoid toxicity from endogenous haem, such as during bruising [94] or in erythrocyte recycling 
in the spleen [95]. Dipterans do not contain haemoglobin instead they use an elaborate tracheal 
system to diffuse oxygen into the organism [96] (moreover, where arthropods do have an 
oxygen transportation protein, it is haemocyanin, which does not contain haem [97]). However 
An. gambiae and the other haematophages still require free haem for development, synthesis 
of haemoproteins, generation of pigments and other biological processes. As a result, HO is 
required to perform a role in haem homeostasis. Larger dietary haem concentrations in An. 
gambiae and other haematophages may require different reaction mechanisms and/or 
expression patterns in order to prevent oxidative stress. 
 
1.8 Haem oxygenase as a detoxificant of dietary haem in An. gambiae 
Haem degradation occurs in other haematophages - Ae. aegypti [78] and R. prolixus [77], and 
alongside An. gambiae, these insects have putative HOs in their genomes. It is uncertain 
whether or not HOs in these haematophages are significantly different in structure and function 
to the extensively characterised HO-1. Sequence analysis suggests that there is minimal 
variation around the active site. This is to be expected, because the substrate has not changed 
structurally only its location and concentration has. R. prolixus is a potential exception 
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however, as its  HO appears to use a haem which has two cysteinylglycine residues attached to 
it. As An. gambiae has to deal with massive influxes of haem, it could be expected that there 
might be differences in affinity and reaction rates in AgHO. There might be differential 
expression patterns in AgHO, however this is yet to have been confirmed through EST analysis 
[66-69]. It could be expected that AgHO is differentially regulated in response to oxidative 
stress like human HO-1.  
 
1.9 Haem oxygenase as a vector control target 
Assuming AgHO plays a key role in An. gambiae blood digestion, then it presents a potential 
“Achilles heel”, that might be exploited as part of a vector control strategy. Inhibition of haem 
aggregation in R. prolixus leads to oxidative stress, however does not lead to insect death [56]. 
Thus the mode of action of an HO inhibitor might not necessarily lead to an instant knockdown 
or killing effect, as is seen in traditional insecticides with neurotransmitter targets. Known 
inhibitors of haem oxygenase include zinc and tin protoporphyrins (ZnPP and SnPP) [98], 
which compete for the active site of haem oxygenase. The use of porphyric insecticides was 
first proposed with the haem biosynthesis pathway as a target [99], the mode of  action – 
accumulation of porphyrins and oxidative stress – is expected to be the same as in haem 
oxygenase inhibition, as evident by inhibition of haemozoin synthesis and RpBV production 
in R. prolixus fed with SnPP-IX, presumably due to RHBP and RpHO inhibition [100]. A major 
effect of feeding R. prolixus with such inhibitors is a significant reduction in oviposition. 
Inhibition of AgHO may therefore have a similar detrimental impact on oviposition, which 
makes it ideal for a vector control strategy.  
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1.10 Research Objectives 
It is unknown what the specific role of AgHO is, though it seems likely that it plays an 
important physiological role in haem catabolism, and other processes such as egg development. 
AgHO has not yet been characterised, and this is essential in order to understand its biological 
role(s) and its potential as a target for vector control. Thus, the main aim of this study is to 
clone and characterise AgHO with respect to haem degradation in An. gambiae. The in vitro 
characterisation will examine the haem oxygenase enzyme itself, as well as its redox partner, 
AgCPR. The in vivo approach will examine the role of haem oxygenase in a biological context. 
 More specifically, the objectives of this project are: 
i. An in silico investigation into haem oxygenase, and its similarities and differences with 
respect to other enzymes, 
ii. Cloning and expression of AgHO, 
iii. Biochemical characterisation of recombinant AgHO, including verification of putative 
AgHO as a classical haem oxygenase by identification of its reaction products, 
iv. Comparative characterisation of insect and human CPRs, including AgCPR, 
v. Examination of the in vivo role of AgHO using classical haem oxygenase inhibitors. 
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Chapter 2 – General Materials and Methods 
 
2.1 RNA extraction 
RNA extraction from tissues was carried out using the RNAqueous® Micro Kit from 
Thermofisher. Extraction was performed on insect and mammalian tissues according to the 
RNAqueous® protocol. 
 
2.2 cDNA synthesis 
cDNA synthesis was conducted on extracted RNA using the Superscript III First Strand 
Synthesis kit from Thermofisher Scientific. The reaction mixture was set up in a 50µL tube 
according to Table 2.1. As the cDNA to be synthesised would use mRNA as a template, the 
oligo(dT) priming method was used. 
 
Table 2.1. Reaction composition of first strand DNA synthesis – RNA volumes are 
approximate. Total RNA should be no more than 5µg. 
Component Volume (µL) 
RNA 2 
50 µM oligo(dT)20 primer 1 
DEPC treated H2O 6 
10mM dNTP mix 1 
Total 10 
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The mixture was incubated at 65oC for five minutes and then placed on ice for at least 
one minute. The cDNA synthesis mix in Table 2.2 was prepared, and added to each 
RNA/primer mixture. 
 
Table 2.2. cDNA synthesis mix 
Component Volume (µL) 
10X reaction buffer 2 
25mM MgCl2 4 
0.1 M DTT 2 
RNaseOUT 1 
Superscript III RT 1 
 
The reaction mixture was incubated for 50 minutes at 50oC, before being terminated by 
incubating at 85oC for 5 minutes and afterwards placed on ice. 1µL RNase H was added to the 
tube and incubated for 20 minutes at 37oC. 
 
2.3 Primer design 
As can be expected, primer design was largely dictated by the nucleotide sequence of the cDNA 
to be amplified. There were three rules followed when designing proteins. Firstly, it was 
ensured that primers were 18-30 base pairs in length in order to ensure specificity to the 
appropriate sequence. Second, the nucleobase furthest to the 3’ was always a guanine or 
cytosine. Lastly, the melting temperature of the reverse and forward primers were aimed to be 
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within 2oC of the one another, but this rule was circumvented in favour of the other two in 
instances where it was otherwise impossible. 
 
2.4 Primer synthesis 
Primers were designed as per the “Primer design” protocol above and were ordered from and 
synthesised by Eurofins Genomics. 
 
2.5 Polymerase chain reaction (PCR) 
Polymerase chain reactions were typically carried out in a 25µL reaction volume with the 
composition outlined in Table 2.3. The enzyme system used was Phusion HF by Thermofisher. 
 
Table 2.3. PCR Reaction components 
Component Volume (µL) Final 
Concentration 
Nuclease-free H2O Add to 25µL - 
5X HF buffer 5 1X 
10mM dNTPs 0.5 200µM 
10µM forward primer 0.5 0.2µM 
10µM reverse primer 0.5 0.2µM 
Template DNA < 2.5 < 125ng per 
reaction 
10mM MgCl2 < 1 < 200µM 
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Phusion DNA polymerase 0.25 0.02U/µL 
 
This is the standard PCR enzyme mixture. MgCl2 was only used when templates were 
proving difficult to amplify. Thermal cycling of the reaction mixture was carried out on a 
thermal cycler according to the sequence shown in Table 2.4. 
 
Table 2.4. PCR thermal cycling timetable 
Cycle stage Temperature 
(oC) 
Time (s) Cycles 
Initial denaturation 98 30 1 
Denaturation 98 10  
Annealing Variable 30 35 
Extension 72 30  
Final extension 72 600 1 
Hold 4 ∞ - 
  
If PCR yields were low, the cycle number was increased to 40. The annealing 
temperature was based on the melting temperatures of the forward and reverse primers. If the 
forward and reverse primers had different melting temperatures, the lower of the two was used 
at the annealing stage, although primer design tries to avoid this becoming a problem. 
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2.6 Agarose gel electrophoresis 
All gels were made using Tris Acetate EDTA (TAE) buffer with 0.5-2.0% agarose by mass 
and 0.5mg mL-1 ethidium bromide. Set gels were submerged in TAE and DNA samples were 
applied to wells at a volume of 15μL per well. 5μL DNA ladder was added in at least one well 
per gel (GeneRuler 1kB, Hyperladder I or Hyperladder IV, depending on availability and 
expected fragment size). Samples were run at 90 – 120 volts for as long as required for 
appropriate resolution. 
 
2.7 Restriction digest 
All restriction digests were carried out using Fast Digest enzymes from Thermofisher. The 
reaction mixture was set up according to Table 2.5. 
 
Table 2.5. Reaction composition of restriction digest 
Component Volume (µL) 
DNA (up to 1µg) 2 
Restriction Enzyme 1 1 
Restriction Enzyme 2 1 
Fast Digest 10x Buffer 2 
H2O 16 
Total 20 
 
The mixture was then incubated at 37oC for 1 hour. The enzymes were inactivated by 
incubation at 65oC for ten minutes. 
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2.8 DNA ligation 
Plasmid inserts were prepared for ligation by creating sticky ends, i.e. performing restriction 
digests according to the MCS of the plasmid. Plasmids were linearized using the same 
restriction enzymes. 
 The ligation reaction was catalysed by T4 DNA ligase (Thermofisher), according to the 
reaction mixture outlined in Table 2.6. 
 
Table 2.6. Reaction composition of DNA ligation – DNA volumes are approximate. Insert 
DNA concentration should be in a 3:1 ratio with plasmid DNA. 
Component Volume (µL) 
10x T4 DNA ligase buffer 2 
Plasmid DNA 1 
Insert DNA 3 
Nuclease free H2O 13 
T4 DNA ligase 1 
Total 20 
 
The reaction was incubated for 10 minutes at room temperature. 
 
2.9 Escherichia coli transformation 
E. coli cells were of two strains – BL-21* (DE3) One Shot® for expression and DH5α for 
subcloning. All cells were purchased from Thermofisher Scientific. 10ng DNA was added to a 
  
29 
 
single vial containing 50μL competent cells. Cells were mixed by being gently tapped, and 
then incubated on ice for 30 minutes. Cells were transformed via heatshock by being introduced 
to a waterbath prewarmed to 42oC for 30 seconds. The cells were then immediately returned to 
the ice. 250µL 37oC SOC medium was added to the cell mixture, then the vial was incubated 
at 37oC, shaking at 200rpm for 1 hour. The grown mixture was then pipetted onto an LB agar 
plate containing appropriate antibiotic (100µg/mL ampicillin unless otherwise stated), and 
incubated overnight at 37oC. All transformation work was conducted under a hood with care 
taken to ensure proper sterile technique. 
 
2.10 Plasmid purification by Miniprep 
The Miniprep kit was purchased from Qiagen, and uses their proprietary buffers, tubes and 
protocols. 
Bacteria with plasmids to be isolated were picked from single colonies and grown 
overnight at 37oC in 5mL LB broth containing the appropriate antibiotic. Bacteria were then 
pelleted by centrifugation at 5000rpm for 6 minutes. 
 The pelleted bacteria were resuspended in 250µL buffer P1 and transferred to a 1.5mL 
Eppendorf tube. 250µL buffer P2 was added and the tube was gently mixed by inversion. 
350µL buffer N3 was added and immediately mixed by gentle inversion. Tubes were next 
subjected to centrifugation at 13,000g for 10 minutes. 
 The supernatants from the centrifugation step were carefully pipetted into a QIAprep 
spin column and centrifuged at 13,000g for 60 seconds. The flow-through was discarded, and 
0.5mL buffer PB was added to the column and centrifuged at 13,000g for 60 seconds. The 
flowthrough was discarded, 0.75mL buffer PE was added to the column, and it was centrifuged 
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at 13,000g for 60 seconds. The flowthrough was discarded, and the column was again 
centrifuged at 13,000g for 60 seconds. 
 The spin column was moved to a fresh 1.5mL Eppendorf tube. 50µL buffer EB was 
added, and the column was rested for three minutes. Isolated plasmid was recovered by 
centrifuged at 13,000g for a final 60 seconds. Plasmid concentrations were estimated by 
Nanodrop spectroscopy. 
 
2.11 DNA sequencing 
DNA sequencing was performed externally by the University of Sheffield’s DNA sequencing 
service and by Source BioScience. Everything to be sequenced was sent in duplicate, with the 
appropriate forward and reverse primer pairs. Sequencing primers were the initial PCR primers 
in the case of PCR amplicons, and plasmid primers in the case of cloned or subcloned plasmid 
constructs. 
 
2.12 Preparation of growth media 
Luria-Bertani (LB) broth was made with 10g tryptone, 10g NaCl and 5g yeast extract, dissolved 
in 1L H2O. Terrific broth (TB) was made with 12g tryptone, 24g yeast extract, 2.2g KH2PO4, 
9.4g K2HPO4 and 4mL glycerol, dissolved in 996mL H2O. LB agar plates were made with 10g 
tryptone, 10g NaCl, 5g yeast extract and 15g agar, dissolved in 1L H2O. 
Once dissolved, all media and the glassware they are stored in and/or were grown in 
were autoclaved to ensure sterilisation. Care was taken to ensure that autoclaving occurred as 
soon as possible after the media was dissolved, such that bacterial growth was prevented. 
Antibiotic was added to the media when it had reached a temperature of 50oC. LB agar was 
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poured into plastic agar plates after having had antibiotic added, but before the liquid had begun 
to solidify. 
Any SOC medium used was that packaged along with competent cells and was 
therefore not prepared by me. 
 
2.13 Protein expression 
Unless otherwise stated, bacterial protein expression starts with a fresh transformation of BL-
21* E. coli cells (LifeTechnologies). Single transformed colonies are used to inoculate 10mL 
TB containing the appropriate antibiotic. Unless otherwise stated, this antibiotic is ampicillin 
at a concentration of 100µg mL-1. 
 After an overnight incubation at 37oC with shaking at 180rpm, the 10mL culture is used 
to inoculate 1L of TB with antibiotic in a 2L Erlenmeyer flask. This culture is then incubated 
at 37oC with shaking at 180 rpm for approximately 5 hours. The optical density (OD) at 600nm 
of 300µL of the culture was then checked on an Epoch spectrophotometer. Once the culture 
had an OD of 0.3 – 0.5 Abs, the shaking incubator’s temperature was reduced to that required 
for expression (25oC for pOPIN constructs, 16oC for pCold constructs) with shaking reduced 
to 160 rpm. Once this temperature was reached by the incubator, the OD was checked again. 
Once the OD of the culture had reached 0.7 Abs, the culture was induced by addition of IPTG 
to a final concentration of 0.5mM. The culture was incubated further for at least another 16h, 
depending on the protein being expressed. Bacteria were harvested by centrifugation at 
8000rpm for 10 minutes. 
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2.14 Creation of cell lysate for protein purification 
The pellet obtained from the protein expression protocol was placed on ice and resuspended in 
25mL ice cold lysis buffer (note that the lysis buffer is different depending on which protein is 
expressed, see results chapters for details). Once resuspended, PMSF to a final concentration 
of 1mM was added to each resuspended pellet. These pellets were sonicated on ice at an 
amplitude of 60-80% for twenty seconds, then left to stand for ten seconds, with this being 
repeated for a period of seven minutes. The lysates created were then centrifuged at 30000g for 
25 minutes, after which time the supernatant was purified. All steps take place on ice where 
possible. 
 
2.15 Ni-NTA protein purification 
 Ni-NTA columns were created by adding 2mL shaken Ni-NTA resin into a plastic 
elution column containing a filter disc. The ethanol storage solution runs through the column, 
leaving an Ni-NTA column with 1mL resin bed volume. This column was then rinsed with 
20mL H2O, followed by 20mL wash buffer. 
 The supernatant from the creation of cell lysate protocol was filtered through a PORE 
SIZE filter before being applied to the resin, which was sealed at the bottom. The lid was 
replaced, and the resin/supernatant mixture was incubated, shaking at 4oC for one hour. 
 The column was affixed to a clamp stand and held over a falcon tube, the lid and stopper 
were removed, and the flowthrough was collected. 
10mL wash buffer was used to rinse the resin, and the flowthrough was collected in a 
separate tube. This step is repeated, with the flowthrough collected in another separate tube. 
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10mL elution buffer was used applied to the resin, and 10 1mL fractions were collected in 
Eppendorfs. Aliquots of these fractions were applied to an SDS-PAGE gel to assess purity and 
presence of the protein of interest. 
 
2.16 Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) 
SDS-PAGE gels were made by first allowing a 12.5% acrylamide resolving gel to set, then 
pouring a 3% acrylamide stacking gel on top. 
The resolving gel was made using the reactants described in Table 2.7. After mixing, 
these reactants had 100µL fresh 0.1g mL-1 ammonium persulphate (APS) and 10µL TEMED 
added to catalyse polymerisation. The solution was poured between two pairs of glass plates 
up to 1.5cm below the top, and 100µL 2-propanol was pipetted onto the solution. The 2-
propanol is immiscible with the gel solution, and floats on top of it, thereby making the 
resolving gel flat on top. The gel was allowed to set by leaving it to stand at room temperature 
for 1 hour. 
The stacking gel was made using the reactants described in Table 2.7. Again, after 
mixing these reactants had 50µL fresh 0.1g mL-1 APS and 5µL TEMED added. The 2-propanol 
was poured off from the resolving gel, and the stacking gel solution was poured in. Gel combs 
were slotted into the top of the glass plate cassettes so that wells would be formed. The stacking 
gel was left to stand for half an hour so that the gels would set. 
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Table 2.7. SDS-PAGE gel composition. Enough for two 12 x 8cm gels, 0.75mm thickness 
Resolving gel Stacking gel 
Component Volume Component Volume 
30% acrylamide bis 4.16mL 30% acrylamide bis 0.625mL 
H2O 3.14mL H2O 3.0mL 
1.5M Tris HCl, pH 8.8 2.50mL 0.5M Tris HCl, pH 6.8 1.25mL 
10% SDS 100µL 10% SDS 50µL 
 
 After having set, gels to be run were placed in a gel tank, clamped in place, and then 
submerged in SDS-PAGE running buffer (made from a dilution of 10x stock, the stock was 
144g glycine, 30.2g Tris base and10g SDS, dissolved in 1L H2O). 
 All protein samples to be run were of a volume of 25µL, mixed with 25µL 2X Laemmli 
buffer (950 µL BioRad premixed 2X Laemmli buffer, 50µL β-mercaptoethanol) in 
microcentrifuge tubes. These sample tubes were incubated at 95oC for 10 minutes in order to 
denature the protein samples. 
 Up to nine protein samples can be run on one gel (each gel has ten wells, at least one is 
ear marked for PageRuler+ Prestained Protein ladder from Thermofisher). 25µL of each 
denatured protein sample was pipetted into each well. 
 The gel was subjected to a voltage of 60V until the dye front had moved into the 
resolving gel, after which time the voltage was increased to 90V. The gel was allowed to run 
until the dye front reached the bottom of the gel (approximately an hour and a half). 
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2.17 Protein dialysis 
Protein samples were applied to a Pur-A-LyzerTM Midi Dialysis Kit tubes (Sigma-Aldrich) in 
aliquots of 50-800µL. The dialysis tubes were then floated in 1L of cold dialysis buffer 
(different according to which protein was used) and incubated at 4oC for at least 16 hours. 
 For samples in a volume of more than 4mL (for instance, haemoglobin), the sample 
was pipetted into a rinsed length of dialysis tubing which was secured at both ends with clamps. 
The tubing was submerged in 10L cold H2O, and incubated overnight at 4
oC. 
 
2.18 Quantification of protein concentration 
Protein concentration was quantified using the Bradford method, specifically the Quick Start™ 
Bradford assay (BioRad). This assay required BSA protein standard at ten concentrations from 
0.1 – 1.0 mg mL-1. 5µL of each standard was added in triplicate to separate wells in a 96-well 
plate, plus one set containing no standard. 
 5µL of the protein sample to be quantified was added to empty wells on the plate. In 
cases where the protein concentration was completely unknown, the sample was diluted 1 in 5, 
1 in 10 and 1 in 20, to try and ensure that the absorbance value obtained for the sample wells 
could be located in the linear portion of the standard curve generated by the BSA standards. 
 Next 45µL of H2O was added to each well, followed by 200µL Quick Start
™ Bradford 
reagent. This was allowed to stand at room temperature for five minutes, before absorbance at 
595nm was measured on a plate spectrophotometer. 
 The BSA standards were used to generate a standard curve, which was used to calculate 
the protein concentration, in mg mL-1 of the samples. 
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2.19 Concentrating protein samples 
When protein samples were in volumes too high (such as application to a desalting column) or 
concentrations too low, they were concentrated by use of an Amicon Ultra-15 Centrifugal Filter 
Unit, with a 10kDa pore size (this is well below all the proteins studied). No more than 15mL 
protein was applied to the column, then it was spun down at 4000g for fifteen minutes at a time 
in a centrifuge pre-chilled to 4oC. The process was repeated until the protein sample was of 
either the volume or concentration required. 
 
2.20 Buffer exchange/desalting 
Buffer exchange took place on either a PD-10 desalting column or a PD Minitrap G-25 column 
(both from GE Healthcare). Columns were rinsed through with 5 times bed volume H2O, 
followed by five times bed volume of the final sample buffer. Sample was then applied, 
flowthrough discarded, and sample eluted in final buffer. For PD-10, sample volume was 
2.5mL, and final buffer volume was 3.5mL, for the PD Minitrap G-25 column, sample volume 
was 0.5mL and final buffer volume was 1mL. 
 
2.21 Plate spectrophotometry 
All 96-well plate based assays were performed using disposable 96-well plates (Nunc), and on 
either an Epoch Microplate Spectrophotometer (BioTek) or a FLUOstar Omega plate reader 
(BMG Labtech) for temperature dependent assays. 
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2.22 Homology modelling of proteins 
All homology models were performed using the SWISS-MODEL workspace [101-104], using 
specified templates. Images were created and manipulated using PyMOL [105]. Estimations of 
surface electrostatics were performed using PyMOL also, and are hence a qualitative rather 
than quantitative measure of surface potential. Table 2.8 shows the quality scores for models 
created. 
 
Table 2.8. Quality scores for protein homology models generated  
Model Page GMQE QMEAN4 
AgHO 47 0.59 -4.05 
AgHO docked with AgCPR 50 0.62 -7.77 
AgCPR docked with AgHO 50 0.78 -6.93 
 
2.23 An. gambiae rearing 
Mosquito eggs were rinsed into a plastic tray containing c. 300mL distilled H2O and allowed 
to hatch. Once hatched, larvae are fed daily with a pinch of TetraMin fish food flakes which 
had been ground into a powder. Larval populations are split down and divided amongst 
multiple trays to avoid larval density becoming a detriment to health. 
After approximately 8 – 10 days, pupation will have occurred. At this stage, pupae are 
manually removed from the larva trays with a Pasteur pipette and placed into a smaller plastic 
pot containing c. 50mL distilled H2O. This pot is placed into a BugDorm 2.0 adult mosquito 
cage and adults are allowed to emerge. 
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Adult mosquitoes are allowed to feed via cotton wool soaked in 10% sucrose water ad 
libitum. If eggs are required from the adults they are blood fed. Adults can be blood-fed from 
2 days post-emergence. 
Blood feeding took place either using human blood purchased from the NHS and 
administered using a Hemotek feeding apparatus set to 37oC, or directly from a human limb 
which was in contact with the cage wall. Feeding was allowed to take place, in the dark, for 1 
hour (Hemotek) or 15-10 minutes (human). A plastic pot containing water soaked cotton wool 
in contact with a 12.5cm diameter circle of Whatman filter paper was placed in the blood-fed 
cage two days post bloodmeal. The paper was left in the cage for a further two days to allow 
mosquitoes to lay. This egg paper was then rinsed into a larva tray. 
In circumstances where mosquito adults were anaesthetised, the mosquito cage was 
refrigerated at 4oC for one hour. The mosquitoes were then manually moved to a petri-dish 
which had be pre-chilled on ice. The mosquitoes remained on ice until the anaesthetic effect 
was no longer required, at which point they would be returned to standard rearing conditions. 
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Chapter 3 - Cloning and Expression of AgHO 
 
3.1 Introduction 
In spite of studies into the numerous adaptations haematophagous insects have to a haem-rich 
diet, such as haem aggregation [54-56] and haem-binding proteins [61, 63], haem catabolism 
in disease vectors is poorly characterized. Several HOs have previously been cloned and 
expressed, including mammalian (human and rat [82, 106, 107]), bacterial (Neisseria and 
Corynebacterium [108, 109]) and D. melanogaster [76] HOs. These studies vindicate the use 
of a heterologous Escherichia coli expression system, and will provide a platform for 
preliminary structural characterization using in silico modelling, and strategies for cloning and 
functional characterization of AgHO. 
 Whilst HO activity was originally studied using isolated liver microsomes [110], 
cloning and expression of diverse HOs has since been successfully performed in E. coli.  
Heterologous expression in bacteria allows for easy purification of active HO enzyme in order 
to study its activity. Many HO studies also incorporate the expression of a CPR enzyme to act 
as the redox partner, although artificial redox partners, such as ascorbic acid have also been 
used [76]. As bacteria do not have a true CPR enzyme, other redox partners have been 
expressed to study their HOs, such as flavodoxins, putidaredoxins, E, coli NADPH reductase, 
and human CPR [109]. 
When expressed in E. coli systems, the HO is always in a truncated form, missing its 
N-terminal transmembrane domain, with the exception of bacterial enzymes, which lack this 
domain altogether. When studying cytochromes P450, the CPR and P450 enzymes are full 
length and are coexpressed. The P450 system is then studied using isolated bacterial 
membranes. This is because the membrane domains of these enzymes are required for efficient 
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docking of the enzymes and P450 activity. This strategy has not been employed for study of 
HOs, because P450s are easy to quantify on the membrane spectrally; a characteristic not 
present in HOs. 
Human HO-1 is among the best studied of the haem oxygenases. Its full length, 
membrane bound form has proved intractable to work with, so studies of HO-1 are invariably 
carried out on its truncated form. HO-1 has been expressed in an E. coli system, and purified 
using ion exchange chromatography, using previous insights gained from expression of rat HO 
[106, 107]. A fusion protein of human HO-1 and human CPR was created and purified in the 
same way, and was found to have oxygenase activity 2 times higher than that of HO-1 and CPR 
separately [107]. E. coli expression systems have also been used as a basis for crystallisation 
trials. Crystallisation has been successfully carried out in rats [111] humans [80] and numerous 
bacterial species [112] 
 D. melanogaster has been successfully expressed and characterised as a truncated form 
called DmΔHO, alongside a similarly truncated cytochrome P450 reductase, DmΔCPR [76]. 
As with human HO-1 expression, truncation led to successful expression of soluble protein. 
DmΔHO expression did not turn culture medium or bacterial colonies green with biliverdin 
accumulation, unlike previously expressed mammalian and bacterial HOs. This implies that 
DmΔHO may be unable to use endogenous E. coli reductases as redox partners. Another 
difference between DmΔHO and HO-1 is interaction with CPR. Whereas HO-1 interacts well 
with CPR, electron transfers between DmΔHO and DmΔCPR is inefficient. 
 The first aim of this chapter is to analyse in silico the attributes of AgHO and compare 
it with better known HOs such as human HO-1. The second aim is to clone and express a 
functional AgHO enzyme for use in biochemical characterisation. 
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3.2 Materials and Methods 
3.2.1 AgHOΔ31 expression 
Protein expression was carried out according to the protocols in Chapter 2, with the exception 
that all buffers contained 150mM NaCl, 50mM Tris pH 8.0. Lysis buffer and wash buffer also 
contained 50mM imidazole, elution buffer contained 400mM imidazole. 
 
3.2.2 AgHO activity assay 
AgHO reactions were carried out in a final volume of 90µL containing phosphate buffered 
saline, 10µM AgHO:haem complex, 10µM AgCPR and 250µM NADPH. NADPH, AgCPR 
and AgHO were omitted from each control system. 
The AgHO:haem complex was created by incubating AgHO with a twice equimolar 
concentration of haem in a volume of 500µL. The mixture was allowed to stand for five minutes 
before applying to a PD Minitrap G-25 column and eluted. 
The reaction was initiated with addition of NADPH, and immediately subjected to 
scanning UV-Vis absorption spectroscopy in the range 350-800nm and repeated 30 minutes 
after addition of NADPH.  
 
3.2.3 Codon optimisation of synthetic AgHO 
The AgHO DNA sequence was modified to retain the correct amino acid sequence, but with a 
codon bias more suited to E. coli expression. A range of restriction sites were added for 
compatibility with pCold-II and other expression vectors, see Appendix 3.4 for the full codon 
optimised sequence and added restriction sites. 
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The holding vector pMK contained a kanamycin selection marker allowing for single 
tube restriction digest and ligation into Amp+ expression vectors could be performed. 
 
3.2.4 Synthetic AgHO expression 
Synthetic AgHO was excised from pMK using NdeI and EcoRI. The reaction mixture was then 
incubated with linearized pCold-II and ligated using T4 ligase. The mixture was then used to 
transform DH5α E. coli cells, which were plated on Amp+ LB plates. The pCold-IIAgHO was 
isolated from these cells via Miniprep. 
Protein expression was carried out according to the protocols in Chapter 2, with the 
exceptions that all buffers contained 150mM NaCl, 50mM Tris pH 8.0, 0.1% Triton X100. 
Lysis buffer contained 50mM imidazole and 0.5% Triton x100, wash buffer contained 50mM 
imidazole, elution buffer contained 400mM imidazole. 
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3.3 Results 
3.3.1 Identification and sequence analysis of AgHO 
The putative AgHO gene, AGAP003975 was identfied by querying the genome database 
VectorBase for the words “heme oxygenase.” The gene is located on the 2R chromosome, and 
contains a single intron. The size of the genomic sequence is 867bp. The coding sequence is 
750bp, coding for a 249aa, 29.5kDa protein [66, 113]. Figure 3.1 compares the AgHO amino 
acid sequence with other haem oxygenases identified via blast or by literature search. Table 
3.1 shows the amino acid identity and similarity between the HOs in Figure 3.1. Appendix 3.1 
shows a phylogram of these haem oxygenases. 
                                                         :.  * : *   :   .:     
P.aeruginosa       ---------------------MDTLAPESTRQNLRSQRLNLLTNEPHQRLESLVKSKEPF  39 
G.morsitans        -----------MATAKEN-KD-----D-VEPDMVYTKELRAATKDVHKLSDVLVNAKFAF  42 
D.melanogaster     MSASEETIA--DSQVSENVED-----V-EFVDMAFTKELRKATKDVHNLTDVLVNAKIAL  52 
C.quinquefasciatus -------MA--------ASTT-----T-TEKTVSFTKAMRVATREIHNVSDGLVNAKLAF  39 
A.aegypti          --------------------------------MSFTKEMRVATRDIHNVSDALVNAKLAF  28 
R.prolixus         --------------------------M-ETENIPFNKILRRETRDIHSVSDALVNAKLAI  33 
A.mellifera        --------------------M-----K-TNNQDTFCKKMRKATKEIHSISDSLVNAKLAF  34 
C.diptheriae       --------------------------M-TTATAGLAVELKQSTAQAHEKAE---HSTFMS  30 
Synechocystis      -------------------------------MTNLAQKLRYGTQQSHTLAE---NTAYMK  26 
H.sapiens HO-2     MSAEVETSEGVDESEKKNSGALEK-EN-QMRMADLSELLKEGTKEAHDRAE---NTQFVK  55 
H.sapiens HO-1     ---------------------MERPQP-DSMPQDLSEALKEATKEVHTQAE---NAEFMR  35 
R.norvegicus       ---------------------MERPQL-DSMSQDLSEALKEATKEVHIRAE---NSEFMR  35 
A.gambiae          ----------------------------MAQNVPFSKQMRIATREIHNVSDALVNAKLAF  32 
Variants            
 
                      .               :     :*                      *        *: 
P.aeruginosa       ASRD------NFARFVAAQYLFQHDLEPLYRN---EAL--ARLFPGLASRARDDAARADL  88 
G.morsitans        ALSDDTVW----ADGLLSFYEIYKFLENNLTE---------ELLPKELHRV--KEFEKDF  87 
D.melanogaster     ALSDDEVW----YDGLLAFYELYKFFETHLPE---------RLLPKEFHRT--AAFERDF  97 
C.quinquefasciatus ALYDSAVW----AEGLLVFYEIFKFLEQHVAH---------DFLPEEFHRT--EQFEQDL  84 
A.aegypti          ALYDSGVW----AEGLLIFYDIFKYLEENVSH---------DFLPEEYHRT--QQFEEDL  73 
R.prolixus         SFSDKDVW----AEGLLIFYEIFRFLEQAMSANKESNLC--KMYVNGMERT--SAFEEDL  85 
A.mellifera        GFLDNSVW----ADGLLVFYEVFRYLELAMIRWKDTEIG--LFLHEELRRT--EAFEVDL  86 
C.diptheriae       DLLEGRLGVAEFTRLQEQAWLFYTALEQAADAVRASGFAESL-LDPALNRA--EVLARDL  87 
Synechocystis      CFLKGIVEREPFRQLLANLYYLYSALEAALRQHRDNEIISAIYFPE-LNRT--DKLAEDL  83 
H.sapiens HO-2     DFLKGNIKKELFKLATTALYFTYSALEEEMERNKDHPAFAPLYFPMELHRK--EALTKDM  112 
H.sapiens HO-1     NFQKGQVTRDGFKLVMASLYHIYVALEEEIERNKESPVFAPVYFPEELHRK--AALEQDL  93 
R.norvegicus       NFQKGQVSREGFKLVMASLYHIYTALEEEIERNKQNPVYAPLYFPEELHRR--AALEQDM  93 
A.gambiae          ALYDSRVW----AEGLLIFYDVFKHLEQRVPH---------DFLPPEMHRT--AQFEQDL  77 
Variants                                                          L     S 
 
                        *                :               .*      :   .   *.  :  
P.aeruginosa       ADL--GHP-------VPEGDQSVR---------EADLSLAEALGWLFVSEGSKLGAAFLF  130 
G.morsitans        DYF-VGENWRDTYEIRPAVKKYLEHLEEVNKK-SKILLFAYAYQM-Y--MALMSGGQLLQ  142 
D.melanogaster     AYF-YGSDWRKDYEIRPAVQKYLEHLEKIAAQ-NELLLFAYSYQM-Y--MALMSGGQMLQ  152 
C.quinquefasciatus AFY-LGADWKAKYQPRKEVCDYLKHLEQIERE-NPNLLVAYVYHL-Y--MGLLSGGQILQ  139 
A.aegypti          TFY-LGADWKSKHQPRKEVCDYIKHLEQLQGE-NPNLLVAYVYHL-Y--MGLLSGGQILQ  128 
R.prolixus         KFY-LGDDWKKNYTVRESVAKYLSHLKELEST-NTDLLIAYVYHL-Y--MGLLSGGQILR  140 
A.mellifera        EFY-LGKEWKKNLNLRDSVTKYLIHLKEIEDT-EPILLIAYIYHL-Y--MGLLSGGIILR  141 
C.diptheriae       DKLNGGSEWRSRITASPAVIDYVNRLEEIRDNVDGPALVAHHYVR-Y--LGDLSGGQVIA  144 
Synechocystis      TYY-YGPNWQQIIQPTPCAKIYVDRLKTIAAS-EPELLIAHCYTR-Y--LGDLSGGQSLK  138 
H.sapiens HO-2     EYF-FGENWEEQVQCPKAAQKYVERIHYIGQN-EPELLVAHAYTR-Y--MGDLSGGQVLK  167 
H.sapiens HO-1     AFW-YGPRWQEVIPYTPAMQRYVKRLHEVGRT-EPELLVAHAYTR-Y--LGDLSGGQVLK  148 
R.norvegicus       AFW-YGPHWQEAIPYTPATQHYVKRLHEVGGT-HPELLVAHAYTR-Y--LGDLSGGQVLK  148 
A.gambiae          RYY-LGEGWLERHTPKAEVRAYLKHLQELEQE-NANLLLAYVYHL-Y--MGLLSGGQILQ  132 
Variants           L      R        P 
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                   .                                                            
P.aeruginosa       KKAAALELDENFGARHLAEPEGG-------------------------------------  153 
G.morsitans        KKR--------MMARKLW-PDKQENIQEQ-------------IDSEKPSNPDDLTTRPMP  180 
D.melanogaster     KKR--------MIARKMW-IFSKNDDEEQQKQADKEAELATARAADGSVDKDDLEARPMP  203 
C.quinquefasciatus KRR--------NITRKFN-PFATA-G-EPN------------------------------  158 
A.aegypti          KRR--------NFTKKFN-PFAN--G-NGA------------------------------  146 
R.prolixus         KKR--------EIGKRLLVNSK---D-SNT------------------------------  158 
A.mellifera        KKR--------EFMQKIW-PFK---E-YQM------------------------------  158 
C.diptheriae       R----------MMQRHYGVD--P-------------------------------------  155 
Synechocystis      N----------IIRSALQLPE-G-------------------------------------  150 
H.sapiens HO-2     K----------VAQRALKLPSTG-------------------------------------  180 
H.sapiens HO-1     K----------IAQKALDLPSSG-------------------------------------  161 
R.norvegicus       K----------IAQKAMALPSSG-------------------------------------  161 
A.gambiae          KRR--------SIGRRIN-PFRRADA-EPV------------------------------  152 
Variants                                        A 
 
 
                                                      .:     :           :  .*  
P.aeruginosa       --------RAQGWKS----------------FVAILDGI--ELNEEEERLAAKGASDAFN  187 
G.morsitans        LQVPICPDGCAATYF------PEKISDLKAKLRTILNKHYVNFDEQTKADFIEESRNVFI  234 
D.melanogaster     AQVTICPPGCEATYF------PEKISVLKAKLRRVFNNHYGAFDDDLRAAFIEESRNVFR  257 
C.quinquefasciatus ------RGAALTTFE------EHSIFELKQKMRSNIDKFGESLDEETRQQMMEESRRVFE  206 
A.aegypti          ------RGAALTTFE------EHSIYELKQKMRKTIDEFGDGLDEDTRKRMMDESRKVFE  194 
R.prolixus         ------KGNAVTDFG------NLNIHDLKQKIVDNVNSIADSLDEDTKFKIIVESRMVFK  206 
A.mellifera        ------NGNNITNFK------NSNIFQLKQHMRDTMNKIAETLDEDTKNKLIEESKTVFI  206 
C.diptheriae       --------EALGFYHFEGIA---KLKVYKDEYREKLNNL--ELSDEQRENLLKEATDAFV  202 
Synechocystis      --------EGTAMYEFDSLPTPGDRRQFKEIYRDVLNSL--PLDEATINRIVEEANYAFS  200 
H.sapiens HO-2     --------EGTQFYLFENVD---NAQQFKQLYRARMNAL--DLNMKTKERIVEEANKAFE  227 
H.sapiens HO-1     --------EGLAFFTFPNIA---SATKFKQLYRSRMNSL--EMTPAVRQRVIEEAKTAFL  208 
R.norvegicus       --------EGLAFFTFPSID---NPTKFKQLYRARMNTL--EMTPEVKHRVTEEAKTAFL  208 
A.gambiae          ------PDAAVTTFE------DHSIYELKQRLRKIVDDFGARLDEETRQRMLDESRKVFE  200 
Variants            
 
 
                       :.                                                       
P.aeruginosa       RFGDLLE-----------------------------RTFA--------------------  198 
G.morsitans        YNSDVVRSVKGVNRANIRKLAIVVLFFV--------------------------------  262 
D.melanogaster     LNIEVVRTIKGVNRANLRKLALALIFVS--------------------------------  285 
C.quinquefasciatus LNNRIIRTVQGVNRANVKTLIYVALLMM--------------------------------  234 
A.aegypti          MNNEIIKTVKGVNRANIKTIVYVIVLII--------------------------------  222 
R.prolixus         LNNEIVKSIEGTNVILLKKVFIFSVIVL--------------------------------  234 
A.mellifera        LNNEIIRSIQGTGTIILKKTVCFVIPIM--------------------------------  234 
C.diptheriae       FNHQVFADLGKGL-----------------------------------------------  215 
Synechocystis      LNREVMHDLEDLIKAAIGEHTFDLLTRQDRPGSTEARS-------------TAGHPITLM  247 
H.sapiens HO-2     YNMQIFNELDQAGSTLARETLEDGFPVHDGKGDMRKCPFYAAEQDKGALEGSSCPFRTAM  287 
H.sapiens HO-1     LNIQLFEELQELLTHDTKDQ----SPSRAP--GLRQRASN-KVQDSAPVETPRGKPPLNT  265 
R.norvegicus       LNIELFEELQALLTEEHKDQ----SPSQTE--FLRQRPAS-LVQDTTSAETPRGKSQIST  265 
A.gambiae          LNNTIIRTVEGVGSANMRIVRYIAMAIA--------------------------------  228 
Variants                  K 
 
 
P.aeruginosa       ----------------------------------------  198 
G.morsitans        -------------------SIYFAIKLARR----------  273 
D.melanogaster     -------------------SIVVAVKFALK----------  296 
C.quinquefasciatus -------------------IYFAVKYLFF-----------  244 
A.aegypti          -------------------LYFVLKQFILK----------  233 
R.prolixus         -------------------IIFMLWKLV------------  233 
A.mellifera        -------------------LLFLAFFVSFRKI--------  247 
C.diptheriae       ----------------------------------------  215 
Synechocystis      -VGE------------------------------------  250 
H.sapiens HO-2     AVLRKPSLQFILAAGVALAAGLLAWYYM------------  315 
H.sapiens HO-1     -RSQAPLLRWVLTLSFLVATVAVGLYAM------------  292 
R.norvegicus       SSSQTPLLRWVLTLSFLLATVAVGIYAM------------  293 
A.gambiae          -------------------AIILMQYVVRNQFGHEQEQTL  249 
Variants                                           D 
                                                   V 
 
Figure 3.1. Alignment of putative and confirmed haem oxygenases. Included are haematophagous insects 
(An. gambiae, An. funestus, C. quinquefasciatus, R. prolixus, G. morsitans), non-haematophagous arthropods 
(A. mellifera, D. melanogaster), mammalian (H. sapiens, R. norvegicus) and bacterial HOs (C. diphtheriae, 
Synechocystis) Amino acid residues that are identical white on a black background, conservative divergences 
are grey 
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Table 3.1. Amino acid identity and similarity between AgHO and other haem oxygenases 
Haem oxygenase % Identity with AgHO % Similarity with AgHO 
P. aeruginosa 18.68 43.00 
G. morsitans 36.94 61.25 
D. melanogaster 36.54 54.75 
C. quinquefasciatus 61.88 79.50 
Ae. aegypti 62.23 79.75 
R. prolixus 44.03 69.25 
A. mellifera 40.48 69.00 
C. diptheriae 19.06 47.75 
Synechocystis 19.67 45.50 
H. sapiens HO-1 21.68 33.00 
H. sapiens HO-2 21.68 40.50 
R. norvegicus 20.08 39.00 
 
Also shown in Figure 3.1 are the polymorphic variant amino acids observed as a result 
of the high SNP frequency in An. gambiae [114]. None of these mutations are on residues 
predicted below to be involved with catalytic activity.  
 Table 3.2 shows those amino acid residues which have previously been implicated as 
being important for HO function, and highlights differences in sequence between HO-1 and 
AgHO.  
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Table 3.2. Functional residues in HO-1 and conservation in AgHO 
HO-1 
Residue 
AgHO 
residue 
Function Conservation 
K18 R12 Propionate binding Conservative divergence 
T21 T15 Propionate binding via water 
molecule 
No divergence 
H25 H19 Proximal haem iron binding No divergence 
A28 S22 Proximal haem contact Conservative divergence 
E29 D23 Proximal haem contact Conservative divergence 
Y134 Y118 Distal haem contact No divergence 
T135 H119 Distal haem contact Non-conservative 
divergence 
R136 L120 Distal haem contact Non-conservative 
divergence 
G139 G123 Distal haem binding residue, 
provides binding flexibility 
(contact is on amino acid 
backbone), ligand 
discrimination, opening and 
closing of active site 
No-divergence 
S142 S126 Distal haem contact No-divergence 
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G144 G128 Distal haem binding residue, 
provides binding flexibility 
(contact is on amino acid 
backbone), ligand 
discrimination, opening and 
closing of active site 
No-divergence 
L147 L131 Distal haem contact No-divergence 
K149 K133 Interaction with CPR No-divergence 
K153 I137 Interaction with CPR Non-conservative 
divergence 
R185 I175 Interaction with CPR Non-conservative 
divergence 
F207 F199 Proximal haem binding (not on 
either binding helix) 
No-divergence 
F214 I206 Haem α-meso carbon binding Semi-conservative 
divergence 
 
Figure 3.1 shows the high levels of conservation of the H25 and T19 residues, which 
may stress their importance in haem binding. A28 and E29 are a point of divergence between 
putative HOs. Visible in Figure 3.1 is the predicted distal haem binding pocket of HO (bases 
139-144), another highly conserved region. HOs are somewhat unique in the fact that, rather 
than incorporating haem as a prosthetic group, HOs use haem as the cofactor for its own 
degradation [80, 115]. This sets HOs apart from the classical haemoproteins such as catalases 
  
48 
 
and cytochromes P450. Bases G139 and G144 provide HO-1 with flexibility and allow the 
distal helix to get closer to the haem than in other haemoproteins [80]. The backbone atoms of 
these amino acids directly contact haem in HO-1. G144 is 100% conserved, while G139 is 
conserved in all enzymes bar G. morsitans, D. melanogaster and Pseudomonas aeruginosa. In 
human HO-1, semi-, non- and conservative mutants of either G139 or G144 yielded loss of 
oxygenase activity, likely via displacement of the distal helix [116]. An exception is the G139A 
mutant, which still catalyses haem – note that G. morsitans and D. melanogaster both have 
alanine at this position. The other mutants effectively turned HO-1 into a peroxidase, indicating 
that a role of these conserved residues is to supress ferryl species formation [116] The 
flexibility of the distal haem helix is likely due to the fact that glycine and alanine are the 
smallest two amino acids, and their conservation in AgHO implies the flexibility of the pocket 
is important in An. gambiae as well as in humans. Y134, T135, R136, S142 and L147 are distal 
helix residues which contact haem [80]. Y134 has 100% conservation and L147 has one semi-
conservative mutation in C. diphtheriae. 
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3.3.2 Structural prediction of AgHO 
In order to inform design of AgHO expression constructs, in silico analysis of the gene was 
carried out. Figure 3.2 shows the predicted structure of AgHO. Due to low quality scores in 
comparison with human HO-1, interpretation of individual residue function must be treated 
 
Figure 3.2. Haem binding residues in AgHO  
  
Figure 3.3. Structure of the haem binding pocket - Highlighted are the proximal (green) 
and distal (blue) helices which make up the haem binding pocket, A shows the two helices 
which make up the pocket, B shows the surface of the pocket 
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with caution, however, predictions of surface structure to indicate potential binding sites with 
AgCPR may be made. 
The crystal structure of human HO-1 reveals that haem is bound between two α-helices 
(proximal and distal) [80]. These helices are conserved in AgHO, and contain the important 
haem binding residues highlighted in Table 3.2 (K18, T21, H25, A28, E29, Y134, T135, R136, 
G139, S142, G144 and L147). Human HO-1 residues G122 and G127 are conserved in AgHO, 
and Figure 3.4 shows that they are involved with distal helix flexibility – a conserved structural 
motif between HO-1 and AgHO. 
The predicted surface charge of AgHO is illustrated in Figure 3.5. The positive potential 
at the iron centre of the haem is visible and is essential for haem coordination to the H19 
residue. Also visible is a clearly positive area corresponding with the binding domain of the 
propionate haem chains, and the negative region corresponding with the opposite end of the 
haem molecule, adjacent to the haem α carbon. Given that these domains are associated with 
 
Figure 3.4. Surface electrostatic potential of AgHO binding pocket Blue indicates 
positive potential, red indicates negative potential, white is neutral 
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haem binding and orientation this suggests a role for these positively charged amino acids in 
haem orientation. 
Human HO-1 exhibits regiospecificity in the production of BV-IXα which seems 
dependent on propionate charge interactions [80]; these are important in orienting the α-meso-
carbon for hydroxylation in human HO-1. Conserved amino acids implicated in propionate 
binding are K18, K22, Y134, K179 and R183, of these, Y134 and K179 are conserved in 
eukaryotes. Because of conservation around this domain across humans and insects, it is 
unlikely that the divergent regiospecificity observed in some insects is because haem is not 
positioned in the same orientation. 
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Figure 3.5.Surface electrostatic potential of AgHO in putative docking conformation 
with AgCPR, based on structural homology with RnHO and RnCPR – A, AgHO (blue) 
docked with AgCPR (surface model); B, Putative AgHO docking surface on AgCPR; C, 
Putative AgCPR-docking helices on AgHO; Blue indicates positive potential, red indicates 
negative potential, white is neutral. 
Note that for these structures, the terminal transmembrane domains are missing. The 
transmembrane domains and therefore the membrane these proteins are situated on would 
be located downwards relative to the enzymes. 
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 In order to examine the docking of AgHO with its redox partner, AgCPR, homology 
models were created using the crystal structure of Rattus norvegicus HO and CPR in binding 
conformation [88]. Rat CPR has a modified hinge region (four residues removed) to produce 
an “open” conformation, capable of electron transfer to HO. Figure 3.5 shows the structure of 
AgHO and AgCPR resulting from this modelling.  
The predicted AgHO binding surface on AgCPR shows that negative and positive 
patches are visible on the FMN and FAD domain surfaces respectively. The areas associated 
with HO binding provide FMN close proximity with HO bound haem, allowing electron 
transfer to haem. 
Eukaryotic HOs contain C-terminal transmembrane domains that is not shared with 
bacterial HOs, and likely contributes to CPR docking [117]. 
 
3.3.3 Cloning of AgHO from An. gambiae cDNA 
In order to clone the full length AgHO coding sequence, primers were designed complementary 
to the 5’ and 3’ ends of AgHO, with modifications to allow for ligation into the pJET1.2 holding 
vector (BamHI and HindIII restriction sites). The designed primers are shown in Appendix 3.2. 
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mRNA was isolated from homogenised An. gambiae and used to synthesise cDNA. 
This cDNA which was used as a template for amplification and cloning (Figure 3.6). The 
AgHO insert in pJET1.2 was sequenced using amplification primers and the dideoxy-
termination method, and found to be identical to AGAP003975. 
For expression, AgHO was subcloned into the pOPIN-F expression vector according to 
the protocols in Chapter 2. AgHO contains a C-terminal transmembrane domain [117]. 
Previously expressed recombinant HOs have been expressed using constructs which were 
truncated at the C-terminus [76, 106, 107]. The full length sequence, plus a series of truncations 
from the C-terminus were therefore produced to optimise protein solubility, as summarised in 
Appendix 3.3. 
 
Figure 3.6. Isolation of AgHO from An. gambiae cDNA Lane 1, molecular mass markers; 
Lanes 2, AgHO amplified from cDNA; Lane 3, AgHO amplified from AgHO-pOPIN-F 
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The truncation series was created by PCR. The primers for this PCR are described in 
Appendix 3.2, and the AgHO:pJET1.2 plasmid was used as a template. Each of these amplicons 
was subject to restriction digest with BamHI and HindIII before being ligated into pJET1.2. 
These plasmids were transformed into competent E. coli and miniprepped to increase copy 
number. The truncated and full length AgHO inserts were removed from the pJET1.2 holding 
vector by restriction digest (BamHI and HindIII), and ligated into linearised pOPIN-F. The 
inserts were confirmed by sequencing using the initial amplification primers. 
 
Table 3.3. TMPred analysis highlights two possible transmembrane regions The first 
region is deep in the centre of the enzyme, the second corresponds with identified 
transmembrane regions in previously expressed HOs 
Starting aa Finishing aa Length of 
domain (aa) 
Score Orientation 
112 128 17 797 i-o 
219 237 19 1906 o-i 
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Figure 3.7. AgHOΔ31 expresses soluble protein. SDS PAGE gel of cell lysates of 
different AgHO truncation constructs. 1, AgHOΔ10; 2, AgHOΔ15; 3, AgHOΔ31; 4, 
AgHOΔ46; U, uninduced control culture; I, induced culture. 
AgHOΔ31 is the only construct which yields soluble enzyme 
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Only AgHOΔ31 expressed soluble protein, as shown in Figure 3.7 (hereafter referred 
to as AgHOΔ31). This construct was then used as a starting point to scale up expression. 
Optimal expression (shown in Figure 3.8) occurred with a 48 hour incubation post-induction, 
producing ~2mg total pure protein per litre of cell culture (See Appendix 3.4 for time course). 
 
Figure 3.8. SDS-PAGE gel of purification of AgHOΔ31 
Lane 1, molecular mass markers; Lane 2, Ni-NTA column flowthrough (unbound protein); 
Lane 3, Wash buffer flowthrough; Lanes 4-8, AgHOΔ31 elutions 
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In order to determine if AgHOΔ31 was catalytically active, the protein was incubated 
with haem and spectral measurements done to determine haem catabolism. As shown in Figure 
3.10, the characteristic decrease in Soret peak absorbance (380-400nm) associated with haem 
catabolism is not observed with AgHOΔ31. MdCPR, HsCPR, and the artificial electron donor 
ascorbic acid were used also, and no reactivity was observed. Also absent was a biliverdin peak 
at 680nm. 
Analysis of AgHOΔ31 by 1H 1D NMR indicated misfolded protein. Although this 
construct was not used further for biochemical studies, the amounts produced were sufficient 
for the production of antibodies. Polyclonal rabbit antisera against AgHO (α-AgHO) was 
produced by Davids Biotechnologie (Appendix 3.4 for antibody validation). 
 
Figure 3.9. Absorption spectra of AgHOΔ31 in complex with haem shows the enzyme 
is inactive 30 minute incubation of AgHO with haem, AgCPR and NADPH revealed no 
significant changes to the haem spectrum characteristic of haem catabolism 
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3.3.5 Expression and purification of codon optimised AgHO 
Due to low yield and catalytic inactivity, a codon optimised AgHO was designed and 
synthesised (Appendix 3.6). The soluble truncation of AgHO may have had an effect on the 
conformation of the catalytic domain of AgHO. As full length AgHO would not express 
normally, the DNA sequence was altered to take advantage of codon redundancy; producing 
the same amino acid sequence, but with a codon bias more similar to that of E. coli. Expression 
trials showed that the ideal growth conditions for AgHO occurred with a 48 hour incubation 
post-induction, producing ~5mg total pure protein per litre of cell culture. 
 
3.3.6 Activity assay of codon optimised AgHO 
 The UV-Vis spectra in for the assay clearly show reduction in the haem Soret region at 
380-400nm (Figure 3.10), indicative of haem catabolism. There was also a modest reduction 
in the haem α/β peaks at 560-610nm, and an increase in the 660-700nm region, which is 
associated with formation of biliverdin. Taken together, this is an indication of enzyme activity 
thus AgHO was used for further biochemical analysis. 
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3.3.7 Antibody generation 
Since the inactive AgHOΔ31 was shown to be misfolded, 500µL protein at a concentration of 
0.5mg mL-1 was sent to Davids Biotechnologie for generation of polyclonal rabbit antisera, and 
affinity purified α-AgHO antibody. These antibodies were tested and found to be specific to 
AgHO. 
  
 
Figure 3.10. Changes in the absorption spectra of codon optimised AgHO in complex 
with haem show the enzyme is catalytically active 30 minute incubation of AgHO with 
haem, AgCPR and NADPH revealed a clear reduction at the haem Soret peak  
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3.4 Discussion 
This chapter describes the cloning and expression of AgHO. Sequence analysis shows that 
AgHO shares 23% amino acid sequence identity with Homo sapiens HO-1 and 67% structural 
identity. The four residues previously found to be important for haem binding are conserved in 
AgHO: T15, H19, G122 and G127. T15 is on the proximal haem binding helix and indirectly 
contacts haem via a water molecule. H19 is also on the proximal helix directly coordinates with 
haem iron. G122 and G127 are located on the distal helix of the haem binding pocket. These 
are important because they contact the haem porphyrin ring via the amino acid, and also they 
mediate flexibility of the distal helix itself. From the structural homology model, the flexibility 
of this helix appears to help in giving the pocket its shape [80]. 
 Analysis of the electrostatic surface of the protein reveals how AgHO may bind haem 
and how it may dock with AgCPR. An acidic area containing the residues R12, R16, Y118, 
K169 and R173 forms the “entrance” to the haem binding pocket. The positive potential of this 
domain of the protein, its conservation in HO-1 and the position of the haem substrate in the 
crystal structure of HO-1 suggest that these residues are responsible for correctly orientating 
the haem in the haem binding pocket. Presence of this orientation domain, and the fact that the 
biliverdin product isolated from the closely related Ae. aegypti is a modified biliverdin α 
implies that AgHO likely hydrolyses biliverdin at the α-position only.  
Structural analysis also confirmed that AgHO is a membrane bound protein with a C-
terminal hydrophobic transmembrane domain. Knowledge of the extent of this domain was 
used to inform the design and construction of a series of expression plasmids truncated at the 
3’ end to varying extents. These expression plasmids were used in expression trials to obtain a 
soluble and catalytically active recombinant AgHOΔ31. One of the expression constructs 
yielded mg quantities of protein, but a lack of catalytic activity and 1D NMR analysis showing 
that this enzyme was misfolded meant it was not suitable for biochemical characterisation. The 
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fact that this misfolding occurred across different batches, and with different expression 
conditions suggests that the misfolding may have been because of the C-terminal truncation. 
 Instead, the full length AgHO was cloned, but failed to express when using the native 
cDNA sequence amplified from An. gambiae. A codon optimised version of the gene was thus 
created. Full length AgHO was successfully expressed from this construct, with a significant 
yield and catalytic activity. 
 This construct was used for the biochemical characterisation of AgHO as described in 
the next chapter. According to structural analysis, AgHO has the characteristic features of a 
true haem oxygenase, such as a haem binding pocket and a potential CPR docking domain, but 
biochemical analysis, such as confirmation of reaction products, must occur before AgHO is 
confirmed as a true haem oxygenase. 
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Chapter 4 – Biochemical analysis of Anopheles gambiae haem 
oxygenase 
 
4.1 Introduction 
Haem is of key importance to all insects. Most insects use haem as a nutrient in embryonic 
development [118, 119], and as the prosthetic group in haemoproteins such as nitric oxide 
synthase [120], catalase [72] and the cytochromes P450 [121, 122]. 
As discussed in Chapter 1, haem is also potentially toxic, due to its ability to interrupt 
phospholipid membranes and participate in the generation of ROS which damage proteins, 
nucleic acids and membranes. Though other haem detoxification methods [54, 56, 62] and 
haem biosynthesis itself [118] are relatively well characterised in insects, haem degradation by 
enzymatic oxygenation is less well known. There is only one instance of the isolation and 
characterisation of an insect HO, D. melanogaster [76]. Due to its potentially key role in 
bloodmeal detoxification, the biochemical characterisation of An. gambiae haem oxygenase is 
an important area of research, one which this chapter will focus on. 
The characterisation of D. melanogaster HO (DmΔHO) was conducted on an E. coli 
expressed enzyme which had been truncated at the N-terminus to remove the transmembrane 
domain, and was studied alongside a similarly truncated CPR (DmΔCPR) [76]. This study 
suggests that DmΔHO had haem oxygenase activity and is a true HO, however it is one which 
has a different active site structure to other known HOs such as human and rat. The DmΔHO 
reaction was found to degrade haem to biliverdin, carbon monoxide and iron in the presence 
of both the DmΔCPR/NADPH reducing system, and an artificial ascorbate reducing system. 
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Differences observed between DmΔHO and mammalian HOs include the way in which 
haem binds at the active site. Mammalian and cyanobacterial HOs have been observed to bind 
haem via a histidine residue at the proximal face, and a water molecule at the distal face. This 
binding mode is supported by homology modelling of AgHO, although this is not surprising 
given that the template is human HO. EPR spectroscopy has shown that the haem-DmΔHO 
lacks the six-coordinate high-spin binding mode as in other HOs, and that the haem iron is not 
involved in binding. DmΔHO catalysis leading to haem degradation is therefore predicted to 
be different to mammalian systems, with the proximal histidine residue being unimportant for 
catalytic activity. A similar observation has been made previously from site directed 
mutagenesis of HmuO from Corynebacterium diphtheriae. Here, the H20A mutant had its 
binding histidine removed, and was still capable of the initial meso-hydroxylation of haem, but 
not the whole reaction pathway [123]. 
DmΔHO produces three biliverdin isomers (α, β, δ), which distinguishes it again from 
other known haem oxygenases, which only produce biliverdin-α. The distal binding site helix 
in human HO-1 sterically prevents access of the hydroperoxy species to the β-meso, δ-meso 
and γ-meso carbons, which explains the regiospecificity of human HO-1. DmΔHO producing 
three isomers is another piece of evidence for a structurally different active site. 
This chapter aims to describe the biochemical characterisation of recombinant AgHO 
and verifies its ability to degrade haem to produce the three reaction products associated with 
HO mediated haem degradation: biliverdin, carbon monoxide and ferrous iron. This chapter 
also characterises the binding of haem by haem oxygenase to experimentally confirm the 
presence of structural motifs identified in Chapter 3. Finally, the pH and temperature optima 
of AgHO are determined in order to help place this enzyme into a physiological context. 
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4.2 Materials and Methods 
4.2.1 Creation of the AgHO-haem complex 
 The first step to spectroscopic analysis of the AgHO reaction is to create an AgHO-
haem complex. AgHO was mixed in a 1:2 molar ratio with haem. In silico analysis shows that 
AgHO only has one haem binding site, therefore a 1:2 molar ratio equates to a 2x excess of 
haem. After being mixed with haem, the AgHO was applied to and eluted from a PD Minitrap 
G-25 column for buffer exchange. The protein complex was then concentrated such that it 
could be used in assays. 
 
4.2.2 Spectral analysis of AgHO complex variants 
In vivo, the iron requires electrons from NADPH (via CPR) in order to be reduced, 
however in vitro haem iron can be reduced artificially by creating a reducing environment and 
introducing carbon monoxide forming a complex of ferrous haem and carbon monoxide. The 
ferrous CO complex was created by adding sodium dithionite powder to an aliquot of the ferric 
complex (creating a reducing environment [124]), the solution was then saturated with CO by 
bubbling the gas through the solution [109, 125, 126]. 
 The ferrous dioxyhaem complex was created by passing the ferrous-CO complex over 
a sephadex G25 column removing excess reductant and carbon monoxide. 
 All complexes were scanned spectroscopically from 750nm – 350nm in 90µL in a 
quartz cuvette, at a concentration of 10µM, in a buffer of 150mM NaCL, 50mM Tris, pH 7.4, 
0.1% Triton x100. 
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4.2.3 Calculation of the extinction coefficient of the haem-AgHO complex 
The extinction coefficient was calculated using the pyrimidine haemochrome method [127, 
128]. 10µM AgHO-haem complex in a buffer of 150mM NaCl, 50mM Tris, pH 7.4, 0.1% 
Triton x100 was mixed 1:1 with a solution of 0.2 M NaOH, 40% (v/v) pyridine, 500 μM 
potassium ferricyanide in a final volume of 1mL and placed in a 1mL quartz cuvette. The 
solution was observed via scanning absorption spectroscopy from 700nm to 350nm to obtain 
the oxidised spectrum. 
Approximately 5mg sodium dithionite was added, and the solution was mixed 
thoroughly. The pyridine haemochrome spectrum was recorded repeatedly until it stopped 
changing, and the concentration of heme was determined from the extinction coefficient at 557 
nm, using the value of 34530 M-1 cm-1. 
 
4.2.4 Haem binding assessment by titration 
Haem binding was assessed by increasing the concentration of haem whilst keeping the AgHO 
concentration fixed. The reaction mixture (100µL solution, 10µM AgHO in a buffer of 150mM 
NaCl, 50mM Tris, pH 7.4, 0.1% Triton x100) was placed in a 90µL quartz cuvette. The 
reference cuvette contained only buffer. 
 Change in absorbance of the complex was tracked via scanning absorption spectroscopy 
from 700nm to 350nm, with the reference cuvette in the blank chamber. 2µL of a 100µM 
solution of haem was added to sample and reference cuvettes, and after five minutes, the sample 
was observed again. This was repeated until the haem concentration in each cuvette was 20µM. 
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4.2.5 Cytochrome P450 reductases used for biochemical analysis of AgHO 
The CPRs used in this chapter are AgCPR, MdCPR and HsCPR. AgCPR were expressed 
according to the protocols outlined in Chapter 2. The AgCPR plasmid was provided by Mark 
Paine (LSTM) [90]. MdCPR was provided by Evangelia Morou (University of Crete). HsCPR 
was from Sigma. 
 
4.2.6 Identification of biliverdin as an AgHO reaction product 
The reaction mixture (100µL solution, 10µM AgHO-haem complex, 3µM CPR, 300µM 
NADPH in a buffer of 150mM NaCL, 50mM Tris, pH 7.4, 0.1% Triton x100) was placed in a 
90µL quartz cuvette. The reference cuvette contained only buffer and CPR. The reaction was 
initiated with addition of NADPH, and absorbance from 750nm to 350nm was immediately 
measured. Absorbance was measured every ten minutes for two hours. 
 Control systems were used which each omitted one reactant of NADPH, CPR, and 
AgHO to ensure that haem degradation was not spontaneous, non-enzymatic or CPR driven. 
 
4.2.7 Identification of CO as an AgHO reaction product 
The final reaction mixture was 100µL containing 10µM AgHO-haem complex, 3µM MdCPR, 
300µM NADPH, 150µM myoglobin in a buffer of 150mM NaCL, 50mM Tris, pH 7.4, 0.1% 
Triton x100. All components except for myoglobin and NADPH were placed in in a 90µL 
quartz cuvette, and then blanked. The reference cuvette contained only buffer and CPR. 
Myoglobin was added to the sample cuvette, the reaction was initiated with addition of 
NADPH, and absorbance from 600nm to 350nm was immediately measured. Absorbance was 
measured every ten minutes for two hours. 
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 Control systems were used which each omitted one reactant of NADPH, CPR, and 
AgHO. 
 
4.2.8 Identification of ferrous iron as an AgHO reaction product 
This reaction relies on 3-(2-Pyridyl)-5,6-diphenyl-1,2,4-triazine-p,p′-disulfonic acid, better 
known as Ferrozine [129]. Ferrozine binds iron, producing a distinct change in absorption at 
562nm as it does so. 
The reaction mixture (100µL solution, 10µM AgHO-haem complex, 3µM MdCPR, 
250µM Ferrozine, 300µM NADPH in a buffer of 150mM NaCL, 50mM Tris, pH 7.4, 0.1% 
Triton x100) was placed in a 90µL quartz cuvette. The reference cuvette contained only buffer 
and CPR. The reaction was initiated with addition of NADPH, and absorbance from 750nm to 
350nm was immediately measured. Absorbance was measured every ten minutes for two hours. 
 Control systems omitted, in turn, NADPH, CPR, and AgHO. The Ferrozine assay 
proved reliable, and was used to determine pH and temperature optima. 
 
4.2.9 AgHO pH experiments 
Each reaction mixture (200µL solution, 10µM AgHO-haem complex, 3µM MdCPR, 250µM 
Ferrozine, 300µM NADPH in a buffer of 150mM NaCL, 50mM Tris, 0.1% Triton x100) was 
placed in a well in a Nunc 96-well plate. There were six different pHs for the 50mM Tris buffer; 
6.5, 7.0, 7.5, 8.0, 8.5, 9.0. Four reaction wells were set up for each buffer – three experimental 
wells and one control well. The reaction was initiated with addition of NADPH, the control 
wells had buffer added rather than NADPH. Absorption at 562nm was measured every 15 
seconds for 5 minutes. 
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4.2.10 AgHO temperature experiments 
Each reaction mixture (200µL solution, 10µM AgHO-haem complex, 3µM MdCPR, 250µM 
Ferrozine, 300µM NADPH in a buffer of 150mM NaCL, 50mM Tris pH 7.4, 0.1% Triton 
x100) was placed in a well in a Nunc 96-well plate. Four reaction wells were set up– three 
experimental wells and one control well. The spectrophotometer was set to 20oC, then the plate 
was introduced and allowed to equilibrate to the correct temperature for five minutes. The 
reaction was initiated with addition of NADPH, the control wells had buffer added rather than 
NADPH. Absorption at 562nm was measured every 15 seconds for 5 minutes. The experiment 
was repeated at 25oC, 27.5oC, 30oC, 32.5oC, 35oC, 37.5oC and 40oC. 
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4.3 Results 
4.3.1 Spectral analysis of the AgHO-haem complex 
Using the AgHO-haem complex, the mode of the haem binding can be investigated. Human 
HO-1 has been observed to allow water, carbon monoxide and oxygen to co-ordinate to haem 
iron at the sixth “vacant” valence position, the others being four nitrogens in the porphyrin 
ring, and the proximal helix histidine [80]. DmΔHO has been observed not to bind in this way, 
however, and does not coordinate with histidine [76]. From the structural models in the 
previous chapter, it appears as though AgHO binds via histidine similar to HO-1 and 
dissimilarly to DmΔHO. In the AgHO-haem complexed form, haem iron is in a ferric state. 
 
 
Figure 4.1. Spectral shift of the AgHO-haem complex under different redox conditions 
– black is the ferric haem complex, red is the ferrous carbon monoxide-haem complex and 
green is the ferrous dioxyhaem complex 
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Table 4.1. Absorption maxima for haem complex spectra verify mode of haem binding 
Complex Soret peak 
maximum (nm) 
α peak maximum β peak maximum 
Ferric haem 398 603 579 
Ferrous CO-haem 412 564 535 
Ferrous Dioxyhaem 400 570 - 
 
 The spectra in Figure 4.1 show changes in haem-AgHO complex absorbance based on 
the oxidation state of haem iron. The absorption maxima for peaks of interest are shown in 
Table 4.1. The ferric form of the complex had a Soret Peak at 398nm, with smaller peaks in 
the visible region at 603nm and 579nm. Bubbling CO through the enzyme solution in the 
presence of sodium dithionite reduced the iron to a ferrous-CO form, with a Soret maximum at 
412nm, and smaller peaks at 564 and 535nm in the visible range. Exchange of the gas phase of 
the solution by passing through a Sephadex G-25 column indicated a conversion of the ferrous-
CO form to a ferrous dioxy form with Soret peak at 400nm and diminished α/β peaks. 
These changes correspond with haem-HO spectra observed for bacterial and eukaryotic 
haem oxygenases [106, 107, 109, 110]. 
 
4.3.2 Study of binding affinity of AgHO for haem 
The extinction coefficient of the AgHO-haem complex was calculated using the pyrimidine 
haemochrome method [127, 128]. The extinction coefficient at 398nm (ε398) was calculated to 
be 105.73mM-1 cm-1. This value was used to accurately estimate the concentration of the 
AgHO-haem complex during the calculation of the dissociation constant. 
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The binding affinity of AgHO haem was examined by titrating haem into cuvettes containing 
AgHO (sample) and buffer (control) and monitoring the absorption spectrum. Figure 4.2 shows 
the absorption spectra across this titration, and Figure 4.3 shows the absorption maxima across 
the titration. 
These data show that AgHO binds haem in a 1:1 stoichiometry since the Soret peak 
absorbance increases up to the point at which there is an equimolar concentration of AgHO and 
haem in the cuvette. After this point, continuing to add haem to both sample and reference 
cuvettes yields no increase at the Soret peak due to the fact that AgHO binding sites are 
saturated. Use of a one-site binding model estimates the dissociation constant (KD) for AgHO 
for haem to be 3.9 ± 0.6 µM. 
 
Figure 4.2. AgHO haem titration spectra Optical absorption spectra for 10μM AgHO 
titrated with 2-20μM of haem. 
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4.3.3 Identification of biliverdin as an AgHO reaction product 
Figure 4.4 shows haem catabolism with AgHO and three different CPRs: AgCPR, 
MdCPR and HsCPR. Each of the experiments shows a reduction in absorption at the haem 
Soret peak (398nm) and at the haem α/β peaks (603nm, 579nm), indicating catabolism of haem. 
Each experiment also shows the appearance of a broad absorption peak centred at 680nm, 
corresponding with one of the observed absorption peaks for biliverdin. 
AgCPR the lowest rate of activity of the CPRs tested as measured by the extent of the 
reduction of the Soret peak over two hours. This may be related to a lack of N-terminal 
membrane anchor, in comparison with MdCPR and HsCPR, which were both full length. 
Control systems did not yield reduction in absorption at the Soret peak or α/β peaks, there was 
also no recorded increase at 680nm. From this point forward, only MdCPR was used. 
 
Figure 4.3. Stoichiometry of haem binding to AgHO – Absorbance of the AgHO-haem 
complex at 412nm as a function of 412nm absorption 
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Figure 4.4. Absorption spectra showing detection of biliverdin as a reaction product of 
AgHO mediated haem catabolism A is with AgCPR, B is with MdCPR and C is with 
HsCPR. Black is the spectrum at time 0 (immediately after initiation of reaction by addition 
of NADPH), red is 2 hours after initiation 
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Figure 4.5. Spectral shift of myoglobin Soret peak shows production of CO by 
AgHO mediated haem catabolism – A - Soret peak absorbance maximum shifting to 
a higher wavelength as a result of CO binding, B - increase in absorbance at myoglobin 
α/β peaks as a result of CO binding 
Red is immediately after reaction initiation by addition of NADPH to control and sample 
cuvettes, black is 30 minutes after reaction initiation. 
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4.3.4 Identification of carbon monoxide as an AgHO reaction product 
Carbon monoxide is produced by HO mediated haem catabolism. It is undetectable by 
absorption spectroscopy, but can be observed indirectly by measuring CO binding to 
myoglobin. 
 Figure 4.5 shows the spectral differences of myoglobin brought about by the production 
of CO by haem catabolism. The myoglobin Soret peak shifts to a higher wavelength and the 
myoglobin α/β peaks have increased absorption. These changes are characteristic of CO 
binding to a haemoprotein. Control systems which were not initiated by NADPH, or which had 
no CPR reducing equivalent produced no such spectral changes in myoglobin. 
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Figure 4.6. Increase in absorption at 562nm shows Ferrozine binding to ferrous iron 
produced by AgHO mediated haem catabolism – A - Soret peak absorbance decreasing 
with haem catabolism, whilst absorbance at 562nm increases due to formation of Ferrozine-
ferrous iron complex; B – Increase in absorbance at 562nm due to formation of Ferrozine-
ferrous iron complex. 
Black is immediately after reaction initiation by addition of NADPH to control and sample 
cuvettes, red is 10 minutes after reaction initiation, green is 20 minutes after reaction 
initiation, blue is 60 minutes after reaction initiation. 
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4.3.5 Identification of ferrous iron as an AgHO reaction product 
As with CO detection, ferrous iron is not directly observable using absorption spectroscopy. 
Therefore ferrozine is used; ferrozine is an organic compound that binds Fe2+ ions [129]. 
 Figure 4.6 illustrates the release of Fe2+  by haem when degraded by AgHO. The peak 
centred at 562nm is characteristic of formation of a ferrozine - metal ion complex which is 
magenta in colour. The only possible ferrozine ligand in this reaction system is Fe2+, therefore 
the 562nm peak comes about due to ferrous iron being released during AgHO mediated haem 
catabolism. 
 This reaction is ideal to examine other parameters of the AgHO reaction, such at 
temperature and pH optima as the 562nm peak is in a region of the absorbance spectra area far 
removed  from potentially interfering peaks. Also, it will bind iron at a constant rate over a 
wide pH range (4-10) [129].  
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4.3.6 Effect of pH on AgHO 
The ferrozine assay was repeated across a range of pHs in order to examine the effect of pH on 
AgHO activity. The results are shown in Figure 4.7. 
 AgHO has the highest reaction rate at pH 7.5 (ANOVA; F(5,12) = 4.568, p = 0.0145), 
mirroring physiological conditions. Reaction rate drops off rapidly at pH 9, possibly due to 
inhibition of AgHO binding to haem via haem propionate groups, or due to denaturation of the 
functional conformation of AgHO. 
 
 
Figure 4.7. The pH optimum for AgHO activity is pH 7.5 – Using formation of Fe2+-
ferrozine complex to measure the AgHO reaction rate shows that activity is highest at 
around pH 7.5. 
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4.3.7 Effect of temperature on AgHO 
The ferrozine assay was repeated across a range of temperatures in order to examine the effect 
of temperature on AgHO activity. The results are shown in Figure 4.8. 
 Highest activity was measured at 27.5oC (ANOVA; F(7,16) = 4.459, p = 0.0063), with 
activity minimal at 20oC. 
  
 
Figure 4.8. The temperature optimum for AgHO activity is 27.5oC – Using formation 
of Fe2+-ferrozine complex to measure the AgHO reaction rate shows that activity is highest 
at around 27.5oC. 
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4.4 Discussion 
This chapter represents the first time that a haematophagous insect HO has been isolated and 
characterised in vitro. Binding studies confirmed that AgHO binds haem in a 1:1 stoichiometry. 
Similarities in Soret and α/β peak maxima between AgHO, rat and Corynebacterium haem 
oxygenases [107, 109] provide evidence that the AgHO binding site is similar, with H19 at the 
proximal haem face and coordination via a water molecule with T15. 
The KD of AgHO was estimated to be 3.9 ± 0.6 µM using a one-site binding model. 
This value is comparable to previously measured dissociation constants of 2.5 ± 1 µM for C. 
diphtheriae HmuO [109] and 0.84 ± 0.2 µM for human HO-1 [130], however it is far lower 
than the 27 ± 1 µM value obtained for DmΔHO [76]. The disparity between AgHO and 
DmΔHO may have arisen due to the unique nature of DmΔHO binding, which does not appear 
to be shared by AgHO. 
 Analysis of the AgHO reaction shows that AgHO is a true haem oxygenase, in that it 
conforms to the previously observed haem degradation pathway of haem being hydrolysed to 
form biliverdin, carbon monoxide and ferrous iron. Biliverdin has been observed to be 
produced from enzymatic haem degradation, measured by increases at 680nm wavelength, as 
the haem Soret peak at 398nm decreases in absorbance. Carbon monoxide and ferrous iron 
production have been observed indirectly by their effects on the absorbance of myoglobin and 
ferrozine respectively. Haem catabolism was found to be inefficient when using a truncated 
AgCPR, compared to full length HsCPR and MdCPR. This suggests that the hydrophobic tail 
of CPRs are an important aspect of HO:CPR docking. Further experiments using truncated 
HsCPR and MdCPR would be useful to determine the accuracy of this hypothesis. 
 The data obtained on AgHO driven haem degradation in this chapter have been 
qualitative. Quantitative analysis of HO reactions are difficult, particularly without employing 
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biliverdin reductase. Biliverdin reductase (BVR) is a mammalian enzyme not present in An. 
gambiae which catalyses the conversion of biliverdin to bilirubin, a spectroscopically distinct 
reaction product with a Soret peak at 460 nm. Mammalian haem oxygenase studies have 
successfully employed biliverdin reductase to examine kinetic parameters of HOs. Use of BVR 
in AgHO systems did not yield any results, possibly due to divergent BVR binding residues in 
AgHO inhibiting BVR:AgHO docking [82]. 
 Ferrozine has only once been used as a substrate for measuring haem oxygenase activity 
[131]. Here it has been found to have a number of advantages for the characterisation of AgHO 
activity. Firstly, the change in its absorbance that arises when ferrozine binds ferrous iron is 
away from other, potentially interfering spectroscopic peaks, such as the Soret peak. Secondly, 
it can be easily employed in a microplate style assay, thus facilitating examinination of 
variables such as temperature and pH parameters on enzyme activity, as its complexation with 
iron is stable across most biologically relevant temperatures and pHs. With further work, this 
assay may be able to accurately examine the kinetics of AgHO with respect to haem, something 
that is otherwise intractable given the spectroscopic changes when haem is bound by AgHO, 
and following catabolism. Another advantage is direct comparison between HOs, without the 
need for BVR. Comparing the reaction rates of HOs using BVR is confounded by the fact that 
both the reaction rate of haem degradation and the BVR:HO docking is being measured 
simultaneously, whereas the ferrozine assay only measures liberation of ferrous iron. The assay 
also has potential for future work with haem oxygenase inhibitors. 
 The pH and temperature parameters discovered for AgHO are consistent with the 
physiological context of AgHO. Vertebrate blood has a pH of 7.4, increasing to 7.6 when 
ingested by Anopheles. Moreover, eukaryotic cytosol pH is 7.4. The temperature optimum for 
AgHO was 27.5oC, which corresponds to the behaviour of blood fed mosquitoes that seek 
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temperatures in the range of 26-28oC at which to rest [132]. The high AgHO activity during 
the post-bloodmeal resting phase might aid in rapid digestion. 
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Chapter 5 – Development of a bioassay to investigate the in 
vivo role of AgHO 
5.1 Introduction 
As has been discussed in previous chapters, the disposal of excess haem is a vitally important 
process which prevents the oxidative damage that high concentrations of haem can inflict [40-
43]. Given the huge quantities of haem released by An. gambiae over the course of 
haemoglobin digestion, it is clear that mechanisms to limit haem toxicity are of key importance. 
These mechanisms are yet to have been studied in detail in An. gambiae. Some, such as 
formation of haem aggregates, have arisen independently in numerous species as diverse as 
blood flukes [133], malaria parasites [52], and haematophagous insects including R. prolixus 
[56], Ae. aegypti and An. gambiae [134]. Other defence mechanisms include haem binding 
proteins, which have been investigated in blood feeding insects [61, 135], but not An. gambiae. 
 Disposal of haem is carried out by the haem oxygenase enzyme in an extremely wide 
range of species, from bacteria to mammals. It makes sense that AgHO acts in concert with 
other mechanisms (aggregation, haem binding proteins) to ameliorate haem-mediated toxicity. 
It has been observed that in haematophagous insects [77, 78], including An. gambiae (data not 
shown), that the bloodmeal changes from a red to a green colour, and in other insects, this has 
been associated with a reduction in haem concentration and an increase in biliverdin IX 
concentration. This is likely the result of haem oxygenase activity. 
 Having expressed recombinant AgHO and examined its haem oxygenase activity in 
vitro, the next step is to examine its in vivo role and insecticide target potential. AgHO knockout 
can be achieved by gene knockout or via inhibition of enzyme activity. Time constraints 
precluded the use of RNAi, therefore this chapter aims to estimate the in vivo role of AgHO 
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via inhibition of AgHO activity by ingestion of inhibitors. Previous studies in R. prolixus have 
shown that tin protoporphyrin inhibits haemozoin formation and haem degradation, resulting 
in the promotion of oxidative stress and reduction in reproductive capacity [100]. These results 
show that haem analogues may be used to inhibit HO activity and examine physiological 
outcomes. The aim of this chapter, is to develop a viable bioassay to apply AgHO inhibitors to 
An. gambiae mosquitoes. The second aim is to use this assay to study the role of the AgHO 
mediated haem degradation pathway using a range of haem analogues – zinc protoporphyrin 
(ZnPP), tin protoporphyrin (SnPP) and copper protoporphyrin (CuPP).  
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5.2 Materials and Methods 
5.2.1 Feeding inhibitory globins to An. gambiae as part of a bloodmeal 
5.2.1.1 Preparation of inhibitory globins 
Inhibitory globins were made using the acidified butanone method [100, 136]. A solution of 
50mg mL-1 bovine haemoglobin was dialysed against ddH2O for 16 hours at 4
oC. The pH of 
the protein solution was adjusted to 2.0 with dropwise addition of 1M HCl. The haemoglobin 
was placed in a 50mL falcon tube on ice alongside falcon tubes containing butanone. 
Once ice cold, the butanone was mixed gently with the protein solution and left on ice, 
shaking at 40rpm for 2 hours. The mixture was left to stand for ten minutes to allow the two 
liquid phases to separate. The organic phase was removed using a serological pipette and 
analysed for haem content on a spectrophotometer. This process was repeated at least three 
times, until no more haem was detected in the organic phase. The aqueous phase was 
extensively dialysed against ddH2O for 16 hours at 4
oC to remove any remaining butanone. 
The dialysed globin product was mixed in an equimolar mount of 5mM ZnPP-IX 
dissolved in DMSO to make the metalloporphyrin-globin complex, referred to hereafter as 
ZnPP-globin. 
 
5.2.1.2 Feeding inhibitory globins to mosquitoes 
Cohorts of An. gambiae mosquitoes, strain Kisumu, were bloodfed on heparinized human 
blood supplemented with 0μM, 40μM, 100μM and 400μM ZnPP-globin. The inhibitor 
supplement was in a volume of 500μL, added to 4.5mL blood. The mosquitoes were fed via 
hemotek bloodfeeders, for two hours, in darkness. Mosquitoes were visually confirmed to have 
fed. Those individuals which had not fed were excluded. 25 individuals from each feeding 
group were isolated and kept under standard conditions (see Chapter 2), and fed 10% sucrose 
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ad libitum. After two days, an egg paper was introduced to allow mosquitoes to lay. After two 
further days, the egg paper was removed and laid eggs were counted. 
 
5.2.2 Microinjection of protoporphyrin into An. gambiae 
5.2.2.1 Determination of ZnPP amount to microinject 
In order to establish a quantity of ZnPP to microinject into An. gambiae thoraces, the bloodmeal 
volume was weighed. This was achieved by cold-anaesthetising mosquito cohorts before a 
bloodfeed, and weighing them. The mosquito cohort was then allowed to bloodfeed as normal. 
After the bloodfeed, the mosquitoes would be anaesthetised and weighed again. An average 
bloodmeal size was determined by calculating the difference in the mass of the cohort. The 
mosquitoes are not allowed access to 10% sucrose during the bloodmeal here, to ensure that 
changes in weight are strictly related to the bloodmeal and not sugar consumption. These 
calculations are outlined in Table 5.1, where bloodmeal volume is calculated based on a blood 
density of 1.06 g cm-3. These figures are in line with previously reported mosquito bloodmeal 
sizes  
 
Table 5.1. Bloodmeal sizes in An. gambiae, strain Tiassale 
Mass of 50 
mosquitoes, pre-
bloodmeal  (g) 
Mass of 50 
mosquitoes, post-
bloodmeal (g) 
Mass of 50 
bloodmeals (g) 
Mean mass of An. 
gambiae 
bloodmeal (mg) 
Mean volume of 
An. gambiae 
bloodmeal (μL) 
0.0583 0.145 0.0868 1.74 1.64 
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5.2.2.2 Microinjection of ZnPP 
Based on the calculations in Table 5.1, 65 nL 10mM ZnPP was injected into the thoracic 
cavities of An. gambiae strain Tiassale mosquitoes whilst cold-anaesthetised. 10mM NaOH 
was used as a solvent. As previously, surviving mosquitoes were isolated in groups of ten (one 
group injected with an equivalent of 400μM ZnPP, the other with an equivalent volume of 
NaOH solvent) and kept under standard conditions and fed 10% sucrose ad libitum. After two 
days, an egg paper was introduced to allow mosquitoes to lay. After two further days, the egg 
paper was removed and laid eggs were counted. 
5.2.3 Feeding free protoporphyrin to An. gambiae as part of a bloodmeal 
10mM ZnPP stocks were made by dissolving ZnPP in 50mM NaOH. The ZnPP was added to 
blood in a volume of no more than 200μL in 5mL heparinized human blood. Final 
concentrations of ZnPP in blood were 0μM, 40μM, 100μM and 400μM ZnPP. 
Cohorts of An. gambiae mosquitoes, strain Tiassale, were fed the inhibitor-
supplemented blood via hemotek bloodfeeders, for two hours, in darkness. Mosquitoes were 
visually confirmed to have fed. Those individuals which had not fed were excluded. 25 
individuals from each feeding group were isolated and kept under standard conditions (see 
Chapter 2), and fed 10% sucrose ad libitum. After two days, an egg paper was introduced to 
allow mosquitoes to lay. After two further days, the egg paper was removed and laid eggs were 
counted. 
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5.3 Results and Discussion 
5.3.1 Trials of AgHO inhibition methods 
5.3.1.1 Effect of bloodmeal ZnPP-globin on An. gambiae fecundity 
Figure 5.1 shows preliminary data suggesting that application of ZnPP-globin could have a 
dose dependent effect on oviposition rates in An. gambiae. Increasing concentrations of ZnPP-
globin over the range chosen yield a measurable reduction in oviposition, therefore this is a 
potentially viable bioassay. 
  
 
 
 
Figure 5.1. Dose dependent response of oviposition to concentration of ZnPP-globin in 
the bloodmeal (experiment performed once) 
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5.3.1.2 Effect of microinjected ZnPP on An. gambiae  
Table 5.2 shows that injection of ZnPP has a detrimental effect on An. gambiae fecundity, 
meaning that it has potential as a bioassay. Table 5.3 shows that up to 90% of mosquitoes were 
unable to be resuscitated following microinjection. There is not a significant difference 
between mortalities in different treatment cohorts, indicating that mortality here is due to either 
the procedure itself (mechanical damage from thoracic microinjection) or the NaOH solvent. 
This solvent cannot be changed, as an equimolar amount of OH- is a requirement for dissolving 
ZnPP. An alternative solvent, DMSO, is incompatible with the microinjection apparatus. The 
mortality during fecundity analysis is estimated after ten surviving mosquitoes from the 
microinjection procedure are isolated and provided with sugar water. 
 
Table 5.2. Effect of microinjected ZnPP on fecundity 
Equivalent concentration of ZnPP (μM) Eggs laid by cohort of ten mosquitoes 
0 407 
400 0 
 
Table 5.3. Effect of microinjected ZnPP on mortality 
Equivalent concentration of 
ZnPP (μM) 
Mosquito mortality within 1 
hour of microinjection 
procedure 
Mosquito mortality during 
fecundity analysis (96 hours) 
0 89% 20% 
400 90% 20% 
 
 
  
91 
 
5.3.1.3 Effect of bloodmeal ZnPP on mosquito fecundity 
Figure 5.2 shows that like ZnPP-globin, free ZnPP has a dose dependent effect on mosquito 
fecundity. Again, increasing concentrations of ZnPP over the range chosen yield a measurable 
reduction in oviposition, therefore this is a potentially viable bioassay. 
 
5.3.1.4 Evaluation of methods of in vivo haem oxygenase inhibition 
All the tested protocols for in vivo AgHO inhibition yield a phenotype in which oviposition is 
inhibited by high concentrations of ZnPP. However, each assay has advantages and 
disadvantages. 
 Application of ZnPP-globin has the advantage of being ingested similar to natural 
ingestion of haemoglobin. It resulted in a measurable phenotype (reduction in oviposition). The 
 
Figure 5.2 – Dose dependent response of oviposition to concentration of ZnPP in the 
bloodmeal (experiment performed once) 
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major shortcoming of this protocol is the creation of the inhibitory globin. The process is very 
resource-wasteful, expensive and time-consuming. Also, haem removal from the globin is not 
100% efficient, and is difficult to quantify. It is therefore difficult to estimate how accurate the 
inhibitory globin concentration is. There is no guarantee that the inhibitory globin is formed as 
predicted; this assay may simply involve the application of inhibitory protoporphyrin in 
conjunction with globin protein. Furthermore, a battery of controls would be required to 
conclusively state that the inhibition occurring is due to the inhibitor itself, or because other 
factors, such as diluted nutrient, application of malformed globin or trace amounts of solvents 
such as DMSO or butanone. 
 Though microinjection of protoporphyrin directly into the mosquito thorax did achieve 
a differential phenotype between control and inhibitor treatments, the bioassay is a poor one. 
Firstly, since the injection is into the thorax and not into the bloodmeal bolus itself, the 
treatment is not representative of AgHO application in the midgut. This makes the calculation 
of an equivalent of 400μM in the bloodmeal is irrelevant. This is also a very time consuming 
assay. The biggest concern is mosquito mortality. The fact that only ten percent of mosquitoes 
survive the injection procedure makes this assay extremely wasteful in terms of live mosquito 
resources. There is also a concern that the effects of inhibitors are exaggerated, as the mosquito 
system is dealing with massive mechanical damage, in addition to the hypothesised oxidative 
stress. 
 The best assay is the feeding of free protoporphyrin via the bloodmeal. It has most of 
the advantages of the protoporphyrin-globin assay, with none of the drawbacks. One potential 
shortcoming is the fact that the application of inhibitor is not the same as in the globin assay, 
i.e. there is no digestion of haemoglobin to release inhibitor. In this respect it may not be as 
accurate at estimating the normal in vivo function of AgHO. However, in terms of potential for 
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insecticide development, it is just as useful. The free protoporphyrin feeding bioassay is the 
one which will be used for the remainder of the in vivo inhibition analysis. 
 
5.3.2 Effect of HO inhibitors on oviposition 
 Three different haem-analogues were applied as in section 5.2.3: ZnPP, SnPP and 
CuPP. Both zinc [98] and tin [137] protoporphyrins are canonical haem oxygenase inhibitors, 
and copper protoporphyrin is a canonical control for haem oxygenase inhibition - that is, it does 
not inhibit the haem oxygenase reaction, but does participate in other physiological processes 
which other inhibitors do, such as inhibition of guanylyl cyclase [138]. Figures 5.3 and Figure 
5.4 show that there is a dose dependent response in which, as the concentration of inhibitory 
protoporphyrin in the bloodmeal increases, oviposition rates decrease. This trend is present in 
both ZnPP (ANOVA; F(3,8) = 40.44, p < 0.0001) and SnPP (ANOVA; F(3,8) = 135.2, p < 
0.0001) , and appears to be more potent in SnPP, in line with previous mammalian studies 
[137]. 
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Figure 5.3. Dose dependent response of oviposition to ZnPP in the bloodmeal 
 
Figure 5.4. Dose dependent response of oviposition to SnPP in the bloodmeal 
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Figure 5.5 shows the application of CuPP to mosquitoes via the bloodmeal, and shows 
an insignificant effect on fecundity (t-test, t(4) = 0.69, P = 0.53). There seems to be a small 
impact on fecundity, possibly related to background effects of protoporphyrin feeding, but too 
insignificant to draw conclusions from, other than that CuPP works as a negative control in An. 
gambiae as it does in mammalian systems. 
 
 
  
 
Figure 5.5. Increasing CuPP concentration in the bloodmeal does not effect oviposition 
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5.4 Conclusion 
This chapter represents the first time a HO inhibitor’s effects on mosquitoes have been 
estimated, and points towards the utility of using HO inhibitors in vector control. The role of 
AgHO as a dietary detoxificant is shown here. Use of the CuPP negative control suggests that 
the effect on oviposition by ZnPP and SnPP is due to inhibitory effects on the haem degradation 
pathway, as opposed to effects on other physiological processes, such as the guanylyl cyclase 
pathway. 
 What has not yet been ascertained is the specific mode of action of these inhibitors in a 
physiological context. Whilst it seems clear that these inhibitors compete for the active site of 
haem oxygenase [139], it is not necessarily clear why this should have an effect on oviposition. 
One possibility is oxidative stress on the mosquito. It has been shown that inhibition of haem 
oxygenase with SnPP-globin leads to an increase in oxidative stress in R. prolixus [100], and 
oxidative stress is a known factor towards decreased reproductive fitness in insects [140]. 
Another factor to look at is the reaction products of haem oxygenase, and whether or not these 
are essential for any aspect of oogenesis. The fate of biliverdin is largely unknown, however in 
Ae. aegypti, 7% of total blood meal iron is directed to egg formation [119]. It may follow that 
without sufficient iron from haem degradation, oogenesis is arrested. Another possibility is 
lack of carbon monoxide. Haem degradation is a key source of carbon monoxide, and given its 
role as a signalling molecule, a lack of endogenous CO may inhibit signals involved with 
oviposition behaviour or nutrient trafficking in oogenesis. 
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Chapter 6 – Functional comparison of insect and human 
cytochrome P450 reductases 
 
6.1 Introduction 
NADPH-dependent cytochrome P450 reductase (EC 1.6.2.4) is a membrane bound enzyme 
required for electron transfer from the NADPH electron donor to a number of diverse electron 
acceptors, including flavoproteins like squalene monooxygenase, and haemoproteins such as 
the cytochromes P450, cytochrome b5 and haem oxygenase. Transfer occurs along the pathway 
NADPH → FAD → FMN → haem. 
CPRs from numerous organisms have been expressed and characterised, including H. 
sapiens, R. norvegicus, Petroselinum crispum, Musca domestica and An. gambiae. In most 
organisms except plants (which contain multiple CPR genes [141]), CPR is a single gene, 
believed to have evolved as a result of gene fusion between an FMN- and an FAD-containing 
flavoprotein [142]. These two domains remain functionally and structurally distinct, and can 
be heterologously expressed as functionally active separate enzymes. 
In total, there are four CPR domains [142]. There are the two major catalytic domains, 
the FMN-binding domain, structurally similar to flavodoxins, and the NADPH/FAD-binding 
domain, which is structurally similar to ferredoxin-NADP+ reductase. There is also a linker 
domain that likely plays a role in positioning the two catalytic domains for optimal electron 
transfer [87]. The fourth domain is the transmembrane region, which is relatively structurally 
unknown owing to difficulties in its crystallisation. 
The FMN-binding domain is the point at which electrons are transferred from the CPR 
enzyme cofactors to the haem moiety on the electron accepting enzyme. In cytochromes P450, 
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electrons are further transferred to perform a monooxygenase reaction which catabolises their 
substrate. In haem oxygenase, the transferred electrons are used for haem degradation. 
Accordingly, the FMN-binding domain contains negatively charged residues important for 
binding at the haem pockets of HO and P450s [86, 143, 144]. 
CPR enzymes have high levels of conservation at residues involved in cofactor binding 
and orientation. HsCPR and AgCPR have an amino acid similarity of 53.3% and an amino acid 
identity of 54.1%. However, despite such high conservation, differences in cofactor binding 
are evident between these two CPRs that suggest that AgCPR may be a target for selective 
inhibition.[90]. It has been found that AgCPR has a KD for 2’ 5’ ADP which is ten-fold lower 
than that of HsCPR, explaining why it fails to bind 2’ 5’ ADP-Sepharose columns (these 
columns can usually be used to affinity purify CPRs [86, 144, 145]). It was also found that 
HsCPR was more sensitive to inhibition by nucleotide analogue inhibitors (such as 2’ 5’ ADP) 
which bind at the NADPH binding site. 
These differences may be a random reflection of the phylogenetic distance between 
HsCPR and AgCPR, or alternatively, they may be due to differences in biology. Examination 
of these two CPRs, alongside other haematophagous and non-haematophagous insects may 
inform which of these explanations is more likely. 
This chapter aims to address the question of whether AgCPR is a selective target for 
inhibition, and to what extent differences in cofactor binding or other biochemical aspects 
differ amongst insects. Given the predicted importance of haem oxygenase for haem 
detoxification, the question of whether there are functional differences separating the CPRs of 
haematophagous and non-haematophagous insects is raised, particularly as regards possible 
preferences for HO interaction over interaction with P450s. 
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6.2 Materials and Methods 
6.2.1 High-Throughput Expression Screening 
The screening procedure was conducted according to standard OPPF procedures [146]. 
DNA was available from sources in the Vector Department at Liverpool School of 
Tropical Medicine. mRNA Apis mellifera was obtained from Dr Graham Moores at 
Rothamsted Research Institute, H. sapiens cDNA was obtained from the Parasitology 
Department at LSTM. Where the source material was mRNA, it was used as a template for 
cDNA synthesis. The HsCPR amino acid sequence was used for a Blast query in order to 
identify the CPRs shown in Table 6.1. Their cDNA sequences are shown in Appendix 6.1. 
Table 6.1. CPR accession numbers 
CPR Accession Number Database used 
AaCPR AAEL003349-RA Vectorbase 
AgCPR AGAP000500-RC Vectorbase 
AmCPR XP_006569767.1 Beebase 
CqCPR CPIJ014664 Vectorbase 
DmCPR NP_477158.1 Flybase 
GmCPR GMOY007231-RA Vectorbase 
HsCPR NP_000932.3 NCBI CCDS database 
RpCPR RPRC005729-RA Vectorbase 
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cDNA templates were used as templates for PCR amplification using KOD Hot Start 
DNA polymerase (except in the repeated PCR of AmCPR, where Phusion Flash DNA 
polymerase was used) Since the protocol uses pOPIN expression primers and the InFusion 
enzyme system. Primers were designed to be complementary to the gene fragment of interest 
(in this case, the CPR cDNA) at the 3’, and to the pOPIN cloning site at the 5’. Primers are 
detailed in Appendix 5.3. PCR products were analysed using agarose gel electrophoresis. 
The PCR products were purified using AMPure XP Magnetic Bead Purification. 
Because the templates were held in pJET1.2, which has the same antibiotic resistance marker 
as pOPIN-F (amplicillin), the reaction products were DpnI treated to eliminate false positives 
with ampicillin selection on agarose plates. 
The purified inserts were next cloned into linearised pOPIN-F using lyophilised 
InFusion recombinase by mixing followed by incubation at 42oC for 30 minutes. These newly 
created plasmids were then immediately used to transform OmnimaxII E. coli cells. These cells 
were grown overnight at 37oC on LB agar containing ampicillin, X-Gal and IPTG. 
Two positive white colonies were picked per construct and used to inoculate Power 
Broth and grown overnight at 37oC, shaking at 220rpm. These cultures were used for Miniprep 
and for creation of glycerol stocks. The Minipreps were verified using PCR with KOD Hot 
Start DNA Polymerase. 
Constructs were verified for correct coding sequence by sequencing before expression. 
Each plasmid was used to transform, separately, B834(DE3) and Rosetta(DE3)LysS E. coli 
cells. The transformed cells were grown overnight at 37oC on LB agar containing the 
appropriate antibiotic(s). 
Individual colonies were picked and used to inoculate Power Broth and grown 
overnight at 37oC, shaking at 220rpm. 
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The cultures were used to inoculate either fresh Power Broth or Overnight Express 
Instant TB Medium, these cultures were grown at 37oC, shaking at 220rpm for 3-5 hours, until 
the OD reached 0.5. At this point the Power Broth cultures were moved to an incubator set to 
20oC, shaking at 220rpm. Once the cultures had equilibrated to the lower temperature, they 
were induced by addition of IPTG. Overnight Express cultures were moved to an incubator set 
to 25oC, shaking at 220rpm. This culture autoinduces. Both sets of cultures were left in the 
incubators for 24 hours. 
These cultures were subjected to freeze-thaw and lysozyme cell lysis followed by Ni-
NTA purification. The purified cell lysates were visualised using SDS-PAGE. 
 
6.2.2 Scaled up expression and purification of CPRs 
Expression was carried out largely as described in Chapter 2. The cell line used for 
transformation was BL-21*, and the growth medium was TB. After IPTG induction, incubation 
was carried out at 25oC for 16h. Purification was carried out as described in Chapter 2; the 
wash buffer used was 150mM NaCl, 50mM Tris HCl pH 7.4, 20mM imidazole, and the elution 
buffer was 150mM NaCl, 50mM Tris HCl pH 7.4, 200mM imidazole. 
 Pooled pure fractions had their protein concentration determined by Bradford assay, 
and were reconstituted with FMN at a concentration of 2:1 FMN:CPR. The CPRs were then 
applied to a PD-10 column to desalt and remove excess unbound flavin, as per the protocols in 
Chapter 2. The PD-10 column was pre-equilibrated with 150mM NaCl, 50mM Tris HCl pH7.4, 
which was also used to elute the protein from the column. 
The CPR activity assay was performed at regular intervals over the course of the 
purification procedure to ensure that active CPR was present. The samples tested were the cell 
lysate post sonication, the initial Ni-NTA flowthrough (to ensure that a significant amount of 
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enzyme was not being lost), the eluted Ni-NTA fractions, the pooled sample, and the PD-10 
eluate. 
 
6.2.3 Cytochrome P450 reductase activity assay 
CPR activity was measured by cytochrome c reduction when using NADPH as an electron 
donor. 1μL of the enzyme source (cell lysate, Ni-NTA column flowthrough fractions, or pooled 
purified enzyme) was added to 150µL of 100mM cytochrome c in a 96 well plate in duplicate. 
150µL of H2O was added to one well as a negative control, 150µL of 100mM NADPH was 
added to the other. Absorbance at 550nm was immediately monitored every 20 seconds for 5 
minutes. The slope of the curve was compared between the initiated reaction well and the 
negative control in order to confirm CPR activity. 
 
6.2.4 Spectral analysis of CPRs 
For the oxidised spectrum, 1.5μM of purified CPR in a sample buffer (150mM NaCl, 50mM 
Tris HCl, pH 8.0) was placed in a 1mL quartz cuvette and scanned from 700 – 380nm in a Cary 
4000 absorption spectrophotometer. For the reduced spectrum, NADPH was added from a 
5mM stock to a final concentration of 1.5μM, and the sample scanned immediately. The 
solution was incubated at room temperature for 30 minutes and scanned again to obtain the air-
stable semiquinone spectrum [90]. 
 
6.2.5 Cytochrome c kinetics 
The rate of change of absorbance of horse heart cytochrome c (Sigma-Aldrich, UK) at 550 nm 
was measured at 25°C using a Biotek Epoch platereader essentially as described [90]. 0.75 
pmol purified CPR was pre-incubated with 0–110 µM cytochrome c (dissolved in 0.3 M 
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potassium phosphate buffer; pH 7.7 in a total volume of 200µl for 2 min at 25°C. Reactions 
were initiated by the addition of NADPH to a final concentration of 50 µM and rates measured 
in triplicate for 2 mins, a linear reaction range. 
 
6.2.6 NADPH kinetics 
The rate of change of absorbance of horse heart cytochrome c (Sigma-Aldrich, UK) at 550 nm 
was measured at 25°C using a Biotek Epoch platereader essentially as described [90]. 0.75 
pmol purified CPR was pre-incubated with 50 µM cytochrome c (dissolved in 0.3 M potassium 
phosphate buffer; pH 7.7 in a total volume of 200µl for 2 min at 25°C. Reactions were initiated 
by the addition of NADPH to a final concentration of 0-160 µM and rates measured in triplicate 
for 2 mins, a linear reaction range. 
 
6.2.7 Inhibition measurement 
Measurement of cytochrome c reduction was carried out at 25°C with 50 µM 
cytochrome c and 0.75 pmol purified AgCPR or hCPR essentially as described [90]  using 0.3 
M potassium phosphate buffer, pH 7.7, and different concentrations of 2′, 5′-ADP, 2′-AMP, 
NADP or diphenyliodonium chloride (Sigma-Aldrich, UK). Reactions were initiated by the 
addition of NADPH to the final concentrations shown in Table 6.2 corresponding to their 
apparent KM values. 
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Table 6.2. Final concentration of NADPH in each inhibition experiment – Concentration 
corresponds with the experimentally determined KM value for the CPR 
CPR AgCPR AmCPR CqCPR DmCPR HsCPR RpCPR 
NADPH concentration 
(μM) 
13 21 34 31 4 25 
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6.3 Results 
6.3.1 Identification of candidate species for CPR analysis 
CPR candidates were selected from a range of available species that would allow the study of 
haematophagous, non-haematophagous and mammalian enzymes. The species chosen were 
An. gambiae, Ae. aegypti, C. quinquefasciatus, D. melanogaster, G. morsitans and R. prolixus.  
 
6.3.2 High throughput expression of CPR  
Each CPR had two variants to be screened: a full length gene and an N-terminal 
truncation to enhance solubility [90, 147]. The limits of this N-terminal domain were defined 
by alignments with previously truncated CPRs, namely AgCPR and HsCPR. 
As PCR is often the rate limiting step of an expression screen, the full length genes 
were amplified and cloned into pJET2.1 to be used as PCR templates. 
 All of the initial amplifications were successful with the exception of AmCPR 
constructs. These underwent a second attempt at PCR amplification, this time with a range of 
annealing temperatures. The PCR was successful for AmCPR with a higher annealing 
temperature (62oC).
 These amplicons were cloned into pOPIN-F. Miniprepped pOPIN-FCPR plasmids were 
subjected to PCR to confirm that the cloning was successful. Only full length AaCPR and full 
length DmCPR failed to be cloned and transformed correctly. The fact that pOPIN-F primers 
and the InFusion method were used eliminates the need to check that the insert is in the plasmid 
in the correct orientation, as would be necessary with traditional T4 ligase mediated cloning. 
 All the successfully cloned CPRs were used in expression trials. Figure 6.4 shows the 
cell lysates from these expression trials after being subjected to Ni-NTA purification. AmCPR, 
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CqCPR, DmCPR, HsCPR and RpCPR all had constructs with successful expression. 
Successful expression came from those constructs with the N-terminal transmembrane domain 
removed (see Appendix 6.4 for truncation details). These five CPRs were taken forward for 
scaled up expression and characterisation. AaCPR and GmCPR had negligible expression, and 
were discontinued. The pOPIN-AgCPR also failed to express, therefore a pETM-11-AgCPR 
expression clone was provided by Dr. M. Paine for expression [90]. 
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Figure 6.1 Ni-NTA purified CPRs from OPPF expression screening 
Lane 1, AaCPR; Lane 2, truncated AaCPR; Lane 3, AgCPR; Lane 4, truncated AgCPR; 
Lane 5, AmCPR; Lane 6, truncated AmCPR; Lane 7, CqCPR; Lane 8, truncated 
CqCPR; Lane 9, DmCPR; Lane 10, truncated DmCPR; Lane 11, GmCPR; Lane 12, 
truncated GmCPR; Lane 13, HsCPR; Lane 14, truncated HsCPR; Lane 15, RpCPR; Lane 
16, truncated RpCPR; Lane 17, GFP Control; Lane 18, molecular weight markers 
Bold typeface denotes those expressions which were judged to be successful, and would 
have their expression scaled up. 
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6.3.3 Expression and purification of CPRs 
Scaled up expression was attempted with each of the successfully expressed CPRs from the 
OPPF screen and with AgCPR. 
Figure 6.4 shows the purified protein expressed by the CPR constructs (Appendix 6.4). 
Yields for these soluble CPR proteins are described in Table 6.3. All the CPRs were tested for 
cytochrome c reductase activity and found to be functionally active. 
 
 
 
Figure 6.2. Pooled Ni-NTA purified CPRs from scaled up expression 
Lane 1, molecular weight marker; Lane 2, AgCPR; Lane 3, AmCPR; Lane 4, CqCPR; Lane 
5, DmCPR; Lane 6, HsCPR; Lane 7, RpCPR; Lane 8, molecular weight marker 
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Table 6.3. Yields of expressed CPRs 
CPR Yield, mg protein per litre of culture 
AgCPR 3.2 
AmCPR 5.6 
CqCPR 17.0 
DmCPR 3.4 
HsCPR 8.4 
RpCPR 10.3 
 
6.3.4 Alignment of CPRs and analysis of primary amino acid structure 
The six expressed CPRs are shown aligned in Figure 6.3. A high degree of sequence identity 
is evident, particularly those residues highlighted in Table 6.4. Previously observed differences 
in 2’ 5’ ADP binding between AgCPR and HsCPR could correspond with differences in 
binding residues at the NADPH binding domain. 
AgCPR residues implicated in NADPH binding include R300, R569 and K570 (binding 
of adenine-ribose 5’ phosphate), S596, R597, K602 and Y604 (binding of adenine-ribose 2’ 
phosphate), and W677 (facilitation of electron transfer to FAD). These residues are identified 
by homology with the three-dimensional structure of HsCPR [86]. All of these residues are 
identical in both enzymes with the exception of K570, where HsCPR has an arginine residue 
at the equivalent position. The differences between 2’ AMP binding in AgCPR and HsCPR 
range from negligible to two times stronger in AgCPR, however 2’ 5’ ADP binding is 6 – 10 
fold higher in HsCPR [90]. The divergent K570 residue, which is implicated in binding at the 
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adenine 5’ phosphate may explain the difference in nucleotide analogue sensitivities between 
these two enzymes. 
There is minimal divergence in the residues associated with FMN and FAD binding, 
which is unsurprising given how crucial cofactor positioning is for the function of the CPR 
enzyme. T474 is a cysteine in HsCPR, a conservative change which allows for hydrogen 
bonding between FAD and the amino acid residue. 
The E216, D217, Y218 sequence is an acidic patch allowing for docking with redox 
partners. HsCPR has glutamic acid at the D217 position, which is a conservative change. 
AmCPR, CqCPR, DmCPR, HsCPR and RpCPR all have aspartic acid at the Y218 position, 
likely corresponding with divergences in redox partners.  
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Figure 6.3. Amino acid alignment of six CPRs showing high conservation between 
enzymes Highlighted are known CPR binding motifs. Black shading denotes complete 
conservation, grey denoted conserved divergences 
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 The c. 6kDa membrane anchor domain (Figure 6.6) is the region of least homology. 
However they are all predominantly hydrophobic. 
 One of the most important amino acid residues in CPR is the C-terminal tryptophan. 
This residue stacks against the isoalloxazine ring on FAD, and initially shields it from the 
nicotinamide cofactor. The residue is the focus of a conformational change in the CPR protein, 
and this conformational change facilitates hydride transfer from NADPH to FAD. 
 
Table 6.4. Conservation of important residues in CPRs (Amino acid numbering is according 
to AgCPR sequence) 
Residue Function Conservation 
T91 Hydrogen bonding to FMN 
phosphate 
Conserved 
T93 Hydrogen bonding to FMN 
phosphate 
Conserved 
T142 Hydrogen bonding to FMN 
re face 
Conserved 
 
Figure 6.4. CPR membrane domains with hydrophobic residues highlighted 
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Y143 Stacking with FMN re face Conserved 
G144 Hydrogen bonding with 
FMN re face 
Conserved 
G146 Hydrogen bonding with 
FMN re face 
Conserved 
N178 Hydrogen bonding with 
FMN si face 
Conserved 
Y181 Stacking with FMN si face Conserved 
H183 Hydrogen bonding with 
FMN si face 
Conserved 
N185 Hydrogen bonding with 
FMN si face 
Conserved 
D210, D211, D212 Acidic residues associated 
with redox partner binding 
Conserved 
E216, D217, Y218 Acidic residues associated 
with redox partner binding 
D217E in HsCPR, Y218D in 
all other CPRs 
R300 Binding with 5’ phosphate on 
adenosine ribose moiety of 
NADPH 
Conserved 
R456 Hydrogen bonding with FAD 
si face 
Conserved 
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Y458 Stacking with FAD si face Conserved 
S459 Hydrogen bonding with FAD 
si face, stabilises 
semiquinone form of FAD 
Conserved 
T474 Hydrogen bonding with FAD 
adenine 
T474C in HsCPR 
A475 Hydrogen bonding with FAD 
adenine 
Conserved 
V476 Hydrogen bonding with FAD 
adenine 
Conserved 
Y480 Stacking with FAD adenine Conserved 
V491 Hydrogen bonding with FAD 
pyrophosphate 
Conserved 
T493 Hydrogen bonding with FAD 
pyrophosphate 
Conserved 
C567 Cofactor recognition at 2’ 
phosphate, allows 
conformational change for 
nicotinamide binding 
Conserved 
R569 Binds NADPH adenosine 
ribose 5’ phosphate 
Conserved 
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K570 Binds NADPH adenosine 
ribose 5’ phosphate 
K570R in HsCPR 
S596 Binds NADPH adenosine 
ribose 2’ phosphate 
Conserved 
R597 Binds NADPH adenosine 
ribose 2’ phosphate 
Conserved 
K602 Binds NADPH adenosine 
ribose 2’ phosphate 
Conserved 
Y604 Binds NADPH adenosine 
ribose 2’ phosphate 
Conserved 
C631 Promotes hydride transfer via 
stabilization of the transient 
carbocation formed upon 
release of hydride ion 
Conserved 
D675 Hydrogen bonding network 
with S459 and C631 – 
maintains orientation of FAD 
for hydride transfer, 
stabilises semiquinone FAD  
Conserved 
W677 Stacks with FAD re face, 
changes conformation to 
allow close proximity 
between FAD and NADPH 
Conserved 
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nicotinamide, facilitates 
initial cofactor binding and 
hydride transfer 
 
 
6.3.5 Spectral analysis of CPRs 
 The visible absorption spectra for the six expressed CPRs are shown in Figure 6.5. All 
produced characteristic diflavin reductase spectra with absorption maxima at 379nm and 
454nm. Addition of a stoichiometric amount of NADPH produced a characteristic increase in 
the 500-650nm regions of the spectra indicating formation of an air-stable flavin semiquinone, 
as has been seen previously in human and insect CPRs [90, 147, 148]. Increases in absorption 
in the 340nm – 350nm region are associated with NADPH oxidation to NADP+, after the 
electrons have been stripped of NADPH by the CPR, and passed to the flavin cofactor [148-
150]. 
 
  
118 
 
 
 
Figure 4.3 – Absorption spectra of purified AgCPR 
 
Figure 6.7. Absorption spectra of purified CPRs. Spectra are measured on 1.5 µM 
enzyme. Traces show the oxidised spectra; the reduced spectra with 1.5 µM NADPH and 
measured after 10 seconds; and the air-stable semiquinone measured after 30 min. 
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6.3.6 Cytochrome c kinetics of CPRs 
 All six of the CPRs catalysed the reduction of cytochrome c following Michaelis-
Menten kinetics with respect to cytochrome c concentration. The Vmax, KM and Kcat values are 
shown in Figure 6.8 and Table 6.5. The HsCPR KM for cytochrome c was the lowest; the insect 
CPRs having 2-7 fold greater KM values. Amongst the insect KM values, AgCPR had the lowest 
KM, and DmCPR had the highest value. 
 
 
 
 
Figure 6.8. Initial reaction rates for CPRs at different concentrations of cytochrome c 
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Table 6.5. Catalytic parameters for CPRs with respect to cytochrome c concentration 
 
 
 
 
 
 
Table 6.6. Catalytic parameters for CPRs with respect to NADPH concentration 
Enzyme AgCPR AmCPR CqCPR DmCPR HsCPR RpCPR 
Vmax (nmol 
cytochrome c 
reduced/min/nmol) 
4123 (+/- 107) 2243 (+/- 85) 3716 (+/- 215) 10559 (+/- 433) 1354 (+/- 56) 2214 (+/- 99) 
KM (µM) 12.73 (+/- 1.2) 20.97 (+/- 2.43) 34.17 (+/- 5.03) 30.68 (+/- 3.32) 3.68 (+/- 0.84) 24.98 (+/- 3.17) 
Kcat (s-1) 8.4 9.2 13.4 30.1 5.7 9.9 
Enzyme AgCPR AmCPR CqCPR DmCPR HsCPR RpCPR 
Vmax (nmol 
cytochrome c 
reduced/min/nmol) 
1857 (+/- 125) 2019 (+/- 58) 2954 (+/- 79) 7315 (+/- 370) 1262 (+/- 63) 2181 (+/- 151) 
KM(µM) 14.74 (+/- 3.44) 21.75 (+/- 1.87) 16.57 (+/- 1.47) 43.32 (+/- 5.10) 6.63 (+/- 1.52) 22.35 (+/- 4.56) 
Kcat (s-1) 8.42 9.15 13.39 33.16 5.72 9.89 
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6.3.7 NADPH kinetics of CPRs 
All six of the CPRs catalysed the reduction of cytochrome c following Michaelis-Menten 
kinetics with respect to NADPH concentration. The Vmax, KM and Kcat values are shown in 
Figure 6.8 and Table 6.6. Following a similar trend to the KM values with respect to cytochrome 
c, the HsCPR KM for NADPH was the lowest, and the insect CPRs had 3-8 fold greater KM 
values. Amongst the insect KM values, AgCPR had the lowest KM, and DmCPR had the highest 
value. 
 
 
Figure 6.8. Initial reaction rates for CPRs at different concentrations of NADPH 
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6.3.8 In vitro Inhibition of CPRs 
 In order to investigate differences in inhibition characteristics between the insect and 
mammal CPRs, four CPR inhibitors were used [90]. Three of these inhibitors, 2’5’ ADP, 5’ 
AMP, and NADP+, (see Figure 6.10) are nucleotide analogues of NADPH, which act as 
competitive inhibitors; binding at the NADPH binding domain [148, 151]. The fourth, DPIC 
(Figure 6.11), is an irreversible CPR inhibitor, which is thought to mediate inhibition via an 
NADPH dependent mechanism which results in a covalent modification of FMN (Figure 6.12 
full mechanism in figure caption) [152].[152]  
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Figure 6.10 – Structures of nucleotide analogue inhibitors of CPRs A – 2’5 adenine 
diphosphate (2’5’ ADP), B – 5’ adenine monophosphate (5’ AMP), C – nicotinamide 
adenine dinucleotide phosphate, reduced form (NADP+) 
 
 
Figure 6.11 – Structure of diphenyliodonium chloride (DPIC) A non-competitive 
inhibitor of CPRs  
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Figure 6.12 – Mechanism of DPIC mediated inhibition of CPR via covalent 
modification of FMN 
This mechanism starts with fully reduced enzyme and DPIC. One electron is then 
transferred from DPIC to the fully reduced FMN, giving a flavin semiquinone and a 
diphenyliodonium radical. This diphenyliodonium radical then fragments into a phenyl 
radical and iodobenzene. The phenyl radical can now recombine with the flavin 
semiquinone, which results in an aromatic group being covalently, and irreversibly attached 
to the isoalloxazine of FMN [152]. 
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 All six CPRs were inhibited by all four inhibitory compounds to varying extents 
(Figures 6.12-6.17) IC50 values are shown in Tables 5.6 and 5.7 and are defined as being the 
concentration of inhibitor at which activity of the enzyme is reduced by 50% [148]. 
 
 
Figure 6.12 IC50 curves for AgCPR with CPR inhibitors 
 
Figure 6.13. IC50 curves for AmCPR with CPR inhibitors 
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Figure 6.14. IC50 curves for CqCPR with CPR inhibitors 
 
 
Figure 6.15. IC50 curves for DmCPR with CPR inhibitors 
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Table 6.7 IC50 values for CPRs with CPR inhibitors 
Inhibitor AgCPR AmCPR CqCPR DmCPR HsCPR RpCPR 
IC50 
(μM) 
log IC50 
(μM) 
IC50 
(μM) 
log IC50 
(μM) 
IC50 
(μM) 
log IC50 
(μM) 
IC50 
(μM) 
log IC50 
(μM) 
IC50 
(μM) 
log IC50 
(μM) 
IC50 
(μM) 
log IC50 
(μM) 
2’ AMP 402.2 2.60 (+/- 
0.17) 
760.5 2.88 (+/- 
0.08) 
507.6 2.71 (+/- 
0.07) 
557.6 2.75 (+/- 
0.18) 
301.2 2.48 (+/- 
0.09) 
614.4 2.79 (+/- 
0.10) 
2’ 5’ ADP 27.4  1.44 (+/- 
0.17) 
46.4 1.67 (+/- 
0.17) 
64.1 1.81 (+/- 
0.07) 
214.6 2.33 (+/- 
0.11) 
6.6 0.82 (+/- 
0.10) 
56.6 1.75 (+/- 
0.07) 
NADP+ 57.1  1.76 (+/- 
0.06) 
107.8 2.03 (+/- 
0.11) 
105.1 2.02 (+/- 
0.04) 
155.1 2.19 (+/- 
0.05) 
40.2 1.61 (+/- 
0.05) 
112.3 2.05 (+/-  
0.03) 
DPIC 10.2 1.01 (+/- 
0.21) 
16.5 1.21 (+/- 
0.09) 
3.5 0.54 (+/- 
0.09) 
4.9 0.69 (+/-
0.19) 
61.0 1.79 (+/- 
0.17) 
7.1 0.85 (+/-  
0.16) 
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 Of the competitive nucleotide analogues, 2’ AMP was the inhibitor to which all of the 
CPRs tested were least sensitive, with IC50 values ranging from 301 to 760 μM. The nucleotide 
to which the CPRs were most sensitive was 2’5’ ADP, with IC50 values ranging from 6 to 214 
μM. DmCPR, however, is an exception to this trend, and is more sensitive to NADP+ than 2’5’ 
 
Figure 6.16. IC50 curves for HsCPR with CPR inhibitors 
 
Figure 6.17. IC50 curves for RpCPR with CPR inhibitors 
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ADP (155.1 μM for NADP+ and 214.6 μM for 2’5’ ADP). These data collectively differ from 
the previously found trend for AgCPR where NADP+ is the stronger nucleotide analogue 
inhibitor [90]. 
Between the CPRs, there was least difference in sensitivity to 2’ AMP. HsCPR and 
AgCPR were most readily inhibited, and the IC50 value found for HsCPR (301.2 μM) was less 
than half that of AmCPR (760.5μM) and RpCPR (614.4μM). 
With respect to NADP+, HsCPR was most sensitive; the IC50 (40.2μM) was 2 fold lower 
than all insect CPRs apart from AgCPR, which had a similar IC50 value of 57.1μM and DmCPR 
(155.1μM), where was the IC50 was three fold lower. 
2’5’ ADP produced the strongest inhibition in all CPRs apart from DmCPR. HsCPR 
was again, the most sensitive. The IC50 value for HsCPR (6.6μM) was four times lower than 
AgCPR (27.4μM), over 30 times lower than DmCPR (214.6μM), and 7-10 times lower than 
the other CPRs (46.4 - 64.1μM). 
Finally, DPIC is the only inhibitor for which HsCPR is least sensitive. The IC50 of 
HsCPR for DPIC is 61.0 μM, which is 4-20 times higher than the insect IC50 values (3.5 – 
16.5μM). The sensitivity of insect CPRs to DPIC is also noteworthy in that these values are 
very low in comparison with nucleotide inhibitors. In CqCPR and DmCPR, the IC50 for DPIC 
is 20 – 30 times lower than the most inhibitory nucleotide.  
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6.4 Discussion 
Cytochrome P450 reductase is the obligate redox partner for endoplasmic cytochromes 
P450s and haem oxygenase. Thus CPR is an attractive synergist target, because blocking CPR 
activity would essentially block the activity of both P450s and the HO system [153, 154]. 
HsCPR and AgCPR have previously been observed to have differences with respect to 
nucleotide binding, specifically, AgCPR has been observed to have 10 fold weaker binding 
with 2’5’ ADP than HsCPR [90]. This chapter aims to explore whether these differences extend 
to other insect CPRs, and whether there is any evidence to suggest that there are any differences 
in activity related with a bloodfeeding habit. In order to examine these questions, CPRs from 
six different organisms were cloned and expressed. These included three haematophagous 
insects from two distinct orders (An. gambiae and C. quinquefasciatus from Diptera, and R. 
prolixus from Hemiptera), two non-haematophagous insects from separate orders, (A. mellifera 
from Hymenoptera, and D. melanogaster from Diptera) and one mammal (H. sapiens). Two 
other CPRs were trialled, but their expression was unsuccessful (Ae. aegypti and G. morsitans). 
This study provides the first direct comparison of a range of different insect CPRs with 
human CPR. Expression of soluble recombinant enzymes have allowed for experimental 
observations of kinetic parameters of CPRs and to analyse their inhibition by competitive and 
non-competitive inhibitors. These assays were conducted using the cytochrome c reductase 
assay; cytochrome c reductase is an artificial electron acceptor that produces a change in 
absorbance at 550nm associated with a distinct colour change upon reduction.  
The Vmax values had a similar trend in each kinetic analysis, regardless of whether or 
not the NADPH or cytochrome c concentration was being altered. In both of these kinetic 
experiments, the HsCPR had the lowest Vmax, the three haematophagous insect CPRs and 
AmCPR all had similar Vmax values. Of note is AgCPR, which had a higher Vmax 
NADPH than 
four of the other CPRs, whereas its Vmax 
cyt c was only higher than that of HsCPR. DmCPR is a 
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huge outlier with respect to its Vmax values. It’s Vmax with respect to both substrates is more 
than double that of the other CPRs, and it’s Vmax NADPH is approximately an order of magnitude 
greater than that of HsCPR. 
In terms of KM, again, HsCPR had the lowest values in each kinetic analysis. The KM 
cyt c
 values have exactly the same trend as the Vmax 
cyt c
 values, with the non-haematophagous 
and AmCPR having similar kinetic parameters, and the DmCPR having a markedly higher 
value. The KM
NADPH values are not so straightforward, and there is not so obvious a trend. With 
the exception of the fact that the KM 
NADPH
 for CqCPR and DmCPR is a full order of magnitude 
higher than that of HsCPR, the KM 
NADPH values are similar, and do not follow the same trend 
as the Vmax
 NADPH
 values. 
When comparing the CPRs, particularly of note was DmCPR, which was revealed to 
have a much higher maximum velocity than the other CPRs studied (10 fold in some cases), 
both with respect to NADPH and cytochrome c. Of interest is the fact that KM, which has a 
strong association with tightness of binding (i.e. the higher the KM value, the looser the binding, 
generally speaking), is lower in those CPRs with lower Vmax values, implying that those 
enzymes with a lower maximum reaction velocity have a tighter bind to their substrates. In 
terms of the NADPH binding,  this possibility has previously been considered [151]. The 
conformational change induced by NADPH binding acts upon the C terminal tryptophan 
present in all characterised CPRs. Upon NADPH binding, the protein confirmation alters such 
that the tryptophan moves from its inactive position in which it is shielding the isoalloxazine 
ring on FAD, facilitating hydride transfer from NADPH to FAD. It has previously been 
considered that looser NADPH binding might allow for quicker conformational changes and 
hence quicker hydride transfer and NADP+ clearance [151].  
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However, as the KM cyt c values also generally increased alongside an increase in Vmax 
cyt c, it must be considered that the loose nucleotide binding pocket hypothesis may not be 
relevant to this discussion. This is partially corroborated by the fact that the trends are not 
perfect, for instance, the KM NADPH for AgCPR is the second lowest, whereas its Vmax NADPH is 
the second highest. Other explanations for increased Vmax values independent of a trend in KM 
include more thermodynamically favourable configurations for hydride transfer across the two 
flavin cofactors. Accurate crystal structures would provide more of an insight into how valid 
this hypothesis is. Although since hydride transfer from NADPH for FAD has been found to 
be the rate limiting step in previously studied CPRs, I would suggest that the FAD positioning 
relative to the C terminal tryptophan is more important. The documented Bi-Bi kinetic 
mechanism for CPRs and the distinct cytochrome c and NADPH binding sites [86] suggest that 
the KM values for each substrate do not experimentally confound one another. 
Results showed that all of the insect CPRs had weaker binding for nucleotide analogue 
inhibitors than HsCPR. Inhibition by 2’5’ ADP was between 4 and 32 fold higher in HsCPR 
than the insect CPRs. Likewise, NADP+ and 2’ AMP inhibition was strongest in HsCPR. 
Variation in nucleotide inhibition amongst the insect CPRs does not follow a trend associated 
with bloodfeeding. DPIC inhibition is weaker in human CPR than in insect CPRs, but does not 
follow a trend associated with haematophagy. Overall, the CPRs examined showed variable 
activities, but none to suggest a viable species selective target, though the DPIC mode of action 
(covalent modification of FMN) is more inhibitory to insect CPRs than to humans. 
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Chapter 7 – General Discussion 
This study has explored in depth, what was, until now, a hypothetical haem oxygenase in 
Anopheles gambiae. Recombinant AgHO has been cloned, expressed, and used in biochemical 
assays to verify that it is a canonical haem oxygenase enzyme which catabolises haem into 
biliverdin. The in vivo role of AgHO was examined using an inhibition bioassay. This bioassay 
revealed a key role in insect physiology in that haem oxygenase inhibition led to a marked 
decrease in oviposition. This study also biochemically compared the cytochrome P450 
reductases of humans and five insects, and found that there were no significant enzymatic 
differences between the CPRs of haematophagous and non-haematophagous insects. 
 
7.1 Introduction 
 Malaria is the most important disease in the world, and of its numerous anopheline 
vectors, An. gambiae is the most important because of its wide sub-Saharan distribution, its 
developing insecticide resistance, and its propensity to spread the most frequently lethal strain 
of malaria, Plasmodium falciparum. Because of its importance, An. gambiae is the best 
organism to study novel targets for insecticides for vector control. Lessons learned from such 
study of An. gambiae can be directly applied to malaria control, and inform strategies for the 
control of other vectors. 
 The mosquito bloodmeal is of clear importance. From the point of view of the mosquito 
life cycle, the bloodmeal is a necessity for egg development and production of progeny. Disease 
transmission occurs through the bloodmeal also, therefore it has great potential to be a vector 
control target. Indeed, even outside of vector control, transmission-blocking or “altruistic” 
vaccines directly rely on the bloodmeal for their effect [155, 156]. 
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 As explained in the introductory chapter, haem detoxification methods are a key 
adaptation of haematophagous insects to survive the threat of massive oxidative stress posed 
by haem. Of these adaptations, enzymatic degradation by haem oxygenase remains the least 
well characterised. Addressing this point, and establishing whether or not this haem 
degradation system could be a viable target for insecticides is the purpose of this thesis. 
 
7.2 In silico investigation of AgHO 
The high levels of amino acid identity and similarity between AgHO and other HOs indicates 
that the enzymes are homologous to one another, and these haem oxygenase enzymes share 
evolutionary history. The extent of this homology and conservation suggest that the HO 
enzyme is of vital physiological importance, not only to haematophages. 
 The most highly conserved amino acids of the haem oxygenase protein are those in the 
enzyme active site, and those which are involved with CPR docking. When comparing known 
key amino acid residues between AgHO and human HO-1, it is clear that most residues have 
semi-conservative mutation, conservative mutation or are non-divergent. 4 residues are 
divergent, two of which are involved with haem binding (somewhat on the periphery of the 
active site) and two are involved with CPR binding.  
 Creation of a structural homology model of AgHO reinforces its similarity to HO-1. In 
essence, the haem oxygenase enzyme in both cases is a binding pocket made up of two α-
helices which contain positively charged amino acids which perform two main functions: 
substrate recognition and orientation, and docking with the FMN domain on CPR. 
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7.3 Expression of recombinant AgHO 
Expression of recombinant AgHO was initially difficult. Of a range of nine successfully cloned 
AgHO constructs of varying length, only one yielded soluble protein. Heterologous expression 
of eukaryotic proteins in bacterial systems often leads to insoluble protein products, due to 
dissimilar expression machinery and potential for formation of inclusion bodies and aggregates 
[157]. 
 One clone of AgHOΔ31 was used to successfully express soluble enzyme, and 
unsurprisingly, this construct was the one most similar to previously expressed HOs [76, 80]. 
This soluble protein was however, catalytically inactive. This is unexpected, considering that 
previously expressed proteins which were truncated in a similar way were catalytically active. 
Examination of the structural model shows that the polypeptide removed from the enzyme in 
the expressing clone extended into an α-helix which appears to be part of the main enzyme 
unit, as opposed to simply part of an external transmembrane region. 1D-NMR spectroscopy 
provided confirmation that the AgHOΔ31 was misfolded. This explains the lack of catalytic 
activity, and the source of this misfolding is most likely due to the truncation being too large. 
 In order to overcome the difficulties in enzyme expression, a codon-optimised, full 
length AgHO gene was synthesised. The codon optimisation coupled with the lack of 
truncation allowed for the successful expression of a catalytically active haem oxygenase 
enzyme. 
7.4 Identification of AgHO reaction products 
A series of biochemical tests have been used to prove that AgHO is a canonical haem 
oxygenase. Haem oxygenases are defined as those enzyme which catabolise molecular haem 
with the addition of oxygen. The products of this reaction are biliverdin, ferrous iron and carbon 
monoxide. NADPH is used as a reducing equivalent, and is converted to NADP+ over the 
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course of this reaction. In order to state that AgHO is a true haem oxygenase, each of these 
reaction products was identified in turn. 
 Biliverdin was identified using a straightforward absorption spectroscopy assay. AgHO 
and a CPR were incubated with NADPH and haem and monitored spectroscopically. Over 
time, the haem Soret peak was reduced, indicating the breakdown of haem, and a broad peak 
at 680nm was seen. This broad 680nm peak is characteristic of biliverdin. At the same time, 
the absorbance at 340nm was seen to be reducing, indicating that NADPH was being converted 
into NADP. 
 When haemoproteins bind to carbon monoxide, their absorption spectra change due to 
changes in electron spin in the haem molecule. This phenomenon was used to examine the 
production of carbon monoxide by the haem oxygenase reaction. Myoglobin, which is 
otherwise inert in this reaction system, was added to the haem oxygenase reaction and 
monitored spectroscopically. Movement of the myoglobin Soret peak to a higher wavelength 
confirmed the presence of carbon monoxide. 
 Lastly, ferrozine was used to observe the liberation of ferrous iron over the course of 
the haem oxygenase reaction. Ferrozine is an organic molecule which acts as a bidentate ligand 
for certain metal ions, among them, ferrous iron [129]. As it binds metal ions, ferrozine 
produces a magenta coloured complex, which corresponds with a distinct change in absorption 
at 562nm. Application of ferrozine to the AgHO assay produced evidence that ferrous iron is 
released over the course of the reaction. 
 Ascorbic acid was not used as an artificial reducing agent as it has been in previous HO 
characterisations [76], instead CPRs were used. Where ascorbate was used previously, a 
truncated CPR (DmΔCPR) and a truncated HO (DmΔHO) was used initially, and there was 
little activity. The data in Chapter 4 show that AgHO is compatible with full-length HsCPR 
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and MdCPR, however less catalytically active when an AgCPR with N-terminal truncation. 
Together, these findings suggest that the hydrophobic tail regions are key to efficient docking 
between insect HOs and CPRs. As my study had successful CPR mediated electron transfer, 
ascorbate was unnecessary. 
 
7.5 Estimation of AgHO optima 
The ferrozine assay proved to be the most reliable and repeatable assay due to its distinct 
absorption maximum. For this reason, it was used to estimate pH and temperature optima for 
the AgHO reaction. 
 The pH optimum was found to be close to pH 7.5, which makes perfect sense. Both 
cytoplasmic and blood pHs are approximately pH 7.4. Activity dropped off rapidly at pH 9, to 
an extent which suggested enzyme denaturation. The temperature optimum was a very 
interesting case, being found to be approximately 27.5oC. It is interesting, as this matches 
previously found data which suggest that the ideal resting temperature, post-bloodmeal is 26-
28oC [158]. 
 One of the most valuable insights taken from this part of the study is the application of 
the Ferrozine assay to haem oxygenase research. The fact that the Fe2+-Ferrozine complex has 
a constant rate of formation and a known extinction coefficient means that this assay can be 
used to reliably compare the activities of different haem oxygenases. 
 With some thought, a ferrozine based assay could be designed to probe the effects of 
haem oxygenase inhibition by the protoporphyrin inhibitors employed in Chapter 6. One of the 
problems with assaying these inhibitors is that they have their own absorption profiles which 
obscure interpretation of the AgHO-haem Soret peak. Also, the standard assay uses an AgHO-
haem complex rather than incubating free haem with the enzyme. This is, again, because of 
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difficulties in interpreting the Soret peak, in this case when AgHO binds haem. Employing 
ferrozine should avoid these problems. 
 
7.6 The in vivo role of AgHO and viability of AgHO as an insecticide target 
This project has also involved the development of an AgHO inhibition bioassay, largely based 
on previous work conducted in the American trypanosomiasis vector, R. prolixus [100]. This 
study differs from the R. prolixus study in that here, numerous methods of inhibitor application 
have been trialled. Application of free protoporphyrin has been seen to be the most reliable and 
cheapest method of inhibiting haem oxygenase in vivo. Another advantage over the R. prolixus 
study is that application of free protoporphyrin gives a clearer insight into the phenotype of an 
HO-inhibitory insecticide. 
 This project has found that SnPP and ZnPP being applied in the bloodmeal has an 
inhibitory effect on oviposition in the mosquito. The exact mode of action is still obscure, but 
candidates include inhibition of carbon monoxide signalling, lack of nutrients for oogenesis 
and poor fitness due to oxidative stress. Similarly to the R. prolixus study, no effects on 
mortality were observed. This is likely due to other strategies to ameliorate haem mediated 
toxicity, such as formation of aggregates or binding proteins, or it could simply be that the dose 
was not high enough to mediate insect death. Application of a CuPP control showed that the 
inhibitory effects of the protoporphyrins were on haem oxygenase, rather than other enzyme 
systems. 
 Gene knockdown via RNAi would give an additional insight into the in vivo role of 
haem oxygenase, and this is a clear next step for HO research in Anopheles. It would have the 
advantage of eliminating background fitness effects, although the CuPP control to an extent 
showed the “background” of protoporphyrin application. Again, using these inhibitors in an in 
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vitro AgHO assay would conclusively prove that AgHO inhibition is the mode of action of 
these compounds in inhibiting oviposition. 
A potential advantage of this approach surrounds the relationship between midgut haem 
and parasites. A focus of this project is the toxicity of haem, so it is significant that it is not 
only vector species that are vulnerable to haem toxicity, but so are the parasites the vectors 
transmit. There is strong evidence that haem mediates cell lysis in Trypanosoma brucei [159], 
Plasmodium berghei [160] and P. falciparum [161]. Inhibition of vector HO may well increase 
midgut haem concentrations, which might contribute to vector refractoriness by making the 
midgut a more toxic milieu.  
There are potential hurdles to the field use of these inhibitors; they would not be 
selective to vector species, and would potentially be toxic to other organisms. A method of 
introducing these inhibitors to vector diet without risking leaking into the environment would 
have to be devised. These inhibitors are also expensive, and are not very water soluble. The 
best application for these inhibitors may be a proof of principle for the vector control potential 
of HO inhibition. An in silico approach to rational insecticide design could take over to find a 
more field suitable HO inhibiting insecticide. 
Another potential means of inhibiting AgHO as part of a vector control strategy could 
be the use of altruistic vaccines. Chapter 3 showed that inactivated AgHO can successfully be 
used to generate antibodies, and hence an immune response. If these antibodies bind in a 
position on the enzyme such that they block haem entering the active site, or block AgCPR 
docking, then AgHO could be a viable altruistic vaccine target. Caution must be taken to ensure 
that the immune response is not cross-reactive with any of the human HOs, however α-AgHO 
antibodies have been shown to not have cross-reactivity with GmHO (G. P. G. de Lima, 
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personal communication), so provided the right AgHO epitopes are used, this should not be a 
problem. 
 
7.7 Comparison of CPR activities and inhibition profiles 
High-throughput expression screening allowed for comparison of six CPRs from a range of 
organisms: three haematophagous insects, two herbivorous insects and humans. The initial 
hypothesis in advance of this study was that there are key differences in haematophage CPRs 
related to their blood feeding habit. This hypothesis was based on previous findings which 
showed different inhibitor binding profiles between human and An. gambiae CPRs [90]. 
The hypothesis was not found to be true however. Firstly, kinetic assays were 
performed on the CPRs, with respect to both cytochrome c and NADPH. In terms of Vmax and 
KM parameters, the insect CPRs are somewhat distinct from HsCPR, but there is no clear 
divergence in activity based on haematophagy. D. melanogaster CPR is massively different to 
the other CPRs, having markedly higher parameters relating to a higher activity. 
Four inhibitors were used to obtain IC50 values for each CPR: NADP, 2’5’ ADP, 2’ 
AMP and DPIC. 2’5’ ADP was the inhibitor which had previously been found to have a 
different inhibitory profile in humans and mosquitoes [90], and a difference in sensitivity was 
found here also. Again however, the difference was clearer between humans and insects, rather 
it being a trait restricted to haematophages. 
One of the more compelling features of this study is that HsCPR is not particularly 
sensitive to DPIC, whereas all the insect CPRs are. This finding suggests that the mode of CPR 
inhibition performed by DPIC (that is covalent binding to FMN, rather than active site 
competition as with the nucleotide analogues) could be an avenue of future research for 
insecticides or insecticide synergists. 
  
141 
 
7.8 Conclusion and perspectives 
Drawing from the conclusions found during this study, the following conclusions can be made: 
(i) the AgHO gene codes for an haem oxygenase enzyme which catalyses the degradation of 
free haem into biliverdin, carbon monoxide and ferrous iron; (ii) AgHO inhibition in vivo 
results in decreased oviposition and therefore has potential as an insecticide or synergist target; 
(iii) there is no association between activity or nucleotide binding characteristics of CPR 
enzymes and a blood feeding habit, and there is nothing to suggest that there is a viable species 
selective target. 
 The results gathered in this project do not go as far as to present AgHO inhibition as a 
viable insecticide target as yet. There are numerous avenues that can be pursued to achieve a 
more holistic understanding of AgHO using both in vitro and in vivo approaches. 
Crystallisation of AgHO would be of great utility to make more concrete conclusions on the 
structure of AgHO. The structure would also allow for more detailed comparison with the other 
crystallised haem oxygenases and would provide a template for rational insecticide design. The 
expense to produce and light sensitivity of the haem analogues used in Chapter 5 indicate poor 
suitability for IRS or LLINs. It is unknown whether these compounds would work when not 
directly ingested, and there are potential issues with lack of species specificity. These 
difficulties with protoporphyrins suggest that other compounds which target haem oxygenases 
need to be designed and trialled. The histidine in the haem oxygenase binding site suggests that 
an imidazole derivative may hold promise. Any likely insecticide candidate would have to then 
have its target product profile thoroughly tested to ensure suitability for use in the field. 
Alongside crystallisation, other potential areas of biochemical characterisation would 
be to validate the importance of important amino acid residues (such as the histidine mentioned 
above) involved in propionate binding, Fe2+ coordination and CPR docking by using site 
directed mutagenesis. Also, as mentioned above, in vitro validation of the use of α-AgHO 
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antibodies and whether or not they block the access of haem to the active site, or CPR docking 
would be a proof of principle approach to an altruistic AgHO vaccine. 
Another future research perspective would be to isolate and identify the biliverdin 
produced by AgHO in vitro, and to examine whether the AgBV produced in vivo has any pre- 
or post-hydrolysis modifications as in R. prolixus [77] and Ae. aegypti [78], and whether the 
biliverdin produced is exclusively BV-IXα. One option for further study of AgHO inhibition 
in vivo would be to compare the amounts of biliverdin produced by the mosquito when 
subjected to AgHO inhibition by protoporphyrin analogues. This would provide evidence of 
the extent of AgHO inhibition. Likewise, analysis of oxidative stress in An. gambiae when 
exposed to protoporphyrin analogues would help to explore the hypothesis that AgHO is 
working in a detoxification capacity. AgHO knockdown using RNAi would similarly be a 
powerful tool. 
It is important to remember that AgHO does not act alone, in two ways. Firstly, it cannot 
degrade haem without the assistance of CPR. CPR is somewhat of a generalist redox partner, 
so if the goal of a novel insecticide were to target the haem degradation pathway, CPR presents 
an attractive target, not only because its inhibition would indirectly inhibit AgHO, but also 
because knocking out CPR would knock out the P450 system (and thus, insecticide resistance) 
[91]. A novel insecticide based on, for example, DPIC would act simultaneously as an 
insecticide and an insecticide synergist, so should be explored. AgHO also does not act alone 
considering that haematophages have an array of other strategies to block haem toxicity. The 
extent that AgHO inhibitors also inhibit haem binding proteins and the formation of haem 
aggregates should be examined. 
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Appendices 
Appendix 3.1 – Phylogram of haem oxygenases 
 
Phylogram generated using ClustalW Phylogeny. Shown distance values are in units of number 
of substitutions as a proportion of the length of the alignment. 
 
 
 
 
 
Appendix 3.2 – Primers designed 
Primer 
name 
Primer function Primer sequence (5’ – 3’) 
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pJETF Initial amplification from cDNA for blunt end 
ligation into pJET1.2. Forward primer. NdeI 
restriction site. 
GAGACATATGGCACAAAATGTG
CCTTTTTCG 
pJETR Initial amplification from cDNA for blunt end 
ligation into pJET1.2. Reverse primer. HindIII 
restriction site. 
AAGCTTTCACAACGTTTGCTCTT
GCTCGTG 
pOPINFF Amplification from pJET1.2 for ligation into 
pOPIN-F. Forward primer 
AAGTTCTGTTTCAGGGCCCGATG
GCACAAAATGTGCCTTTTTCG 
 
pOPINFR Amplification from pJET1.2 for ligation into 
pOPIN-F. Reverse primer, full length. 
ATGGTATAGAAAGCTTTACAACG
TTTGCTCTTGCTCGTG 
 
pOPINFRA Amplification from pJET1.2 for ligation into 
pOPIN-F. Reverse primer, AgHOΔ10. 
ATGGTATAGAAAGCTTTAGTTTC
GCACGACGTACTGC 
 
pOPINFRB Amplification from pJET1.2 for ligation into 
pOPIN-F. Reverse primer, AgHOΔ15. 
ATGGTATAGAAAGCTTTACTGCA
TTAATATGATGGCAGC 
 
pOPINFRC Amplification from pJET1.2 for ligation into 
pOPIN-F. Reverse primer, AgHOΔ31. 
ATGGTATAGAAAGCTTTAACGCA
TGTTGGCCGAACCAAC 
 
pOPINFRD Amplification from pJET1.2 for ligation into 
pOPIN-F. Reverse primer, AgHOΔ46. 
ATGGTATAGAAAGCTTTAGTGTT
GTTCAGTTCGAACACTTTC 
 
pOPINFRE Amplification from pJET1.2 for ligation into 
pOPIN-F. Reverse primer, AgHOΔ60. 
ATGGTATAGAAAGCTTTACGCTG
GCGCGTTTCCTCGTCCAG 
 
pOPINFRF Amplification from pJET1.2 for ligation into 
pOPIN-F. Reverse primer, AgHOΔ73. 
ATGGTATAGAAAGCTTTACCACA
ATTTTGCGCAAACGTTG 
 
pOPINFRG Amplification from pJET1.2 for ligation into 
pOPIN-F. Reverse primer, AgHOΔ83. 
ATGGTATAGAAAGCTTTAGTAAA
TGCTGTGATCTTCGAATG 
 
pOPINFRH Amplification from pJET1.2 for ligation into 
pOPIN-F. Reverse primer, AgHOΔ95. 
ATGGTATAGAAAGCTTTACATCC
GGGACCGGTTCTGCATCC 
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Appendix 3.3 – AgHO truncation designs 
Truncation Protein size (aa) Residues removed (aa) New C terminus Approximate protein 
size (kDa) 
AgHO 249 0 EQEQTL 29.2 
AgHOΔ10 239 10 QYVVRN 27.9 
AgHOΔ15 234 15 AIILMQ 27.3 
AgHOΔ31 218 31 GSANMR 25.6 
AgHOΔ46 203 46 VFELNN 24.0 
AgHOΔ60 189 60 DEETRQ 22.2 
AgHOΔ73 176 73 RLRKIV 20.7 
AgHOΔ83 166 83 EDHSIY 19.4 
AgHOΔ95 154 95 AEPVPD 18.1 
 
Appendix 3.4 –AgHOΔ31 expression time course 
 
SDS-PAGE gel. Lanes: 1, Molecular weight markers; 2, purified AgHOΔ31 control (failed); 
3, empty (dye only); 4, empty (dye only); 5, uninduced control; 6, 60 hours post induction; 7, 
48 hours post-induction; 8, 36 hours post-induction; 9, 24 hours no induction; 10, 12 hours no 
induction. 48 hours is the optimal length of time for expression of AgHOΔ31   
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Appendix 3.5 – Confirmation of antibody binding 
 
Western blot. Lanes 1 – 8 contain 15µL 0.1mg mL-1 AgHO. Lane 9 contains uninduced E. 
coli lysate. Primary antibody is α-AgHO (1:1000 concentration). Secondary antibody is HRP 
conjugated goat α-rabbit IgG (1:5000) concentration. Exposure time is 10 seconds. Pictured 
left is overexposed size ruler. 
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Appendix 3.6 - Codon optimised AgHO 
 
  
157 
 
 
  
 
Synthetic AgHO codon optimisation “Quality classes” are on a semi-arbitrary scale. The 
quality value of the most frequently used codon for the given amino acid in E. coli is 
assigned a value of 100. The other codons are assigned a quality value proportionate to 
their frequency of appearance in the E. coli coding genome. A – Codon quality classes for 
AgHO derived from An. gambiae cDNA in E. coli. B – Codon quality classes for 
synthetic codon optimised AgHO. 
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Appendix 6.1 – CPR Coding DNA sequences 
AgCPR 
ATGGACGCCCAGACAGAAACGGAAGTGCCCGCGGGAAGCGTGAGCGACGAACCGTTCCTC 
GGCCCGCTTGACATCGTCCTGCTCGTCAGTCTGCTGGCCGGCACTGCCTGGTATCTGCTC 
AAGGGCAAGAAAAAGGAAAGCCAAGCTAGTCAGTTTAAATCCTACTCGATCCAGCCGACG 
ACGGTGAACACGATGACGATGGTGGAGAACTCGTTCATCAAGAAGCTACAGTCCTCGGGC 
CGCCGGCTCGTAGTGTTTTACGGTTCCCAAACAGGCACGGCAGAGGAATTTGCCGGTCGC 
CTGGCGAAGGAAGGAATCCGCTACCAAATGAAGGGCATGGTCGCCGACCCAGAGGAGTGC 
AATATGGAAGAGCTGCTGATGCTGAAGGACATCGACAAATCGTTGGCCGTGTTTTGCTTA 
GCGACGTACGGCGAGGGCGACCCGACGGACAACTGCATGGAGTTCTACGACTGGATTCAA 
AACAACGATCTAGATATGACCGGTTTGAATTACGCGGTGTTTGGCCTTGGCAACAAAACG 
TACGAGCACTACAACAAGGTCGGCATCTACGTGGACAAGCGTCTCGAGGAGCTCGGTGCG 
AACAGACTGCACAAGGCGGGCGGCCGGTCCTGCATGCACGTCGAGTTCGACATCGAGGGC 
TCGAAGATGCGGTACGAGGCGGGCGACCATCTCGCGATGTACCCGGTGAACGATCGCGAT 
CTGGTCGAGCGGCTCGGCCGGCTGTGCAATGCCGAGCTCGATACGGTCTTCTCGCTCATC 
AACACCGACACGGACAGCAGCAAGAAGCATCCGTTCCCGTGCCCCACCACCTACCGGACC 
GCGCTCACCCACTATCTGGAGATAACGGCGCTGCCGCGCACCCACATCCTGAAGGAGCTG 
GCCGAGTACTGCGGCGAGGAGAAGGACAAGGAGTTCCTGCGCTTCATCTCGTCGACCGCG 
CCCGACGGCAAGGCGAAGTACCAGGAGTGGGTGCAGGACAGCTGCCGCAACATCGTGCAC 
GTGCTCGAGGACATCCCGTCCTGCCATCCGCCGATCGATCACGTGTGCGAGCTGCTGCCC 
CGGCTGCAGCCCCGCTACTACTCGATCTCCTCCTCGTCCAAGCTGCACCCGACGACGGTG 
CACGTGACCGCGGTGCTGGTGAAGTACGAGACGAAGACGGGCCGGCTGAACAAGGGCGTC 
GCGACGACCTTCCTCGCGGAGAAGCACCCGAACGATGGGGAGCCGGCACCGCGCGTACCA 
ATCTTCATCCGCAAGAGCCAGTTCCGGTTGCCGCCCAAGCCGGAAACGCCCGTGATCATG 
GTGGGGCCCGGCACCGGGCTGGCACCGTTCCGGGGCTTCATCCAGGAGCGGGACCACTGC 
AAGCAGGAGGGCAAGGAGATTGGCCAGACGACGCTGTACTTTGGCTGCCGCAAGCGCTCC 
GAGGACTACATCTACGAGGATGAACTGGAAGACTACTCCAAGCGCGGCATCATCAACCTT 
CGCGTTGCGTTCTCGCGCGACCAGGAGAAGAAGGTGTACGTGACGCACCTGCTCGAGCAG 
GACTCGGACCTCATATGGAGCGTGATCGGCGAGAACAAGGGACACTTTTACATCTGCGGT 
GATGCGAAAAATATGGCCACCGATGTGCGAAACATTCTGCTGAAGGTCATCCGCTCGAAG 
GGTGGGCTCAGCGAAACCGAGGCCCAGCAGTACATCAAAAAGATGGAAGCCCAAAAACGA 
TACTCGGCGGACGTGTGGAGCTAA 
AmCPR 
ATGGCAGGTTCTCCAGTATTGGAGAATGAGGATAAAACAGAGATTCTTGATGAACCTCTC 
TTTAGCACTCTTGATATTATCCTTCTCAGTGCTCTTTTATTGGCTGCCCTATGGTGGTTG 
ATGCGCCGAAACAAACAAGAGGAATATACACCTGTCACAAAATCTTATTCTATTCAGCCA 
ACAATATTTCCTACAACGCAAACATCAGAAAATTCATTTATAAAAAAATTGAAAACTTCT 
GGACGAAGTTTAGTAGTATTTTATGGTAGTCAAACTGGAACTGCAGAAGAATTTGCCGGT 
AGGTTAGCCAAGGAAGGTATTCGATACAAAATGAAAGGCATGGTGGCTGATCCAGAAGAA 
TGTGATATGGAAGAATTAATACATCTCAAAACAATACCAAACAGTATGGCAGTATTCTGT 
TTAGCAACTTATGGAGAAGGTGATCCTACAGACAATGCTATGGAATTTATTGATTGGCTA 
AAAAATGGTGATCCTGATTTAAATGGATTAAATTATGCGGTATTTGGTCTTGGAAATAAA 
ACATATGAACATTATAATGAAATAGCTTTATATGTTGATCATAGATTAGAACAACTTGGT 
GCTACTCGTGTCTTTGAACTTGGTTTGGGAGATGATGATGCTAATATAGAAGATGATTTT 
ATTACATGGAAAGATAAATTTTGGCCAACAGTTTGTGAATTCTTTGGAATTGAAGGTGCA 
GGAGAAGATGTTAGTATTAGACAGTATAAACTAACAGAACATATCGATTTATCAATTGAA 
CGCATTTATACTGGTGAAATAGCTCGTCTTCATTCATTTAAGAATCAAAGAGCACCATTT 
GATGCAAAAAATCCTTTCCTAGCTCCAGTAAAAATAAATCGTGAACTTCATGGTTCAACT 
TCAGATAGATCATGTATGCATATAGAATTTGATATAGAAGGATCAAAAATGCGATATGAA 
ACTGGTGATCATTTAGCAGTATATCCTGTAAATAATACGGAATTAGTAAATAAAATTGGA 
GAAAAATGTGGTATAAATTTAGATACAGTGTTTACTCTTACAAATACAGATGAGGAATCT 
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ACCAAGAAGCATCCATTTCCTTGTCCATGTTCTTACAGAACTGCTTTGACACATTATTTA 
GATATTACTAGTAATCCACGCACTCATGTTCTGAAAGAATTAGCAGAATATTGTAGTGAT 
CCAAATGATAAAGAAAAATTAAAATTAATGGCATCAACCAGTGTGGATGGTAAAGCTGCT 
TATCAGCAATGGGTAGTTCAAGAAAATAGAAATATTGTACATATTTTAGAAGATATTCCT 
AGCTTGAAGCCGGCCTTGGATCATCTTTGCGAACTTTTACCAAGATTGCAATGTCGATAT 
TATTCAATTTCCTCATCTCCTAAGTTACACCCATCTTCAATTCATATTACTGCAGTTGTT 
GTGGAATATAAAACACCAACAGGTAGAATTAACAAAGGTGTAACTACTAGCTGGTTAAAA 
GAAAAACATCCTTCACATCCACCATGTTATGTTCCTATTTTTGTTCGAAAATCTCAATTT 
CGTTTACCAACTCGATTATCAACTCCTATTATCATGGTTGGTCCAGGTACTGGAATAGCA 
CCATTTAGAGGTTTTATACAAGAACGTGATCTTGCAAGAAAAGAAGGAAAAGAAGTAGGA 
AATACAATTTTATATTTTGGATGTAGAAAAAAAGATGAAGATTTTCTTTATAAAGATGAA 
CTTGAAGAATATGTAAAAAGAGGTACTTTAATTTTACATACTGCATTTAGTAGAGAACAA 
TCTCAGAAAATATATGTTACACATCTACTAGAAAAAAATAAAGACGAATTGTGGGAAATT 
ATTGGAGAACAAAATGGACATATCTATGTGTGTGGTGATGCAAAAAATATGGCACGAGAT 
GTACACAATATTTTATTAAAAGTTGTGATGGAAAAGGGAAAAATGTCGGAATTAGATGCA 
GCGAATTATATCAAGAAAATGGATTCGCAAAAACGTTATTCAAGTGACGTATGGAGTTGA 
 
CqCPR 
ATGGACGCACAGACAGAGCCGGAAGTGCCCCCGGTGGCGGCGGCAACCGAGGAGCCCTTC 
CTGGGCCCGCTAGACATTGTCCTGCTGCTGGTGCTGGTGGCCGGTGCAGCATGGTACCTG 
CTCAAGAACAAGAAGAAGGAAGCCCAGACTAGTCAGTTCAAGTCGTACTCGATACAGCCC 
ACCGCCGTCAACACGATGACCATGGCGGAGAACTCCTTCATCAAGAAGCTGAAGTCGTCC 
GGTCGACGGCTGGTGGTGTTCTACGGCTCGCAGACCGGAACCGCCGAGGAGTTCGCCGGG 
CGGTTGGCGAAGGAGGGCCTGCGCTACCAGATGAAGGGTATGGTGGCCGACCCGGAGGAG 
TGCGACATGGAAGAGCTGCTGACGCTCAAGGACATCGACAAGTCGCTGGCGGTGTTCTGC 
TTGGCCACGTACGGCGAGGGTGATCCCACCGACAACTGCATGGAGTTCTACGAGTGGATC 
CAGAACAACGACGTGGACTTTACCGGGTTGAACTACGCGGTCTTTGGGCTTGGCAACAAA 
ACGTACGAGCACTATAACAAGGTTGGAATCTATGTCGACAAACGGCTGGAGGAGTTGGGA 
GCAAGTCGTGTCTTCGAGCTGGGACTTGGAGATGATGACGCGAACATTGAGGATGACTTC 
ATCACGTGGAAGGACAAGTTCTGGCCAGCAGTGTGCGACCATTTTGGAATCGAAAGTACC 
GGCGACGAGGTGTTGACGCGTCAGTACCGTCTGCTTGAGCAGCCGGAGACCTCGCCGGAA 
CGTCTGTACACCGGTGAGGTGGCCCGCCTGCACTCGCTCCAGACGCAGCGCCCGCCGTTC 
GATGCCAAGAATCCGTTCATGGCTCCGATCAAGATTAACCGCGAGCTGCACAAGTCCGGT 
GGCCGTTCGTGCATGCACATCGAGTTCGATATCGAGGGATCGAAGATGCGCTACGAAGCT 
GGTGATCATCTGGCGATGTACCCGGTGAACGATTCGGACTTGGTGACCCGATTGGGCAAG 
CTGTGCAATGCCGACCTGGATACGATCTTCTCGCTGATCAACACCGATACGGACAGTAGC 
AAGAAACATCCGTTCCCTTGCCCAACGACGTACAAAACGGCGCTGACGCACTACCTGGAG 
ATCACCGCGCTGCCGAGAACTCACATCCTGAAGGAGTTGGCCGAATACTGCAGCGACGAA 
AAGGACAAGGAGTTCCTGCGGTTCATGTCTTCCACGGCACCCGAAGGCAAGGCCAAGTAC 
CAGGAATGGGTTCAGGACAGCAGCCGTAACATTGTGCACGTACTGGAAGACGTCCCGTCC 
TGCCATCCACCGATTGACCACATCTGCGAGCTGCTTCCGAGACTGCAGCCCCGCTACTAC 
TCGATCTCTTCGTCTTCCAAGCTGTACCCTACCACGGTGCACGTCACGGCCGTTCTGGTC 
AAGTACGTCACCAAGACCGGACGTACCAACAACGGCGTCGCTACGACATTCCTGGCCCAG 
AAGAAGGTTAACGGAGAATCGCTGCCGCGGGTGCCGATCTTCATCCGCAAGAGCCAGTTC 
CGGTTACCGGCGAAAACGGAAACCCCGGTCATCATGGTCGGCCCGGGAACCGGGTTGGCT 
CCCTTCCGAGGCTTTATCCAGGAGCGAGATTTCAACAAGCAGGAAGGCAAGGAAATCGGC 
CAGACCGTCATGTACTTTGGCTGTCGCAAACGGTCCGAGGATTACATCTATGAAGAGGAA 
CTCGAAGACTACGTCAAGCGCGGCGTAATCAGCCTGAGGACAGCCTTCTCGCGTGACCAA 
CCGCAAAAGGTGTACGTTACGCATCTGCTAGAGGAAGACATGGACCTGATCTGGGAAGTG 
ATAGGTGTCAACAAGGGTCACTTCTACATTTGCGGTGACGCCAAGAACATGGCCACCGAC 
GTGCGGAACATTCTGCTCAAGGTGCTGCAATCCAAGGGCAACATGAGCGAGAGTGAAGCG 
ACGCAGTACGTCAAGAAGATGGAAGCCCAGAAGCGGTACTCGGCCGACGTGTGGAGTTAA 
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DmCPR 
ATGGCCAGCGAGCAAACGATTGATGGAGCAGCCGCAATTCCCAGCGGCGGCGGCGACGAA 
CCCTTCCTGGGACTGCTGGACGTGGCCCTATTGGCGGTGCTAATCGGCGGCGCAGCCTTC 
TACTTCCTGCGTAGCCGCAAGAAGGAGGAGGAGCCAACCAGGAGCTATTCCATACAACCC 
ACCACAGTGTGCACCACCAGTGCGTCGGACAATTCGTTCATCAAGAAGCTCAAGGCATCC 
GGACGCAGTCTGGTCGTCTTCTATGGCTCACAGACCGGAACCGGCGAGGAGTTCGCCGGC 
CGTCTGGCCAAGGAGGGCATTCGTTACCGTCTGAAGGGCATGGTTGCCGATCCCGAGGAA 
TGCGACATGGAGGAGCTGCTGCAGCTGAAGGACATCGACAACTCGCTGGCGGTCTTTTGC 
CTGGCCACCTACGGCGAGGGAGATCCCACTGACAACGCCATGGAGTTCTACGAGTGGATC 
ACCAGCGGCGATGTCGATCTGAGCGGGCTAAATTATGCGGTCTTTGGCTTGGGCAACAAG 
ACCTATGAGCACTACAACAAGGTGGCCATCTATGTGGACAAGCGACTGGAGGAGCTGGGC 
GCCAACCGGGTCTTTGAACTGGGACTGGGCGACGATGATGCCAACATCGAGGATGACTTC 
ATCACGTGGAAGGATCGCTTCTGGCCCGCCGTGTGCGATCACTTCGGCATCGAGGGCGGC 
GGCGAGGAAGTGCTCATCCGCCAGTACCGTTTGCTAGAACAGCCAGATGTGCAGCCTGAC 
CGCATTTACACGGGAGAGATCGCCCGCCTGCACTCGATTCAGAACCAGCGCCCGCCCTTC 
GACGCCAAGAACCCATTCCTGGCCCCCATCAAGGTGAACCGCGAGCTGCACAAGGGCGGT 
GGCCGCTCCTGCATGCACATTGAGCTGAGCATCGAGGGTTCCAAGATGCGCTACGATGCC 
GGAGATCATGTGGCCATGTTCCCTGTTAACGACAAGAGTCTGGTGGAGAAGCTCGGCCAG 
CTGTGCAACGCCGATCTGGATACTGTGTTCTCGCTGATCAACACCGATACGGACAGCAGC 
AAGAAGCACCCATTCCCTTGCCCCACTACGTACCGCACCGCTCTGACCCACTACCTGGAA 
ATTACGGCCATACCCCGCACACACATCCTCAAGGAGCTCGCTGAGTATTGTACTGACGAG 
AAGGAGAAGGAGTTGCTGCGCAGCATGGCCTCCATCAGTCCCGAAGGAAAGGAGAAATAC 
CAGAGCTGGATCCAAGACGCCTGTCGCAACATCGTCCACATTCTGGAGGACATCAAATCC 
TGTCGCCCACCCATCGATCACGTTTGCGAGCTGCTGCCCCGCTTGCAGCCTCGTTACTAC 
TCCATCTCGTCGTCTGCTAAGCTGCACCCCACTGATGTCCACGTTACAGCCGTTCTCGTG 
GAGTACAAGACGCCGACGGGACGCATCAACAAGGGCGTAGCCACCACATATCTGAAGAAC 
AAGCAGCCGCAGGGCAGTGAGGAAGTAAAGGTTCCGGTATTCATCCGCAAGTCGCAGTTC 
CGTTTGCCTACGAAGCCAGAGACACCTATCATAATGGTGGGTCCTGGCACTGGCTTGGCC 
CCCTTCCGCGGATTCATTCAGGAGCGACAATTCCTTCGCGATGAGGGCAAGACCGTGGGC 
GAGTCGATTCTCTACTTCGGTTGCCGTAAGCGCAGTGAGGACTACATCTACGAATCCGAG 
TTGGAGGAGTGGGTTAAGAAGGGCACTCTCAACCTGAAGGCCGCCTTTTCTCGTGACCAG 
GGCAAGAAGGTCTACGTGCAGCATCTGCTCGAGCAGGACGCAGATCTTATATGGAACGTG 
ATTGGCGAGAATAAGGGGCACTTCTACATATGCGGTGATGCAAAGAACATGGCCGTGGAC 
GTTAGGAACATTTTAGTGAAAATTTTGTCCACTAAGGGTAACATGAGCGAGGCTGACGCC 
GTGCAGTATATCAAGAAGATGGAGGCTCAGAAGCGCTACTCGGCCGATGTCTGGAGCTAA 
 
HsCPR 
ATGATCAACATGGGAGACTCCCACGTGGACACCAGCTCCACCGTGTCCGAGGCGGTGGCC 
GAAGAAGTATCTCTTTTCAGCATGACGGACATGATTCTGTTTTCGCTCATCGTGGGTCTC 
CTAACCTACTGGTTCCTCTTCAGAAAGAAAAAAGAAGAAGTCCCCGAGTTCACCAAAATT 
CAGACATTGACCTCCTCTGTCAGAGAGAGCAGCTTTGTGGAAAAGATGAAGAAAACGGGG 
AGGAACATCATCGTGTTCTACGGCTCCCAGACGGGGACTGCAGAGGAGTTTGCCAACCGC 
CTGTCCAAGGACGCCCACCGCTACGGGATGCGAGGCATGTCAGCGGACCCTGAGGAGTAT 
GACCTGGCCGACCTGAGCAGCCTGCCAGAGATCGACAACGCCCTGGTGGTTTTCTGCATG 
GCCACCTACGGTGAGGGAGACCCCACCGACAATGCCCAGGACTTCTACGACTGGCTGCAG 
GAGACAGACGTGGATCTCTCTGGGGTCAAGTTCGCGGTGTTTGGTCTTGGGAACAAGACC 
TACGAGCACTTCAATGCCATGGGCAAGTACGTGGACAAGCGGCTGGAGCAGCTCGGCGCC 
CAGCGCATCTTTGAGCTGGGGTTGGGCGACGACGATGGGAACTTGGAGGAGGACTTCATC 
ACCTGGCGAGAGCAGTTCTGGCCGGCCGTGTGTGAACACTTTGGGGTGGAAGCCACTGGC 
GAGGAGTCCAGCATTCGCCAGTACGAGCTTGTGGTCCACACCGACATAGATGCGGCCAAG 
GTGTACATGGGGGAGATGGGCCGGCTGAAGAGCTACGAGAACCAGAAGCCCCCCTTTGAT 
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GCCAAGAATCCGTTCCTGGCTGCAGTCACCACCAACCGGAAGCTGAACCAGGGAACCGAG 
CGCCACCTCATGCACCTGGAATTGGACATCTCGGACTCCAAAATCAGGTATGAATCTGGG 
GACCACGTGGCTGTGTACCCAGCCAACGACTCTGCTCTCGTCAACCAGCTGGGCAAAATC 
CTGGGTGCCGACCTGGACGTCGTCATGTCCCTGAACAACCTGGATGAGGAGTCCAACAAG 
AAGCACCCATTCCCGTGCCCTACGTCCTACCGCACGGCCCTCACCTACTACCTGGACATC 
ACCAACCCGCCGCGTACCAACGTGCTGTACGAGCTGGCGCAGTACGCCTCGGAGCCCTCG 
GAGCAGGAGCTGCTGCGCAAGATGGCCTCCTCCTCCGGCGAGGGCAAGGAGCTGTACCTG 
AGCTGGGTGGTGGAGGCCCGGAGGCACATCCTGGCCATCCTGCAGGACTGCCCGTCCCTG 
CGGCCCCCCATCGACCACCTGTGTGAGCTGCTGCCGCGCCTGCAGGCCCGCTACTACTCC 
ATCGCCTCATCCTCCAAGGTCCACCCCAACTCTGTGCACATCTGTGCGGTGGTTGTGGAG 
TACGAGACCAAGGCTGGCCGCATCAACAAGGGCGTGGCCACCAACTGGCTGCGGGCCAAG 
GAGCCTGCCGGGGAGAACGGCGGCCGTGCGCTGGTGCCCATGTTCGTGCGCAAGTCCCAG 
TTCCGCCTGCCCTTCAAGGCCACCACGCCTGTCATCATGGTGGGCCCCGGCACCGGGGTG 
GCACCCTTCATAGGCTTCATCCAGGAGCGGGCCTGGCTGCGACAGCAGGGCAAGGAGGTG 
GGGGAGACGCTGCTGTACTACGGCTGCCGCCGCTCGGATGAGGACTACCTGTACCGGGAG 
GAGCTGGCGCAGTTCCACAGGGACGGTGCGCTCACCCAGCTCAACGTGGCCTTCTCCCGG 
GAGCAGTCCCACAAGGTCTACGTCCAGCACCTGCTAAAGCAAGACCGAGAGCACCTGTGG 
AAGTTGATCGAAGGCGGTGCCCACATCTACGTCTGTGGGGATGCACGGAACATGGCCAGG 
GATGTGCAGAACACCTTCTACGACATCGTGGCTGAGCTCGGGGCCATGGAGCACGCGCAG 
GCGGTGGACTACATCAAGAAACTGATGACCAAGGGCCGCTACTCCCTGGACGTGTGGAGC 
TAG 
 
RpCPR 
ATGGAAAAAACTATAGGCGCGGAAGAGCAGACGGGACCGTTGGAAGACATTGAAGAACCA 
ATGTTTGGCGTGTTGGATGTGGTATTATTGGTAGCTTTACTTGGAGTAGCCGCTTGGTGG 
CTTATGAGGAATAAAAAAGCTGATGCAGCGCTTAGAGAGAAAACTTACGCCATACAACCA 
ATGGCAATGAGCTCAATGCCACAAAGTACAGAAAATTCTTTTATTAAAAAGTTAAAATCA 
AGTGGACGAAGCCTCATAGTATTCTATGGTAGCCAGACTGGTACTGGTGAAGAATTCGCT 
GGACGTATTGCTAAAGAAGGGATTAGGTATAAAATGAAAGGAATGGTTGCCGATCCAGAA 
GAATATGATATGGAAGATCTAATTCAAATGAAGACAATACCAAACTCATTAGCCGTTTTC 
TGTATGGCAACCTATGGTGAAGGCGATCCAACTGATAATGCCATGGATTTCTATGAATGG 
CTTCAGAATGGTGAAGCAGATCTTACAGGGCTTAATTATGCTGTCTTTGGTTTGGGTAAC 
AAAACTTACGAGCACTATAATGAAGTTGGTATCTACATTGACAAAAGGTTAGAAGAACTA 
GGAGCAACTAGAGTATTTGAACTAGGACTTGGGGATGATGATGCTAACATTGAAGATGAC 
TTTATTACTTGGAAAGACAGATTTTGGCCGACAGTTTGTGCCCATTTTGGTATAGAATCT 
GCGGGAGAAGATGTCTCTGTAAGGCAATACAAACTCACCGAACATATAGAGACAATACCA 
GAGCGAGTGTTCACCGGAGAAGTGGCTAGACTGCATTCACTCATCAATCAGAGACCACCA 
TTCGACGTGAAGAACCCTTACTTAGCGCCAGTAAAAGTTAATAGAGAATTACATAAAGGT 
GGTGGAAGATCTTGTATGCATATTGAATTTGACATTGAAGGATCTAAAATGCGATATGAC 
ACTGGGGACCATGTAGCCGTATATCCAATGAATGACTCAGAATTAGTCAATAAGTTTGGC 
ACATTACTTGGAGTTGATTTAGACACTATTATTACCTTAACAAACACTGACGAGGATTCT 
AGTAAAAAACATCCATTCCCTTGTCCGTGTTCCTATAGGACCGCTTTGACGTATTATATT 
GACATAACATCTAATCCACGTACTCATATTCTTAAAAACGCAGAGTATGCCACAGATCCT 
GAGGAAGCAGCAAAATTGAAGCTGATGGCAAGTACTTGTGCAGATGGTAAACATTTGTAC 
AGCCAGTGGATAAATCAAGATAATAGAAATATTGTTCATATATTAGAGGACTTGCCTTCT 
TGTAAACCCAAATTGGATCATCTTTGCGAATTATTGCCGAGGTTACAATGCCGTTATTAC 
TCAATATCATCGTCATCCAAGCTCTATCCTACCACAGTGCACATTACAGCTGTAAAAGTG 
GAATATGATACTAACACCGGGCGTAGAAACAAAGGTGTTGCTACATCATGGTTAGGAAAA 
AAAATACCAACGGACCCTAATGCCCTTCCTGTTGTTCCTATCTTTTTCAGGAAATCACAA 
TTCAAATTGCCCACAAGACCTCAGACGCCAATAATTATGATAGGGCCTGGTACAGGTTTA 
GCCCCATTTAGAGGATTCATACAAGAACGACATATGGCCAAAGAAGAAGGCAAACCTCTA 
GGAGAAACTATCCTATATTTTGGATGCAGAAAGAAATCAGAAGATTATCTTTACGAAGAA 
GAACTTGATGAATTTGTGAAGAAGGGGACGTTGAAATTACATGTGGCATTTTCACGTGAT 
CAAAAAGAAAAAGTATACGTTACACATCTTTTAGCACAAAATGCTGATGAAATTTGGAAC 
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GTCATTGGTGAAAACAATGGACATTTATATATCTGCGGTGATGCCAGATCGATGGCACGC 
GATGTGCACGATATACTATTAAAAGTGGTACAAGAAAAGGGGAAAATGACTGAAGAAGAG 
GCTAATAATTATGTAAAAAAGATGGAAGCACAAAAGAGATATTCAGCTGATGTTTGGAGT 
TAA 
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Appendix 6.2 – Primers for preliminary amplification 
These primers were used to create a full length CPR insert to be cloned into pJET1.2 and used 
as a template for further amplification. 
Primer 
Name 
Primer Function Primer Sequence (5’ – 3’) 
AaF Ae. aegypti forward ATGGACGCACAGACGGAAC 
AaR Ae. aegypti reverse TTAACTCCACACGTCGGCC 
AgF An. gambiae forward ATGGACGCCCAGACAGAAAC 
AgR An. gambiae reverse TTAGCTCCACACGTCCGC 
AmF A. mellifera forward ATGATGTTTTATATGTACATATGTTTATGTG 
AmR A. mellifera reverse TCAACTCCATACGTCACTTGAATAAC 
CqF C. quinquefasciatus forward ATGGACGCACAGACAGAG 
CqR C. quinquefasciatus reverse TTAACTCCACACGTCGGC 
DmF D. melanogaster forward ATGGCCAGCGAGCAAACG 
DmR D. melanogaster reverse TTAGCTCCAGACATCGGCC 
GmF G. morsitans forward ATGACTGATGAGAAAATCGAAAACG 
GmR G. morsitans reverse CTACCCACATATGTAAAAGTGG 
HsF H. sapiens forward ATGATCAACATGGGAGACTCC 
HsR H. sapiens reverse CTAGCTCCACACGTCCAG 
RpF R. prolixus forward ATGGAAAAAACTATAGGCGCGG 
RpR R. prolixus reverse TTAACTCCAAACATCAGCTGAATATC 
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Appendix 6.3 – pOPINF CPR Primers 
CPR Forward Primer Reverse Primer 
Sequence (5’-3’) Melting 
temperature (oC) 
Sequence (5’-3’) Melting 
temperature (oC) 
AaCPR 
full length 
AAGTTCTGTTTCAGGGCCCGGACGCACAGACG
GAACCGGAG 73.5 
ATGGTCTAGAAAGCTTTATTAACTCCACACG
TCGGCCGAGTATCGC 69.9 
AaCPR 
truncated 
AAGTTCTGTTTCAGGGCCCGACGATGACCATG
GCGGAGAACTCG 72.9 
ATGGTCTAGAAAGCTTTATTAACTCCACACG
TCGGCCGAGTATCGC 69.9 
AgCPR 
full length 
AAGTTCTGTTTCAGGGCCCGGACGCCCAGACA
GAAACGGAAGTG 72.9 
ATGGTCTAGAAAGCTTTATTAGCTCCACACG
TCCGCCGAG 68.6 
AgCPR 
truncated 
AAGTTCTGTTTCAGGGCCCGGACGCCCAGACA
GAAACGGAAGTG 72.9 
ATGGTCTAGAAAGCTTTATTAGCTCCACACG
TCCGCCGAG 68.6 
AmCPR 
full length 
AAGTTCTGTTTCAGGGCCCGGCAGGTTCTCCA
GTATTGGAGAATGAGG 72.2 
ATGGTCTAGAAAGCTTTATCAACTCCATACG
TCACTTGAATAACGTTTTTG 66.2 
AmCPR 
truncated 
 
AAGTTCTGTTTCAGGGCCCGACATCAGAAAAT
TCATTTATAAAAAAATTGAAAACTTCTG 66.7 
ATGGTCTAGAAAGCTTTATCAACTCCATACG
TCACTTGAATAACGTTTTTG 66.2 
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CqCPR 
full length 
 
AAGTTCTGTTTCAGGGCCCGGACGCACAGACA
GAGCCGGAAGTGC 74.6 
ATGGTCTAGAAAGCTTTATTAACTCCACACG
TCGGCCGAGTACC 69.2 
CqCPR 
truncated 
 
AAGTTCTGTTTCAGGGCCCGACGATGACCATG
GCGGAGAACTCC 72.9 
ATGGTCTAGAAAGCTTTATTAACTCCACACG
TCGGCCGAGTACC 69.2 
DmCPR 
full length 
AAGTTCTGTTTCAGGGCCCGGCCAGCGAGCAA
ACGATTGATGGAGC 73.5 
ATGGTCTAGAAAGCTTTATTAGCTCCAGACA
TCGGCCGAGTAGCG 70 
DmCPR 
truncated 
AAGTTCTGTTTCAGGGCCCGACCACCAGTGCG
TCGGACAATTCG 72.9 
ATGGTCTAGAAAGCTTTATTAGCTCCAGACA
TCGGCCGAGTAGCG 70 
GmCPR 
full length 
AAGTTCTGTTTCAGGGCCCGACTGATGAGAAA
ATCGAAAACGTTGTTAGCGG 70.9 
ATGGTCTAGAAAGCTTTACTACCCACATATG
TAAAAGTGGCCGTTATTTTCACC 68.4 
GmCPR 
truncated 
AAGTTCTGTTTCAGGGCCCGACTGCAGCAGTT
ACAGAAAATTCGTTTATTAAGAAATTG 69.5 
ATGGTCTAGAAAGCTTTACTACCCACATATG
TAAAAGTGGCCGTTATTTTCAC 67.7 
HsCPR 
full length 
AAGTTCTGTTTCAGGGCCCGATCAACATGGGA
GACTCCCACGTGG 72.7 
ATGGTCTAGAAAGCTTTACTAGCTCCACACG
TCCAGGGAGTAGC 70.1 
HsCPR 
truncated 
AAGTTCTGTTTCAGGGCCCGACCTCCTCTGTCA
GAGAGAGCAGCTTTG 73.1 
ATGGTCTAGAAAGCTTTACTAGCTCCACACG
TCCAGGGAGTAGC 70.1 
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RpCPR 
full length 
AAGTTCTGTTTCAGGGCCCGGAAAAAACTATA
GGCGCGGAAGAGCAGAC 72.1 
ATGGTCTAGAAAGCTTTATTAACTCCAAACA
TCAGCTGAATATCTCTTTTGTG 66.1 
RpCPR 
truncated 
AAGTTCTGTTTCAGGGCCCGATGCCACAAAGT
ACAGAAAATTCTTTTATTAAAAAGTTAA 67.4 
ATGGTCTAGAAAGCTTTATTAACTCCAAACA
TCAGCTGAATATCTCTTTTGTGC 66.9 
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Appendix 6.4 – CPR Truncations 
Enzyme Truncated 
protein size (aa) 
Residues removed (aa) Approximate 
truncated protein size 
(kDa) 
AgCPR 613 66 65000 
AmCPR 613 67 67500 
CqCPR 613 67 67700 
DmCPR 613 67 67700 
HsCPR 618 63 68000 
RpCPR 613 68 67700 
 
